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ABSTRACT 
G protein-coupled receptor (GPCR) sorting into the degradative pathway is 
important for attenuating signaling. Perturbations in this process can manifest in a variety 
of diseases. Upon agonist activation of the chemokine receptor CXCR4, a GPCR, it is 
rapidly ubiquitinated, internalized to endosomes and sorted for degradation in lysosomes 
via the endosomal sorting complex required for transport (ESCRT) pathway. This process 
culminates in attenuation of CXCR4 signaling. CXCR4 overexpression and increased 
CXCR4 signaling have been associated with several pathologies including immune 
deficiency disorders and over 23 cancers. Yet the mechanisms governing the regulation 
of CXCR4 signaling remain elusive.  
CXCR4 is ubiquitinated by the HECT-domain E3 ligase AIP4 at the plasma 
membrane. AIP4 is also localized on early endosomes and regulates CXCR4 sorting by 
modulating the activity of the ESCRT machinery. In particular, ESCRT-0 ubiquitination 
has been shown to be linked to the efficiency by which CXCR4 is sorted for lysosomal 
degradation. However, mechanistic insight is lacking and the precise role of AIP4 in 
these processes remains poorly defined.  
The objective of this project is to gain a greater understanding of the mechanisms 
mediating AIP4 regulation of CXCR4 degradation. AIP4 is known to interact with other 
E3 ligases, including DTX1 and Cbl-c, but whether these E3 ligases or others are 
 $$!!"
involved in CXCR4 sorting is not known. Here, we show for the first time that the RING-
domain E3 ubiquitin ligase Deltex-3-like (DTX3L) mediates CXCR4 sorting from early 
endosomes to lysosomes. Using several biochemical and immunochemical techniques 
including fixed cell confocal immunofluorescence microscopy, co-immunoprecipitation 
and in vitro ubiquitination assays, we show that upon CXCR4 activation DTX3L 
localizes to early endosomes where it directly interacts with and inhibits the activity of 
the AIP4. Thereby, limiting the extent to which ESCRT-0 is ubiquitinated while 
promoting CXCR4 sorting for lysosomal degradation. Therefore, we have defined a 
novel role for DTX3L in GPCR endosomal sorting and propose that DTX3L may play a 
broad role in endosomal sorting. In addition, our data reveal an unprecedented link 
between two distinct E3 ubiquitin ligases to control the activity of the ESCRT machinery. 
Overall, these findings may prove beneficial in developing strategies to modulate CXCR4 
levels and be broadly applicable to CXCR4-related pathologies. 
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CHAPTER I 
INTRODUCTION 
OVERVIEW OF G PROTEIN-COUPLED RECEPTORS 
G protein-coupled receptors (GPCRs) comprise a superfamily of proteins that 
promote changes in cellular response attributable to nearly every physiological process. 
GPCRs are the largest class of targets for many drugs used to treat a variety of diseases 
highlighting their role pathophysiologically (Overington, Al-Lazikani, & Hopkins, 2006). 
Specifically, GPCRs are integral plasma membrane proteins that consist of single 
polypeptide chains containing seven transmembrane (7TM)-spanning domains that are 
connected by extracellular and intracellular loops (Pierce, Premont, & Lefkowitz, 2002). 
There are over 800 functional GPCRs expressed by the human genome that respond to a 
diverse array of stimuli and control a multitude of physiological processes including 
vision, smell, pain, neurotransmission, muscle contraction and immune responses 
(Fredholm, Hokfelt, & Milligan, 2007; Jacoby, Bouhelal, Gerspacher, & Seuwen, 2006; 
Pierce et al., 2002).  The regulation of GPCR signaling is a tightly controlled process and 
perturbations in GPCR signaling have been linked to several pathologies (Jacoby et al., 
2006; Pierce et al., 2002). 
 According to the International Union of Pharmacology (IUPHAR), GPCRs are 
classified into five distinct groups based on amino acid sequence similarity: Class-I 
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rhodopsin-like (family A), Class-II secretin-like (family B), Class-III glutamate (family 
C), Adhesion and Frizzled/other 7TM families (Hamann et al., 2015).  
 
Class-I receptors comprise the largest group of GPCRs that consists of rhodopsin-like 
receptors. These receptors all have similarity to the first GPCR identified, the rhodopsin 
receptor and possess within their transmembrane helix a conserved Asp-Arg-Tyr (DRY) 
motif. Additionally, there are 273 genes encoding this family of receptors that include 89 
orphan receptors for which no known ligands have been identified so far. Members of 
this family include: !1 and !2 adrenergic receptors, chemokine receptors, opioid receptors 
and dopamine receptors among many more important receptors.  Nearly half of class A 
GPCRs are olfactory receptors that mediate responses to odor (Buck & Axel, 1991). 
 
The second class of GPCRs include secretin-like receptors and are encoded by 48 genes 
(Zalewska, Siara, & Sajewicz, 2014). This class of GPCRs bind large glycoproteins and 
include secretin, calcitonin, corticotropin-releasing factor, growth-hormone releasing 
hormone and parathyroid hormone receptors (B. Martin et al., 2005). Class II GPCRs 
contain a large spanning N-terminal region and differ from Class I GPCRs in their amino 
acid sequence. In particular, these receptors lack the DRY motif found in Class I GPCRs, 
however, Class II GPCRs display the same heptahelical transmembrane structure.  
 
The third class of GPCRs consists of metabotropic receptors encoded by 22 genes. 
Receptors in this class bind to relatively small ligands such as glutamate and Ca2+. 
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Members of this group include metabotropic gamma-amino-butyric acid type B 
(GABAB), calcium-sensing receptor (CaR) and glutamate receptors. Although similar in 
structure, Class III GPCRs share little sequence identity within their amino acid sequence 
with Class I and II (Brauner-Osborne, Wellendorph, & Jensen, 2007). 
 
The fourth group of GPCRs is classified as adhesion receptors of which there are 33 
members. These receptors are characterized by a long N terminal region containing a 
GPCR-Autoproteolysis Inducing (GAIN domain) and by a distinct 7TM region 
displaying little similarity with other families of GPCRs (Arac et al., 2012). Adhesion 
receptors are required for cell to cell as well as cell to extracellular matrix interactions. 
An interesting feature of adhesion receptors is that they undergo proteolysis within the N-
terminal region mediated at the GPCR Proteolysis Site (GPS) of the GAIN domain. 
Based on these characteristics, the structure of these receptors is sub-divided into a long 
spanning extracellular domain (ECD), 7TM domain and intracellular domain (ICD). The 
majority of adhesion receptors are classified as orphan receptors (Schulte, 2010). 
However, it has been identified that several of these receptors bind to small molecules or 
peptides (Hamann, Vogel, van Schijndel, & van Lier, 1996; Stacey et al., 2003; Wandel, 
Saalbach, Sittig, Gebhardt, & Aust, 2012; T. Wang et al., 2005).  
 
The final group of GPCRs are encoded by 11 genes that include Frizzled receptors 
involved in Wnt signaling, Smoothened receptors involved in hedgehog signaling and 
taste receptors that mediate taste responses (Kinnamon, 2012; Schulte, 2010). Taste 
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receptors are subdivided into two types, T1Rs for sweet and umami stimuli and T2Rs for 
bitter stimuli (Kinnamon, 2012). Many of these receptors are important in embryonic 
development and are highly homologous to the second class of GPCRs.  
 
CHEMOKINE RECEPTORS 
Chemokine receptors belong to the Class A superfamily of GPCRs. In mammals, 
approximately 19 chemokine receptors have been identified and each can activate a 
diverse signaling pathway (Murphy et al., 2000). Chemokine receptors bind to shared or 
specific ligands known as chemokines (Allen, Crown, & Handel, 2007). Chemokines are 
small proteins (8-10 kDa) whose function is associated with chemotaxis or cell migration. 
Chemokines are divided into four classes based on the spacing of the N-terminal cysteine 
residues within the proteins structure (i.e. C, CC, CXC, CX3C) (Allen et al., 2007; 
Baggiolini, Dewald, & Moser, 1997; Fernandez & Lolis, 2002). Chemokine receptors are 
named based on the class of chemokine they bind. For example, CXC receptors (CXCR) 
bind to the class of CXC chemokines; CC receptors (CCR) bind CC ligands, etc. 
Chemokine receptors regulate a multitude of cellular processes necessary for 
development as well as hematopoiesis, angiogenesis and inflammation in the adult 
(Baggiolini et al., 1997; Moser & Loetscher, 2001; Premack & Schall, 1996). 
Chemokines are known to regulate immune cell trafficking (i.e. homing, extravasion, 
circulation) among several other biological functions such as cell adhesion and cytokine 
secretion (Zlotnik, 2006).  
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GPCR ACTIVATION  
Activation of GPCRs allows for the transmission of information from the 
extracellular environment into the inside of the cell. Classically, GPCR signaling is 
mediated through associated guanine nucleotide binding proteins (G proteins) that are 
heterotrimers composed of " and !# heterodimer (Gilman, 1987). Coupling of the 
receptor to the associated G proteins allows for the transduction of information from the 
outside of the cell to the inside. GPCR signaling can also be mediated via mechanisms 
independent of the associated G protein. These topics are highlighted in the following 
section. 
 
GPCR SIGNALING 
Upon agonist binding, GPCRs undergo a conformational change primarily within 
the transmembrane regions 3 (TM3) and 6 (TM6) that facilitates the exchange of GDP for 
GTP on the "-subunit of associated G protein (Gilman, 1987; Pierce et al., 2002). This 
event causes dissociation of the heterotrimeric G protein into " and !# subunits which go 
on to activate a diverse array of effector proteins to initiate signal transduction of the 
external stimulus to the internal compartments of the cell (Fredholm et al., 2007; Oldham 
& Hamm, 2008; Pierce et al., 2002).  This signaling culminates in discrete changes in 
cellular response (Figure 1.1). The G"-subunit coupled to a GPCR can vary based on the 
type of ligand that binds to a particular GPCR. G"i inhibits adenylyl cyclase leading to a 
reduction in the conversion of to adenosine triphosphate (ATP) into the second 
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messenger cyclic AMP (cAMP), whereas G"s activates adenylyl cyclase to increase 
cAMP levels. The G"q subunit stimulates phospholipase C (PLC-!) that leads to 
production of diacylglycerol (DAG) and inositol trisphosphate (IP3) from 
phosphatidylinositol bisphosphate (PIP2). The G"12/13 subunit is involved in the activation 
of Rho family GTPases that regulate the actin cytoskeleton. Additionally, the !# subunits 
activate PI3K, PLC- and adenylyl cyclase signaling pathways (Oldham & Hamm, 2008). 
Some GPCR signaling does not involve the heterotrimeric G proteins (Figure 
1.1). This G protein independent signaling can lead to activation of several signaling 
pathways including Janus kinase and signal transducer and activator of transcription 
signaling pathway (JAK/STAT), mitogen-activated protein kinase (MAPK) and p38. 
Taken together both G protein dependent and independent signaling downstream of 
GPCR activation leads to changes in cellular responses including migration, proliferation 
and survival.  
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Figure 1.1 GPCR Activation and Signaling. GPCR activation can lead to both G 
protein and G protein independent signaling. Ligand activation of GPCRs results in 
conformational change in the receptor that promotes the exchange of GDP for GTP on 
the "-subunit. This results in the dissociation of the heterotrimeric G protein into " and 
!# subunits. Certain GPCRs bind preferentially to a subtype of the "-subunit. The G"-
subunit can be further subdivided based on the second messengers they activate. 
Additionally, the !# subunits activate particular second messengers and, hence, 
downstream signaling pathways. G protein independent signaling can also lead to 
activation of several signaling pathways (Dorsam & Gutkind, 2007). 
!"#$%#
&'%()#*'
+,-#*.$/01,2-'*,30#%,*'$405'56,.'$40
#%,*20#3,.$405)26',*$4
057262*$40,2*$40",5,.$40'638
? ?
?
9:!
?
?
?
9;!
<36,=#6'.0>'3'562)?>'$6,*-@0>'3'562)
AB6)#3'""C"#)
D*6)#3'""C"#)
!"#$%&'()*#+($(*,(*'#-).*/0)*.1
!"#$%&'()*#2*,($(*,(*'#
-).*/0)*.1
!DEF
?????
<.'*G"03G3"#$'?
,
?
$
?
H
?
IC3"'C$
9'*'0AB5)'$$,2*
?
D*7,(,6,2*02J0
#.'*G"03G3"#$'
<36,=#6,2*02J0
#.'*G"03G3"#$'
<36,=#6'$
K#LM
?????
:<9
!FK
>72N%'.,#6'.0
$,-*#",*-
3(0040/%#5(6$&*6(67
&,-)#6,2*
!)2",J')#6,2*
OC)=,=#"
'638
PLQPE
R<FQO;<;
&<!F
5ES
 
8 
 
REGULATION OF GPCR SIGNALING 
A key component to the regulation of GPCR signaling involves desensitization, 
internalization and downregulation or recycling of the receptor. Desensitization is the 
process by which receptor signaling following initial activation is rapidly terminated even 
in the continued presence of stimulus. Typically the removal of activated GPCRs from 
the cell surface occurs via a complex process leading to their internalization and 
endocytosis onto intracellular compartments known as endosomes (Marchese, Chen, 
Kim, & Benovic, 2003). On endosomes, GPCRs can be sorted for long-term signaling 
attenuation by degradation in the highly acidic environment of the lysosome (Marchese, 
Chen, et al., 2003; Tsao & von Zastrow, 2000). Conversely, GPCRs can be recycled back 
to the cell surface following dephosphorylation by an endosomal associated phosphatase, 
therefore, resensitizing the GPCR to further rounds of receptor signaling (Pitcher, Payne, 
Csortos, DePaoli-Roach, & Lefkowitz, 1995). 
 
DESENSITIZATION 
Regulation of GPCR signaling can occur at multiple levels including the level of 
the signaling proteins and/or the receptor itself. Following the activation of the associated 
G protein via the exchange of GDP for GTP within the "-subunit, GPCR signaling can be 
terminated through GTP hydrolysis. This is mediated by accessory proteins such 
regulators of G protein signaling (RGS) enzymes. RGS proteins are multifunctional 
enzymes that facilitate GTP hydrolysis and act to turn off G protein dependent signaling 
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pathways (De Vries, Zheng, Fischer, Elenko, & Farquhar, 2000). While effective at 
deactivating G protein-mediated signaling, this process occurs rather slowly within a time 
frame of 50 seconds (Ross & Wilkie, 2000). Alternatively, the process of signal 
termination can occur directly through modification and recruitment of adaptor proteins 
to the GPCR. Receptors can be desensitized intracellularly by a G protein receptor kinase 
(GRK) dependent pathway or through the activities of second messenger-dependent 
kinases including protein kinase A (PKA) and protein kinase C (PKC) (Moore, Milano, 
& Benovic, 2007).  
Stimulation of GPCRs usually results in rapid phosphorylation on serine or 
threonine amino acid residues located within the third intracellular loop by GRKs 
(Krupnick, Goodman, Keen, & Benovic, 1997). Mammalian GRKs are subdivided into 
three groups: The first group is comprised of GRK1 and GRK7, the second GRK2 and 
GRK3 and the third GRK4, GRK5, and GRK6. Early studies identified that GRK2 
regulated agonist-promoted internalization of the M2 muscarinic acetylcholine (M2) 
receptor (Tsuga, Kameyama, Haga, Kurose, & Nagao, 1994). In particular, 
overexpression of GRK2 promoted internalization, whereas a catalytically inactive 
mutant of GRK2 did not. GRK-mediated phosphorylation occurs within a few seconds 
following receptor activation and provides a binding surface for the adaptor protein !-
arrestin, which is required to uncouple the receptor from the associated G protein 
(Gurevich et al., 1995; Lohse, Benovic, Codina, Caron, & Lefkowitz, 1990; Moore et al., 
2007). !-arrestins prevent further coupling to the associated G protein through steric 
hindrance and bridge the receptor to components of the internalization machinery (Lohse 
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et al., 1990). !-arrestins can promote signal termination either through degradation of 
second messengers (Perry et al., 2002) or internalization of the GPCR (Goodman et al., 
1996; Laporte et al., 1999).  This type of GRK and !-arrestin mediated desensitization is 
known as homologous desensitization (Figure 1.2).  
 Alternatively, GPCR signaling can be regulated by heterologous desensitization. 
In this process, activation of one receptor can lead to the activation of a different receptor 
through the activities of PKC or PKA. For example, CXCR4 contains many serines (Ser) 
that are potential PKC phosphorylation sites within its C-terminal tail. Stimulation with 
the phorbol ester phorbol-12-myristate-13-acetate (PMA) activates PKC and can promote 
the phosphorylation and internalization of CXCR4 (Haribabu et al., 1997; Signoret et al., 
1997; Signoret et al., 1998). Mutational analysis of serine residues within CXCR4 C-
terminal tail determined that internalization upon PMA treatment was dependent on upon 
either Ser 324 and Ser 325 or Ser 338 and Ser 339 (Signoret et al., 1998). In particular 
using a phospho-specific antibody, it was demonstrated that PMA treatment could 
mediate phosphorylation of Ser 339. However, the precise mechanism of PMA promoted 
CXCR4 phosphorylation and internalization remains to be explored. Overall, PKC 
regulation of CXCR4 phosphorylation is an important mechanism that regulates also 
CXCR4 plasma membrane expression. 
 Additional examples of GPCRs regulated by heterologous desensitization include 
the dopamine receptor (D3R) (Cho et al., 2007) and metabotropic glutamate receptor 4 
(mGluR4) (Mathiesen & Ramirez, 2006). The desensitization of D3R is mediated by a 
PKC dependent mechanism but independent of GRK/!-arrestin (Cho et al., 2007). In 
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particular, treatment with PMA induces PKC phosphorylation of Ser 229 and 257 in D3R 
leading to its downregulation. In the case of mGluR4, its desensitization is also 
dependent upon PMA activation of PKC (Mathiesen & Ramirez, 2006). Overall, both 
homologous as well as heterologous desensitization promote downregulation of GPCR 
signaling albeit by different mechanisms.  
 
Figure 1.2. GPCR homologous desensitization and internalization. (1) GPCRs under 
basal or resting conditions are associated with heterotrimeric Guanine nucleotide-binding 
proteins (G proteins) that are heterotrimers composed of " and !# heterodimer.  Under 
these conditions the associated "-subunit of the G protein is inactive and bound to GDP. 
(2) Following activation of the receptor upon binding to its cognate ligand, the GPCR 
undergoes a conformation change that leads to the exchange of GDP for GTP on the "-
subunit. This results in dissociation of the heterotrimeric G proteins into " and !# 
subunits, which are able to activate downstream signaling pathways through activation of 
a diverse array of effector molecules. (3) GPCR signaling is typically terminated through 
G protein receptor kinase (GRK) recruitment to the activated receptor leading to 
phosphorylation of serine or threonine residues within the C-terminal tail of the GPCR. 
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(4) Arrestin can bind to the phosphorylated receptor and acts to uncouple the receptor 
from the associated heterotrimeric G proteins through steric hindrance. This G protein 
uncoupling promotes receptor desensitization. (5) Desensitized receptors are internalized 
as a result of the interaction with Arrestin with components of the internalization 
machinery, clathrin and AP2. (6) Receptor is internalized via clathrin-coated pits. 
 
INTERNALIZATION 
One of the major pathways in which a GPCR internalizes is via clathrin-coated 
pits (CCPs) at the plasma membrane. Two important components of the internalization 
machinery include clathrin and clathrin-associated protein (AP) complexes (Figure 1.2) 
(Goodman et al., 1996). Clathrin relies upon adaptor and regulatory proteins to induce 
formation and invagination of CCPs. In particular, clathrin adaptor protein 2 (AP2) is 
recruited to the plasma membrane via the phospholipid PIP2. AP2 functions as an adaptor 
protein and can recognize tyrosine or dileucine-based motifs within the C-terminal tail of 
some GPCRs to facilitate entry into the forming CCP (as reviewed in Marchese, et al. 
2008). Non-visual arrestins (!-arrestin 1 and 2) can interact with both clathrin and AP2 to 
also link the GPCR into the forming CCP. Some of the first studies to demonstrate a role 
for !-arrestins in GPCR internalization came from studies of the !2 adrenergic receptor 
(!2 AR) (Ferguson et al., 1996; Goodman et al., 1996). It was demonstrated that !-
arrestins facilitate !2 AR internalization by binding with high affinity directly to clathrin 
(Goodman et al., 1996). In addition, it has been shown that !-arrestins through discrete 
elements in the C-terminal tail interact with both heavy chain of clathrin and !-subunit of 
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AP2 (Y. M. Kim & Benovic, 2002). This interaction of !-arrestins with the assembled 
CCP promotes recruitment of additional clathrin and clathrin adaptor proteins, 
culminating in the invagination and release of the CCP from the plasma membrane.  
Alternatively, ubiquitin modified GPCRs or those containing short linear peptide 
sequences can be recognized by alternative clathrin adaptors to mediate entry into CCPs. 
In addition to binding !-arrestins, AP2 can bind to receptor tyrosine or di-leucine motifs. 
For example, within its C-terminal tail CXCR2 contains two di-leucine motifs. When 
these motifs are mutated, CXCR2 can still bind !-arrestins, but is unable to bind AP2 and 
internalize (Fan, Yang, Wang, Qian, & Richmond, 2001). Thus in the case of CXCR2, !-
arrestins do not play a role in internalization. Furthermore, ubiquitin can have an indirect 
role in GPCR internalization via ubiquitination of !-arrestins. However, the 
internalization of most GPCRs does not require direct ubiquitination but instead relies 
upon !-arrestin dependent mechanisms (Kang, Tian, & Benovic, 2014). 
 
DOWNREGULATION 
Following internalization, GPCRs can be trafficked to early endocytic 
compartments where they are sorted for degradation in the lysosome or recycling via 
recycling endosomes (Figure 1.3). Ubiquitin modification of some GPCRs at the plasma 
membrane allows for entry into the degradation pathway on early endosomes. This 
ubiquitin dependent downregulation was first described for !2 AR (Shenoy, McDonald, 
Kohout, & Lefkowitz, 2001) and the chemokine receptor CXCR4 (Marchese & Benovic, 
2001). Upon agonist activation, B2AR was shown to be ubiquitinated, thereby, promoting 
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its degradation. CXCR4 downregulation is dependent on AIP4-mediated ubiquitination 
(Marchese, et al., 2003). Other GPCRs that require ubiquitin for their downregulation 
include PAR2, V2 vasopressin receptor (V2R), and the kappa-opioid receptor (KOR) 
(Cottrell et al., 2006; Jacob et al., 2005; N. P. Martin, Lefkowitz, & Shenoy, 2003). For 
these ubiquitin modified receptors, it is thought that ubiquitin acts as a sorting signal that 
allows for the receptor to be recognized by the ESCRT machinery on early endosomes 
and subsequently concentrated into the invaginating domain of the endosome that buds 
off to form multivesicular bodies (MVBs). These MVBs fuse with lysosomes leading to 
receptor degradation (Figure 1.3).  
Some GPCRs are not modified by ubiquitin upon agonist stimulation and, 
therefore, require additional factors for downregulation as is the case for PAR1. In fact, 
PAR1 is constitutively ubiquitinated at the plasma membrane and following agonist 
activation is deubiquitinated promoting its internalization. Once localized onto early 
endosomes, PAR1 is sorted on endosomes independent of endosomal sorting complex 
required for transport (ESCRT) machinery components ESCRT-0 (HRS) and ESCRT-I 
(Tsg101). Instead, the accessory proteins adaptor protein complex 3 (AP-3) and ALG-
interacting protein X (ALIX) are required. AP-3 binds to internalized PAR1 on 
endosomes and facilitates the interaction of PAR1 with ALIX. ALIX binds to the 
YPX(3)L motif of PAR1 (intracellular loop 2) and recruits ESCRT-III (Dores et al., 
2012).  Thus, ALIX mediates sorting of PAR1 into MVBs independent of ESCRT-0-II 
and receptor ubiquitination.  
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Figure 1.3. General model of GPCR endosomal trafficking. Activation of some 
GPCRs does not result in receptor ubiquitination (orange receptor). These receptors upon 
internalization localize to endosomes where they enter the recycling pathway allowing 
for further rounds of signaling at the plasma membrane. Conversely, some activated 
receptors (purple receptor) can be modified at the plasma membrane by ubiquitin (Ub) 
prior to internalization. Internalized receptors localize to the endosome where the 
ubiquitin modified receptor can be sorted to either degradation or recycling pathways 
upon deubiquitination by an endosomally associated deubiquitinase (DUB).  
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RECYCLIING 
Internalized GPCRs can also be trafficked to early endocytic compartment where 
they are sorted for recycling via recycling endosomes. Some ubiquitinated receptors can 
have ubiquitin removed by deubiquitinating enzymes (DUBs) (Figure 1.3). These 
receptors can traffic back to the plasma membrane by recycling endosomes. 
Alternatively, GPCRs that are not ubiquitinated prior to internalization and localization to 
endosomes directly enter the recycling pathway and are returned to the plasma membrane 
to elicit further signaling. 
 
THE UBIQUITIN PATHWAY 
Post-translational modification of protein substrates by ubiquitin dictates the 
cellular fate of the protein. For example, ubiquitin modification of GPCRs plays a major 
role in membrane trafficking process on endosomes. In addition, ubiquitin modification 
of adaptors can regulate signaling downstream of receptors.  This section will focus on 
the ubiquitin pathway and the factors necessary to mediate ubiquitin modification of 
protein substrates. 
 
UBIQUITIN CONJUGATION 
Ubiquitin is a 76 amino acid protein that becomes covalently attached to protein 
substrates through the formation of an isopeptide bond between the C-terminus of 
ubiquitin and the lysine residues on target substrates. Specifically, the epsilon amino 
group of a lysine residue within the protein substrate becomes covalently attached to the 
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C-terminal glycine residue (Gly-76) of ubiquitin. Ubiquitin conjugation of proteins is 
carried out by an enzymatic cascade involving the sequential activity of three enzymes: 
E1, E2 and E3 (Fang & Weissman, 2004; Pickart, 2001). In this process, ubiquitin is first 
activated in an ATP-dependent manner by the E1-activating enzyme (Figure 1.4). The E1 
enzyme forms a thioester bond with activated ubiquitin, which is then transferred to the 
active site cysteine of the E2-conjugating enzyme. The E2 enzyme helps link E1 
activation of ubiquitin to final E3 covalent modification of protein substrates. Final 
substrate ubiquitination is mediated by the E3 ligase that recruits and binds specific 
substrates.  
 
Figure 1.4. The Ubiquitin Pathway. Ubiquitin conjugation to protein substrates is 
dependent upon the activities three enzymes: E1, E2 and E3. The E1 activating enzyme 
activates ubiquitin in an ATP-dependent fashion leading to the formation of a thioester 
bond between activated ubiquitin to the active site cysteine (Cys) in the E1 enzymes. The 
E2 conjugating enzyme accepts the activated ubiquitin forming a thioester linkage 
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between ubiquitin and the active site Cys in the E2 enzyme. Final substrate ubiquitination 
is mediated by the activities of one of two classes of E3 ubiquitin ligases. HECT domain 
E3 ligases accept ubiquitin from the E2 enzyme and lead to direct ubiquitination of the 
protein substrate. In contrast, RING  and RING-like domain E3 ligases facilitate indirect 
ubiquitination of protein substrates by bridging the E2 enzyme in proximity to the 
substrate. Ultimately, this process leads to the covalent attachment of C-terminal glycine 
reside in ubiquitin to epsilon amino group of a lysine residue within the substrate. 
Substrates can either be modified by one ubiquitin (monoubiquitination) or subject to 
modification with multiple ubiquitin molecules (polyubiquitination). 
 
TYPES OF UBIQUTIN MODIFICATION 
Ubiquitin modification of substrates can have multiple outcomes depending on 
the type of ubiquitin modification. There are several types of ubiquitin modifications that 
have been identified. The particular type of ubiquitin modification, monoubiquitination 
versus polyubiquitination, of a substrate will dictate its cellular function. 
Monoubiquitination or multi-mono ubiquitination have been implicated in receptor 
internalization and trafficking (Haglund, Di Fiore, & Dikic, 2003; Polo et al., 2002). 
Ubiquitin itself can act as an acceptor of additional ubiquitin molecules. Within its 
structure ubiquitin has seven lysine residues (K6, K11, K27, K29, K33, Lys 48 and K63) 
that can all be linked to ubiquitin to form poly-ubiquitin chains.  
The most common types of poly-ubiquitin chains are those formed by linkages at 
K48 and K63 (Rotin & Kumar, 2009). K48, as well as K29, linkages have been 
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demonstrated to promote proteolysis of misfolded or damaged substrates mediated by the 
26 S proteasome. K48 poly-ubiquitin chains are recognized by the ubiquitin interacting 
motif (UIM) of proteasomal receptor S5a/Rpn1 (Pickart, 2000; Sparks et al., 2014). 
Overexpression of a dominant negative form of S5a/Rpn1 lacking it UIMs or siRNA 
depletion of RS5a/Rpn1 inhibits proteasomal degradation and stabilization of tumor 
suppressor protein p53 (Sparks et al., 2014). The ubiquitin-associated domain (UBA) 
containing protein Rad23 binds to K48 chains, thereby, inhibiting their interaction with 
the 26 s proteasome and proteolysis. This demonstrates that ubiquitin binding domains 
can both positively and negatively regulate the fate of ubiquitinated proteins (Raasi & 
Pickart, 2003).  
In contrast to K48 linkages, K63 poly-ubiquitin chains play a major role in post-
endocytic sorting and localization of substrates for degradation in lysosomes 
(Erpapazoglou et al., 2012; Lauwers, Jacob, & Andre, 2009). In particular, K63 chains 
have been linked to MVB biogenesis and UBD containing proteins such as the ESCRT-0 
complex recognize K63-modified receptors on endosomes (Erpapazoglou et al., 2012). It 
has also been suggested that the ESCRT-0 complex itself can be modified by K63 
ubiquitination to modulate receptor sorting (Erpapazoglou et al., 2012).  
The less common or atypical poly-ubiquitin linkages have been shown to function 
in several cellular pathways. The function of K6 and K11 poly-ubiquitin chains has been 
implicated in neurodegenerative disorders (Cripps et al., 2006). For example, loss of the 
E3 ligase Mahogunin ringer finger-1 (MGRN1) has been implicated in spongiform 
neurodegeneration. It has been shown that the auto-catalytic activity of the E3 ligase 
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BRCA1 is dependent upon K6 to promote BRCA functioning with the E3 ligase BARD1 
(Wu-Baer, Lagrazon, Yuan, & Baer, 2003). Additionally, K11 poly-ubiquitination plays a 
major role in endoplasmic reticulum-associated degradation (ERAD) pathway (Xu, P et 
al., 2009). K27 and K33 poly-ubiquitin chains have been identified in vitro, however, 
until recently the physiological function of atypical poly-ubiquitin chains linked to K27 
and K33 have started to be demonstrated (Birsa et al., 2014; David et al., 2010; Yuan et 
al., 2014). Recently, it has been shown that K27 poly-ubiquitination of the outer 
mitochondrial membrane protein Miro1 is dependent upon the E3 ligase Parkin following 
mitochondrial damage in human dopaminergic neuroblastoma cells (Birsa et al., 2014). 
Dysregulation of this K27 ubiquitination may play a role in the pathogenesis of 
Parkinson’s disease. K33 poly-ubiquitin chains have been implicated in trans-Golgi 
network (TGN) trafficking (Yuan et al., 2014). The ubiquitin ligase Cul30KLHL20 
mediates K33 poly-ubiquitination of coronin 7 that is essential for the biogenesis of 
transport carriers derived from the TGN. Future studies are needed to further shed light 
on the role of these atypical poly-ubiquitin chains in the regulation of other cellular 
processes including GPCR trafficking. 
 Importantly, it has been shown that HECT-(Homologous to the E6-AP Carboxyl 
Terminus) domain E3 ligases directly contribute to the type of chain linkage formed 
through its interactions with the E2 enzyme whereas for RING (Really Interesting New 
Gene) domain ligases the E2 determines the chain linkage (Christensen, Brzovic, & 
Klevit, 2007; H. C. Kim & Huibregtse, 2009; Li, Tu, Brunger, & Ye, 2007; Schwarz, 
Rosa, & Scheffner, 1998). For example, the HECT domain of E6AP preferentially 
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catalyzes K48 poly-ubiquitin chains whereas other HECT ligases such as Rsp5/Itch 
catalyze K63 poly-ubiquitin chains. The type of E2 does not, however, determine chain 
specificity given that Rsp5 created similar K63 poly-ubiquitin linkages regardless of the 
E2 (Ubc1, Ubc5 and Ubc4). Furthermore, a chimera protein of Rsp5 swapped with the C 
lobe of E6AP conferred Rsp5 the ability to form K48 poly-ubiquitin chains typified by 
the HECT domain of E6AP. Replacement of the C lobe of Itch/AIP4 with that of E6AP 
conferred Itch/AIP4 with the ability to form K48 poly-ubiquitin chain formation 
(Huibregtse, Scheffner, Beaudenon, & Howley, 1995). Thus, the particular type of E3 
ubiquitin ligase as well as E2 conjugating enzyme have a major role in dictating the 
ubiquitin modification of substrates. 
 
E3 UBIQUITIN LIGASES 
E3 ligases represent a diverse family of over 600 identified proteins in the 
mammalian genome (Metzger, Hristova, & Weissman, 2012; Metzger & Weissman, 
2010). Given the vast number of E3 ubiquitin ligases able to interact with discrete 
substrates, E3s often provide a level of specificity to the ubiquitin reaction. E3s are 
generally distinguished by whether they enable indirect or direct modification of protein 
substrates. E3 ligases are divided into two classes: HECT ligases that facilitate direct 
ubiquitination of substrates or ligases that act as scaffolds including RING and RING-like 
F-box domain ligases (Deshaies & Joazeiro, 2009; Metzger et al., 2012). Over 95% of 
mammalian E3 ligases belong to the RING or RING-like domain family and 
approximately 30 ligases belong to the HECT domain family (Metzger et al., 2012).  Of 
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the 95% of RING domain ligases, the RING-like family of F-box containing ligases 
comprise eight members (Petroski & Deshaies, 2005). 
 
RING AND RING-LIKE DOMAIN CONTAINING LIGASES 
RING-domain or RING-like domain containing E3s act as scaffolds in the 
ubiquitination reaction, thereby, facilitating the indirect transfer of ubiquitin from the 
bound E2 enzyme to the protein substrate. Thus, RING domain and RING-like E3s lack 
intrinsic catalytic activity and instead act as adaptors. The RING domain motif is 
characterized by a specific sequence of evenly spaced Cysteines and Histidines residues 
that are able to coordinate two zinc ions in a crossbrace fashion (Metzger et al., 2012). 
This enables E2 binding and E2-mediated ubiquitination of substrates.  
The crystal structure of the RING domain of c-Cbl in complex with the E2 
enzyme UbcH7 and substrate (a ZAP70 kinase peptide) highlights the typical features of 
a RING domain in mediating indirect transfer of ubiquitin (Zheng, Wang, Jeffrey, & 
Pavletich, 2000).  These studies reveal that three-stranded Beta sheets, an alpha helix and 
two large loops form the structure of the RING domain, which is stabilized by two zinc 
ions. UbcH7 binds the RING domain of c-Cbl and is separated by ~60 A from the 
substrate also bound to the RING domain. Moreover, the specificity of the E2 enzyme for 
c-Cbl RING domain lies between the interaction of Phe63 of UbcH7 and Trp408/Ile383 
of c-Cbl RING domain. Interestingly, comparing RING domain of c-Cbl to the crystal 
structure of the HECT domain of E6AP bound to UbcH7 reveals a common structural 
theme between E2 binding to HECT or RING domains even though both are distinct in 
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their structures (Huang et al., 1999). The crystal structures of the dimeric RING-like 
domain ligases such as the U-box ligase CHIP display a similar interaction with the yeast 
E2 Ubc13 and mammalian E2 UbcH5a (Xu et al., 2008; Zhang et al., 2005). UbcH5a 
binds to the CHIP hydrophobic groove that includes Phe62 whereas Ubc13 binds to 
CHIP via Met 64, a residue homologous to Ph63. This suggest that cognate E2s for their 
E3s depends solely on the structural contacts made between the E2 and E3, not the type 
of E3 domain.  
 
HECT-DOMAIN LIGASES 
HECT-domain ligases all possess a highly conserved ~350 amino acid C-terminal 
HECT domain that directly accepts ubiquitin within a conserved cysteine residue and 
facilitates substrate ubiquitination directly. The HECT domain is a bilobal domain 
divided into an N and C Lobe linked by a broad catalytic cleft (Huang et al., 1999). The 
N-lobe is where E2 enzyme binding occurs while the C lobe contains the catalytic 
cysteine residue that forms the thioester linkages with ubiquitin. The two lobes are linked 
by a flexible hinge region that is crucial for E2 transfer of ubiquitin chains to the HECT 
domain catalytic cysteine (Huang et al., 1999; Verdecia et al., 2003). HECT domain 
ligases have been shown to interact with E2 enzymes UbcH5, UbcH7 and UbcH8 (S. 
Kumar, Kao, & Howley, 1997; Nuber, Schwarz, Kaiser, Schneider, & Scheffner, 1996; 
Schwarz et al., 1998). This structure is well demonstrated for HECT domain ligase E6AP 
and UbcH7 (Huang et al., 1999). Phenylalanine 63 of UbcH7 is bound to E6AP on a 
hydrophobic groove within the N lobe region. This brings UbcH7 into close proximity to 
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the active site cysteine within the C-lobe of E6AP. The distance between the active site 
cysteine of the HECT domain and UbcH7 is 41 A. Other HECT domain ligases are 
thought to display a similar structure to E6AP. 
Although HECT ligases are highly homologous in their HECT domain, these 
ligases differ in their N-terminal regions. The binding of substrates occurs in regions 
outside of the HECT domain. HECT ligases are subdivided into three families: HERC, 
Nedd4 and other HECTs (Rotin & Kumar, 2009). The HERC family of HECT ligases is 
distinguished by the presence of regulator of chromosome condensation 1 (RCC1)-like 
domains (RLDs). RLDs can interact with chromatin and may be a Guanine nucleotide 
exchange factor (GEF) the GTPase Ran (Garcia-Gonzalo & Rosa, 2005; Rosa, Casaroli-
Marano, Buckler, Vilaro, & Barbacid, 1996). Nedd4 family members contain two to four 
tandemly linked WW domains able to interact with proline-rich sequences and an N-
terminal calcium-dependent phospholipid-binding domain. Other HECT ligases contain 
only HECT domains or various unique domains. For example, E6AP contains only a 
HECT domain whereas HACE1 (HECT domain and Ankyrin repeat Containing E3 
ubiquitin-protein ligase 1) contains ankyrin repeats in addition to the HECT domain 
(Anglesio et al., 2004; Rotin & Kumar, 2009). 
 
HECT DOMAIN LIGASES IN GPCR TRAFFICKING 
Nedd4 HECT ligases have been implicated in the regulation of plasma membrane 
receptor trafficking (Marchese, Raiborg, et al., 2003; Rotin & Kumar, 2009; Shenoy et 
al., 2008). The Nedd4 family comprises nine mammalian members: Nedd4, Nedd4L, 
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AIP4 (Itch), WWP1, WWP2, SMURF1, SMURF2, NEDL1 and NEDL2. The Nedd4 
ortholog in yeast, Rsp5, was the first Nedd4-related ligase shown to mediate endocytosis 
of a receptor (Belgareh-Touze et al., 2008; Dunn & Hicke, 2001). Following agonist 
activation by alpha-mating factor, it was shown that Ste2p receptor was rapidly 
ubiquitinated by Rsp5. Rsp5 mediates monoubiquitination of Ste2p receptor which 
promotes receptor endocytosis and recognition by UIM containing endocytic adaptors 
epsin and Eps15 (Dupre, Urban-Grimal, & Haguenauer-Tsapis, 2004; Terrell, Shih, 
Dunn, & Hicke, 1998). In mammalian cells, atrophin-interacting protein 4 (AIP4) has 
been shown to mediate ubiquitin dependent downregulation of CXCR4 (Marchese, 
Raiborg, et al., 2003). Additionally, downregulation and desensitization of B2AR 
signaling is dependent on Nedd4-mediated receptor ubiquitination (Shenoy et al., 2001). 
 
ATROPHIN-INTERACTING PROTEIN 4 (AIP4) 
AIP4 was among the first ubiquitin ligases shown to be involved in agonist-
promoted ubiquitination of a mammalian GPCR (Marchese, Raiborg, et al., 2003). AIP4 
belongs to the NEDD4-family of HECT ligases. This ligase contains four tandemly 
linked WW domains, N-terminal calcium-dependent phospholipid-binding domain and a 
conserved carboxyl-terminal HECT domain (Figure 1.5A) (Rotin & Kumar, 2009). A 
unique feature of AIP4 is that is has a proline-rich region (PRR) that binds a subset of 
Src-homology-3 (SH3) domains. Studies have demonstrated that AIP4 can mediate 
substrate ubiquitination through the interaction of the HECT domain with UbcH5 and 
UbcH7 families of E2 enzymes (H. C. Kim & Huibregtse, 2009; Schwarz et al., 1998; 
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Scialpi et al., 2008; Wenzel, Stoll, & Klevit, 2011). Interestingly, AIP4 has been shown 
to interact with other E3 ligases such as Cbl-c, deltex-1 (DTX1) and RNF11. These three 
ligases all belong to the RING domain family of E3 ligases.  
The Cbl family of proteins consists of 3 related proteins: c-Cbl, Cbl-b and Cbl-c 
(Fig 1.5B with domain structure). Unlike c-Cbl and Cbl-b which are ubiquitously 
expressed, the expression of Cbl-c is documented as restricted to epithelial cells (Schmidt 
& Dikic, 2005). These proteins all contain within their structure an N-terminal tyrosine 
kinase binding domain (TKB) that mediates interactions with phospho-tyrosine modified 
proteins, a RING E3 ligase domain that leads to substrate ubiquitination and a proline 
rich region (PRR).  In contrast to c-Cbl and Cbl-b, Cbl-c lacks the C-terminal ubiquitin-
binding domain known as an ubiquitin-associated leucine zipper (UBA). The Cbl family 
of ligases has been implicated in the downregulation of epidermal growth factor receptor 
(EGFR) signaling (Courbard et al., 2002; Ettenberg et al., 1999; Levkowitz et al., 1999; 
Levkowitz et al., 1998). Using a yeast two-hybrid screen it was identified that Cbl-c 
interacts with AIP4 (Courbard et al., 2002). In this study, Cbl-c and AIP4 were shown to 
co-localize in cells upon EGF stimulation, however, the identity of the subcellular 
compartment where there interaction occurs was not demonstrated. Although is can be 
speculated that both proteins are localized to microdomains on early endosomes where 
EGFR is sorted for degradation. Biochemical assays demonstrated that the interaction 
between Cbl-c and AIP4 is mediated through the proline rich region of Cbl-c and the 
WW domains of AIP4. Furthermore, it was shown that AIP4 and Cbl-c act synergistically 
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to downregulate EGFR signaling, although the mechanism by which this occurs remains 
unknown. 
AIP4 interacts directly with DTX1 on endosomes to target DTX1 for degradation 
in lysosomes, modulating its cellular activity (Chastagner, Israel, & Brou, 2006). The 
ortholog of AIP4 in Drosophila (Supressor of Deltex (Su(Dx)), acts as a negative 
regulator of activated Notch signaling and antagonizes the activity of Deltex by 
promoting post-endocytic sorting and degradation of Notch (Mazaleyrat et al., 2003). In 
mammalian cells, it was demonstrated that AIP4 interacts with DTX1 on endosomes 
where is mediates K29 poly-ubiquitination of DTX1 targeting it for degradation in 
lysosomes. These studies conclude that AIP4 antagonizes the cellular function of DTX by 
promoting K29-dependent degradation of DTX in mammalian cells (Chastagner et al., 
2006).  
Another AIP4-interacting RING ligase is RNF11. RNF11 is overexpressed in 
several mammalian breast tumors and has been shown to interact with several HECT-
domain containing ligases including AIP4, Smurf1 and Smurf2 (Kitching et al., 2003). 
However, the role of these ligase interactions physiologically remains to be defined. 
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Figure 1.5. Domain structure of AIP4, Cbl family and DTX family protein 
structure. A. AIP4 domain structure consists of a N-terminal C2 phospholipid binding 
domain, a central proline rich region (PRR), four tandemly linked WW domains and the 
C-terminal HECT E3 ligase domain. B. The Cbl family proteins of ubiquitin ligases are 
comprised of three members: c-Cbl, Cbl-b and Cbl-c. All three proteins consist of a 
Tyrosine Kinase Binding domain (TKB), which interacts with specific phospho-
tyrosines on substrates, RING ligase domain that mediates substrate ubiquitination and 
PRR. Both c-Cbl and Cbl-b also possess a C-terminal ubiquitin-associated leucine zipper 
(UBA) domain whereas Cbl-c lacks the N-terminal UBA domain. These proteins play 
major roles in the regulation of tyrosine kinase signaling pathways through the activities 
of their TKB domain. C. The deltex (DTX) family of ubiquitin ligases is comprised of 
three closely related proteins (DTX1-3) in addition to the distantly related protein known 
DTX3L. DTX ubiquitin ligases have a highly conserved carboxyl-terminal RING 
domain and members of the DTX family of proteins were first identified for their role in 
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Notch signaling. DTX1 and DTX2 contain a basic N-terminal region that binds to 
intracellular Notch ankyrin repeats in addition to a  central PRR and. In contrast, DTX3 
and DTX3L contain a unique N-terminus and lack the central proline-rich region; 
however, DTX3 and DTX3L are highly homologous to the other DTX family proteins 
within the C terminal RING domain. 
 
DELTEX-3-LIKE (DTX3L) 
The DTX family of ubiquitin ligases comprises three closely related proteins 
(DTX1-3) and a distantly related DTX3-like (DTX3L) (Figure 1.5C). DTX proteins were 
first identified to be regulators of Notch signaling (Kishi et al., 2001). DTX proteins form 
a family based on the highly homologous C-terminal RING domain. DTX1 and DTX2 
possess two tandem N-terminal WWE domains that bind to Notch ankyrin repeats 
whereas the N-terminus of DTX3 and DTX3L lack these WWE domains (Matsuno, 
Diederich, Go, Blaumueller, & Artavanis-Tsakonas, 1995; Takeyama et al., 2003). In 
contrast to other DTX members, DTX3L contains an unique N-terminus and lacks the 
central proline-rich region, however, DTX3L is highly homologous to the other DTX 
family proteins within the C terminal RING domain (Takeyama et al., 2003). As 
described above, RING domain ligases bind to E2 enzymes acting as scaffolds to 
facilitate indirect transfer of ubiquitin to substrates. In particular, DTX3L has been shown 
to specifically interact with the UbcH5 family of E2 enzymes to mediate substrate 
ubiquitination, but not UbcH4, UbcH6 or UbcH7. Additionally, DTX3L has been shown 
to heterodimerize with DTX1 leading to enhanced DTX1 activity (Takeyama et al., 
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2003). This interaction is mediated through the unique N-terminal region of DTX3L. The 
relevance of this interaction and whether DTX3L interacts with other E3 ubiquitin ligases 
remains to be explored. 
 
E2 CONJUGATING ENZYMES 
In the human genome there are nearly 40 identified E2 enzymes (Metzger et al., 
2012). The E2 enzymes contain a conserved ubiquitin-conjugating (UBC) domain of 
~160 amino acids that has the catalytic cysteine residue able to form a thioester with 
activated ubiquitin. Recent data on the trafficking of EGFR, a receptor tyrosine kinase 
(RTK), suggest that the E2 enzymes UbcH5b/c (also known as Ubc4/5) in conjunction 
with the E3 ligase c-Cbl is required for degradation and ubiquitination of EGFR 
(Umebayashi, Stenmark, & Yoshimori, 2008). Immunofluorescence studies demonstrated 
that of the E2 enzymes screened (Ubc2, Ubc3, Ubc4, UbcH5a, UbcH5b, UbcH5c, 
UbcH6, UbcH8 and UbcH13), UbcH5b and UbcH5c were the only E2 enzymes to co-
localize with c-Cbl at the plasma membrane as well as the early endosomes following 
EGF stimulation. Furthermore, siRNA-mediated knockdown of UbcH5b/c, but not 
UbcH7, prevented EGF promoted ubiquitination of EGFR (Umebayashi et al., 2008). 
These data highlight the potential importance of specific subsets of E2 enzymes through 
their activities with respective E3s ligases in the regulation of receptor trafficking. While 
it is intriguing that subsets of E2s may regulate RTK ubiquitination and trafficking, 
whether this idea applies directly or indirectly to GPCR trafficking remains to be 
investigated. 
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DEUBIQUITINATING ENZYMES (DUBs) 
Modification of protein substrate with ubiquitin is usually transient and reversible 
by ubiquitin specific proteases  (USPs) or deubiquitinating enzymes (DUBs). DUBs 
mediate cleavage of the isopeptide bond between Ub and its substrates through protease 
activity.  Several studies have identified important DUBs in regulating GPCR trafficking. 
A role for DUBs in GPCR trafficking was first defined in yeast. The deubiquitinating 
enzyme Doa4 was found to localize to the pre-vacuolar compartment where it has a role 
in recycling ubiquitin from cargos destined for degradation in the vacuole (Amerik, 
Nowak, Swaminathan, & Hochstrasser, 2000). 
 In mammals, DUBs and USPs modulate the trafficking of several GPCRs. The 
DUB AMSH has been shown to interact with and regulate ESCRT-0. In particular, both 
AMSH and USP8 have been shown to regulate the ubiquitination and degradation of the 
GPCRs protease activated receptor 2 (PAR2) and delta-opioid receptor (DOR) 
(Hasdemir, Murphy, Cottrell, & Bunnett, 2009; Hislop, Henry, Marchese, & von 
Zastrow, 2009). Depletion of either AMSH or USP8 using siRNA prevented PAR2 
ubiquitin dependent degradation, trapping the receptor in early endosomes (Hasdemir et 
al., 2009). DOR downregulation is also dependent upon deubiquitination activities of 
AMSH and USP8. Overexpression of catalytically inactive mutants of either enzyme 
prevented WT DOR downregulation, whereas downregulation of lysine-less mutant of 
DOR still downregulated in the presence of mutant AMSH and USP8 (Hislop et al., 
2009). 
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USP8 and AMSH indirectly promote CXCR4 sorting by antagonizing the ubiquitin 
modification of ESCRT-0 mediated by the E3 ligase AIP4 (Berlin, Higginbotham, Dise, 
Sierra, & Nash, 2010). Unlike PAR2, both USP8 and AMSH do not regulate 
deubiquitination of CXCR4 itself. Instead, the DUB USP14 has been implicated as a 
direct regulator of CXCR4 ubiquitination (Mines, Goodwin, Limbird, Cui, & Fan, 2009). 
Upon CXCL12 stimulation, USP14 associates with CXCR4 to promote deubiquitination. 
Depletion of USP14 by siRNA or overexpression of USP14 prevented CXCR4 
ubiquitination, thereby, blocking receptor degradation. 
USP8 has recently been shown to control the sorting of lysosomal enzymes necessary 
for lysosomal degradation (MacDonald, Urbe, & Clague, 2014). Lysosomal 
enzymes/hydrolases are sorted away from the Trans-Golgi network to the endocytic 
pathway and are ultimately delivered to the lysosome. Ultimately, delivery of acidic 
hydrolases to the pre-lysosomal compartment allows for degradation of receptors 
delivered to the lysosome. Thus, USP8 plays a role in both sorting at the endosome as 
well as delivery of enzymes to the degradative lysosomal compartment.  
 The highly related DUBs USP20 and USP33 have been implicated as regulators 
of !2AR recycling. Downregulation and desensitization of !2AR is dependent upon 
receptor ubiquitination by Nedd4. On early endosomes, deubiquitination of !2AR by 
USP20 and USP33 promotes receptor recycling (Berthouze, Venkataramanan, Li, & 
Shenoy, 2009). This results in resensitization of receptor signaling at the plasma 
membrane. Altogether the balance of ubiquitination versus deubiquitination in GPCR 
trafficking is important in controlling the magnitude and duration of receptor signaling. 
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FUNCTIONAL ROLE OF GPCR UBIQUITINATION 
GPCR trafficking and endocytosis is also controlled by covalent modification of 
lysine residues within the receptor or adaptor proteins by ubiquitin. Ubiquitination of 
GPCRs regulates cell surface expression and, thus, the level of signaling. The ubiquitin 
moiety can act as a sorting signal that promotes trafficking of the receptor at the 
endosomal compartment. Ubiquitin modification of GPCRs can occur constitutively or be 
promoted by agonist stimulation. Typically, agonist dependent ubiquitination of GPCRs 
occurs at the plasma membrane as is the case for the chemokine receptor CXCR4. 
Although this ubiquitin-dependent trafficking is not exclusive to all GPCRs. Some 
GPCRs themselves are not modified by ubiquitin, however, their endocytic sorting is 
dependent upon additional factors. Proteins can also possess ubiquitin recognition motifs 
that can bind ubiquitinated substrates. In particular, ubiquitination of plasma membrane 
receptors can dictate endocytic sorting via interactions of ubiquitin with endocytic sorting 
machinery. At the endosome the receptor can be recognized by a number of ubiquitin 
interacting proteins that possess ubiquitin binding domains (UBDs) or ubiquitin 
interacting motifs (UIMs). Overall, ubiquitin regulation of GPCRs can have pleiotropic 
effects. 
 
UBIQUITIN IN ESCRT-DEPENDENT SORTING 
Ubiquitinated receptors are targeted at the endosome into forming MVBs by the 
endosomal sorting complex required for transport (ESCRT) machinery, which comprise 
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four conserved protein complexes  (ESCRT0-III) (Table 1.1). The ESCRTs together with 
the AAA-ATPase Vsp4 complex and other accessory proteins act in a concerted fashion 
to recognize and concentrate the ubiquitinated receptor into the invaginating membrane 
of the endosome and facilitate formation of intraluminal vesicles of MVBs (Hurley, 
2008; Marchese, Paing, Temple, & Trejo, 2008; Williams & Urbe, 2007). Thus, ESCRT 
proteins not only concentrate receptors into the invaginating membrane of the endosome, 
but also facilitate the formation of the MVB. MVBs fuse with highly acidic lysosomes 
leading to receptor degradation and, hence, desensitization of receptor signaling.  
The ESCRT proteins were first identified in yeast Saccharomyces cerevisiae as 
class E genes of vacuolar protein sorting (Vps) that associate with endosomes. These 
studies employed indirect immunofluorescence microscopy in which the vacuole was 
indirectly visualized by antibodies against either the vacuolar integral membrane protein, 
ALP, or the subunit of the vacuolar H+-ATPase, V-ATPase (Raymond, Howald-
Stevenson, Vater, & Stevens, 1992). It was demonstrated that class E Vps mutants change 
the morphology of the yeast vacuole (the equivalent of the mammalian lysosome) and 
result in the accumulation of cargoes (i.e. A-ALP and CPY; Ste3p) to a pre-vacuolar 
organelle. This accumulation of cargo in these mutants was attributed to defects in the 
delivery cargo from the limiting membrane of the vacuole to the lumen for degradation 
(Piper, Cooper, Yang, & Stevens, 1995; Raymond et al., 1992).  
Further studies in mammalian cells demonstrated that the ESCRT machinery is 
highly conserved. In mammalian cells, ESCRT comprises four multimeric protein 
complexes (ESCRT-0 – III) in addition to activities of AAA-ATPase-Vps4 (Table 1.1). 
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ESCRT complexes are recruited sequentially to the endosome membrane to mediate 
cargo targeting into the limiting membrane of endosomes leading to the generation of 
ILVs that comprise the MVB.  Three of the four ESCRT complexes (ESCRT-0-II) 
contain UBDs that recognize/interact with the surface of ubiquitin on cargo to facilitate 
sorting into the ILVs of MVBs. UBD containing proteins can be ubiquitinated themselves 
and disruption of individual ESCRT-UBDs results in defective sorting of certain cargoes 
into the MVBs. It is thought that ubiquitin supports ESCRT function by mediating 
changes in the intramolecular interactions between ESCRT proteins or facilitates cargo 
release by changing intramolecular interactions between UBDs and Ubiquitin on cargo. 
 
Table 1.1 Proteins in the ESCRT pathway 
Complex Mammalian 
Protein 
Yeast Protein Domains 
ESCRT-0 HRS 
STAM-1, STAM-2 
Vps27 
Hse1 
FYVE, UIM, VHS, PSAP 
UIM, SH3, VHS 
ESCRT-I Tsg101 
Vps28 
Vps37A, B, C, D 
MVB12A, B 
UBAP1 
Vps23 
Vps28 
Vps37 
Mvb12 
UEV 
 
Coiled-coil 
 
SOUBA 
ESCRT-II EAP30 
EAP25 
EAP45 
Vps22 
Vps25 
Vps36 
Coiled-coil, WH 
PPXY, WH 
GLUE, NZF, WH 
ESCRT-II CHMP2A, B 
CHMP6 
CHMP3 
CHMP4A, B, C 
CHMP5 
CHMP1A,B 
Vps2 
Vsp20 
Vps24 
Vps32/Snf 
Vps60 
Did2 
Coiled-coil 
Coiled-coil 
Coiled-coil, MIR 
Coiled-coil 
Coiled-coil 
Coiled-coil 
Accessory 
Proteins 
ALIX 
VPS4A, B 
LIP5 
IST1 
Bro1 
Vps4 
Vta1 
Ist1 
Bro1 
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RECOGNITION 
ESCRT-0, composed of HRS and STAM-1/STAM-2, initially recognize 
ubiquitinated cargo at the endosome. HRS and STAM exist as a 1:1 complex on 
endosomes through the association of their coiled coil region, however, HRS and STAM 
may also form a heterotetrameric complex (Mayers et al., 2011). Localization of ESCRT-
0 to endosomes is mediated in part through selective binding of the FYVE (Fab1, YOTB, 
Vac1 and early endosome antigen-1) domain in HRS to phosphatidylinositol 3-phosphate 
(PI-3P), an endosomally enriched phospholipid (Raiborg et al., 2001; Stenmark, Aasland, 
& Driscoll, 2002). In addition, HRS and STAM-1/STAM-2 both contain ubiquitin 
binding domains (UBDs) (Bilodeau, Urbanowski, Winistorfer, & Piper, 2002; Henne, 
Buchkovich, & Emr, 2011; Prag et al., 2007; Raiborg et al., 2002; Ren & Hurley, 2010) 
able to interact with several ubiquitin moieties at once (Mayers et al., 2011). In particular, 
the ubiquitin interacting motif (UIM) of HRS interacts with and recruits ubiquitinated 
cargo to be sorted on the endosome (Stringer & Piper, 2011). In addition to interacting 
with ubiquitinated cargoes, HRS can bind to internalized cargo on endosomes contained 
in clathrin coated pits via an interaction of clathrin with the clathrin binding box motif 
(Leu-Ile-Ser-Phe-Asp) within the C-terminus of HRS. The UIM of STAM also 
recogonizes ubiquitinated cargo by binding to both monoubiquitin and polyubiquitin 
chains. Furthermore, the proline rich (PSAP) motif in HRS acts to recruit and link 
ESCRT-0 to ESCRT-I through binding to the UEV (ubiquitin E2 variant) domain in the 
ESCRT-I subunit Tsg101 (Pornillos et al., 2002; Ren & Hurley, 2011). Together HRS 
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and STAM bind to ubiquitinated cargo and initiate the sorting of proteins at the 
endosome. 
 
SORTING 
Following binding and recognition of cargo on endosomes, ESCRT-0 then 
recruits ESCRT-I via binding of the PSAP motif in HRS to the UEV domain in Tsg101 
(Katzmann, Babst, & Emr, 2001). In mammalian cells, ESCRT-I can comprise several 
subunits including Tsg101, VPS28, VPS37A-D and the recently identified UBAP1 
(Agromayor et al., 2012; Chu, Sun, Saksena, & Emr, 2006; Morita et al., 2007; Stefani et 
al., 2011; Tsunematsu et al., 2010). In addition to interacting with HRS, the UEV domain 
of Tsg101 is involved in the further sorting and recognition of ubiquitinated cargo 
(Stuchell et al., 2004). Together with Vps28, Tsg101 recruits ESCRT-II to the endosome. 
In mammalian cells, ESCRT-II is composed of EAP30, EAP25 and EAP45. These 
proteins all contain protein-protein interacting winged-helix (WH) domains. In particular, 
the WH domain of the ESCRT-II subunit EAP25 acts to recruit ESCRT-III to the 
endosome (Babst, Katzmann, Snyder, Wendland, & Emr, 2002; Teo, Perisic, Gonzalez, 
& Williams, 2004). The subunit EAP45 possesses a Gram-like ubiquitin-binding in 
EAP45 (GLUE) domain able to interact with ubiquitin in addition to endosomally 
enriched phosphoinositides (Hirano et al., 2006; Slagsvold et al., 2005).  
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MVB FORMATION AND ESCRT DISASSEMBLY 
The final step in ESCRT-dependent sorting involves recruitment of ESCRT-III to 
endosomes by ESCRT-II. This recruitment ESCRT-III facilitates the concentration of 
receptor into the ILVS of MVBs and the disassembly of the ESCRT-complex by the 
AAA-ATPase Vps4 (Williams & Urbe, 2007). ESCRT-III is composed of the 
mammalian subunits CHMP1A-B, CHMP2A-B, CHMP3, CHMP4A-C, CHMP5 and 
CHMP6 along with the Ist-1 (Rue, Mattei, Saksena, & Emr, 2008). Each subunit of 
ESCRT-III is recruited to the endosomal membrane from the cytosol. On the endosome, 
ESCRT-III subunits are able to bind to microtubule interacting and trafficking (MIT) 
domains of accessory proteins including the deubiquitinating enzyme AMSH and the 
AAA-ATPase Vps4 to facilitate disassembly of the ESCRT- complex. Together, the 
subunits of ESCRT-III act together to cleave the endosomal membrane resulting in the 
formation of intraluminal vesicles. The AAA-ATPase, Vps4, acts to form MVBs. MVBs 
are composed of many ILVs and are considered vesicular intermediates between early 
and late endosomes (Gruenberg & Stenmark, 2004; Piper & Katzmann, 2007). In the 
final sorting step, AAA-ATPase Vps4 disassembles the ESCRT complex, thereby, 
allowing for recycling of the ESCRT components to initiate additional rounds of ESCRT-
mediated sorting. 
 
CXCR4 
The chemokine receptor 4 (CXCR4) is a class A rhodopsin-like G protein coupled 
receptor (GPCR), previously known as CD184 or Fusin (Berson et al., 1996; Moriuchi, 
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Moriuchi, Turner, & Fauci, 1997; Wegner et al., 1998). CXCR4 was first identified as 
one of the co-receptors that together with the T cell receptor CD4 facilitate HIV fusion 
and entry into T cells (Berson et al., 1996). Later it was identified in the normal cellular 
context that CXCR4 binds to the chemokine ligand CXCL12 (a.k.a. SDF-1!) and 
together it was shown that CXCR4/CXCL12 are essential for development of the heart, 
brain, and vasculature during embryogenesis (Nagasawa, Tachibana, & Kishimoto, 1998; 
Tachibana et al., 1998). In addition to binding CXCL12, CXCR4 was recently identified 
to also bind to the highly conserved small molecule ubiquitin as well as to the cytokine 
MIF (macrophage migrating inhibitory factor) (Bernhagen et al., 2007; Klasen et al., 
2014; Saini, Marchese, & Majetschak, 2010). Studies have highlighted that CXCR7 also 
binds to CXCL12. In contrast to CXCR4, CXCR7 binding to CXCL12 does not promote 
activation of classical CXCR4 signaling. It is thought that CXCR7 acts as a scavenger by 
binding to CXCL12 and, thereby, regulates CXCL12 gradients. Taken together, CXCR7 
antagonizes CXCR4 activation and cellular responses (Dambly-Chaudiere, Cubedo, & 
Ghysen, 2007; Naumann et al., 2010). Of the 7 identified CXC-receptors, CXCR4 is the 
most widely studied and highly conserved phylogenetically among different species 
(Arnolds & Spencer, 2014; Knaut, Werz, Geisler, & Nusslein-Volhard, 2003; Nagasawa, 
2014; Schabath et al., 1999; Willett et al., 1997; Zou, Redmond, Qi, Dooley, & 
Secombes, 2015). Yet, detailed information on the regulation of CXCR4 is continuing to 
be delineated. 
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PHYSIOLOGICAL ROLES OF CXCR4  
CXCR4 as well as its ligand CXCL12 have important roles during embryonic 
development and in the adult. The knockout (KO) animals of both genes display identical 
phenotypes. Mice deficient in CXCL12 or CXCR4 die at a late stage of embryogenesis 
(E 17.5) ( Nagasawa, Tachibana, & Kishimoto, 1998; Tachibana et al., 1998). The death 
is due mainly to a defect in formation of the ventricular septum in the heart. In addition to 
displaying defects in heart development, these mice also have defects in vascularization 
of the gastro-intestinal tract, cerebellum formation and hematopoiesis (Ara, Tokoyoda, 
Okamoto, Koni, & Nagasawa, 2005; Q. Ma et al., 1998; Nagasawa et al., 1996; 
Nagasawa et al., 1998; Tachibana et al., 1998).  
In the adult, the CXCL12/CXCR4 signaling axis has a role in tissue repair, 
hematopoiesis and cell homing. Following myocardial infarction, the ischemia produced 
within the heart mediates CXCR4/CXCL12 dependent homing of endothelial progenitor 
cells to initiate cardiac tissue repair (Askari et al., 2003; Heeschen et al., 2004). In 
hematopoiesis, CXCR4 mediates the homing of immature and mature bone marrow cells 
to peripheral sites where CXCL12 gradients are established (Broxmeyer et al., 2003; 
Lataillade, Domenech, & Le Bousse-Kerdiles, 2004; Q. Ma et al., 1998; Moser & 
Loetscher, 2001; Nagasawa et al., 1996). Aberrant CXCR4 signaling due to dysregulated 
CXCR4 expression has been implicated pathophysiologically in many diseases including 
breast cancer, cardiovascular disease, immunodeficiency disorders and lymphomas 
(Balkwill, 2004; Busillo & Benovic, 2007; Hernandez et al., 2003; Muller et al., 2001; 
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Walter et al., 2005; Ahn, Seo, Weinberg, & Arber, 2013; Burger & Kipps, 2002; 
Corcione et al., 2006; Trentin et al., 2004; Zlotnik, 2006).  
  
CXCR4 IN BREAST CANCER 
Dysregulated CXCL12/CXCR4 signaling has also been implicated in metastasis 
of a variety of epithelial carcinomas. CXCR4 is overexpressed in at least 23 types of 
cancer including cancers of the breast, ovary and prostate (Balkwill, 2004; Busillo & 
Benovic, 2007). Cancer cells with upregulated CXCR4 receptor levels can home in on 
distance sites where the CXCL12 ligand is expressed. Additionally, CXCR4 is involved 
in several cellular pathways that regulate invasion, chemotaxis as well as adhesion. As a 
result of these effects, the overexpression of CXCR4 in many cancer types promotes 
metastasis and progression (Balkwill, 2004). In particular, breast cancer subtypes that 
have high expression levels of CXCR4 can metastasize to regions where high levels of 
CXCL12 are expressed such as the lung, liver, lymph nodes and bone marrow (Muller et 
al., 2001). In breast cancer cells, CXCR4 mediated signaling promotes both chemotactic 
and invasive responses. In particular, CXCR4 signaling leads to changes in actin 
polymerization as well as pseudopodia formation that facilitate migratory responses of 
breast cancer cells in vitro. In vivo in a MDA-MB-231 breast cancer xenograft model, 
treatment with a neutralizing anti-human CXCR4 monoclonal antibody was able to 
significantly reduce metastasis to the lymph node and lung (Muller et al., 2001). This 
study overall highlights the importance of CXCR4/CXCL12 in mediating breast cancer 
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metastasis and was one of the first studies to demonstrate that targeting this signaling 
pathway can reduce metastasis.  
 
CXCR4 IN CARDIOVASCULAR DISEASE  
The CXCL12/CXCR4 signaling axis is highly important to the development as 
well as tissue repair within the heart (Askari et al., 2003; Dong et al., 2012; Nagasawa et 
al., 1996; Penn, 2009). Conditional CXCR4-endothelium knockout mice show abnormal 
vascularization demonstrating a requirement for CXCR4 in normal endothelial 
vascularization (Ara et al., 2005; Tachibana et al., 1998). In the adult, the 
CXCL12/CXCR4 signaling axis has a role in tissue repair of the damaged myocardium 
following cardiac ischemia (Penn, 2009; Tang et al., 2009) and in providing protection to 
cardiomyocytes from myocardial reperfusion injury (Cai et al., 2015). During myocardial 
infarction, the resulting ischemia promotes release of CXCL12 from the damaged tissue. 
This leads to an increase in endothelial progenitor cells released from the bone marrow 
and their homing to the damaged myocardium to initiate tissue repair (Abbott et al., 2004; 
Askari & Penn, 2003; Askari et al., 2003; Nagasawa et al., 1996). Perturbations in 
CXCL12/CXCR4 signaling that arise, for example by aberrant CXCR4 expression, may 
lead to impaired homing of endothelial progenitor cells thereby impairing tissue repair 
(Walter et al., 2005). The therapeutic value of CXCR4/CXCL12 in mediating cardiac 
tissue repair remains to be explored. 
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CXCR4 IN WHIM SYNDROME 
Aberrant CXCL12/CXCR4 signaling has been associated with the rare 
immunodeficiency disorder known as WHIM syndrome (Hernandez et al., 2003).  
Specifically, WHIM syndrome is caused by an autosomal dominant mutation in the 
CXCR4 gene. The acronym WHIM denotes the four most common symptoms of this 
syndrome, which include Warts, Hypogammaglobulinemia, Infections, and 
Myelokathexis. These patients exhibit warts as a result of increased susceptibility to 
HPV-infection, a low level of circulating gamma globulins (hypogammaglobulinemia), 
retention of neutrophils in the bone marrow (myelokathexis) and the resulting immune 
deficiency leads to increased infections. Additionally, due to the retention of neutrophils 
in the bone marrow patients exhibit neutropenia (low number of circulating neutrophils) 
(Hernandez et al., 2003; Kawai & Malech, 2009).  
The identified mutations in CXCR4 involve either nonsense (R334X, G336X, 
S338X, E343X) or frame shift (S339fs342X) mutations (Hernandez et al., 2003; Liu et 
al., 2012). Any of these mutations result in truncation of the C-terminal tail of CXCR4 
preventing its internalization and, thus, desensitization. As a result, the receptor is 
hyperfunctional in mediating downstream signaling. This results in disruption of 
chemokine gradients in the bone marrow and results in retention as well as apoptosis of 
neutrophils and other immune cells. Interestingly, one patient diagnosed with WHIM 
syndrome did not display a genetic mutation in the CXCR4 gene per se, however, it has 
been suggested that disruption of downstream regulators of CXCR4 signaling may be 
involved. Mice deficient in GRK6 and arrestin-3 exhibit symptoms similar to WHIM 
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syndrome patients such as neutropenia (Fong et al., 2002; Vroon et al., 2004) indicating 
that defects in CXCR4 desensitization may contribute to WHIM syndrome in the patient 
lacking the CXCR4 genetic mutation.  
 Treatment of WHIM syndrome usually involves infusion with gamma globulins 
(IV-Ig) and/or administration of the mobilizing therapy granulocyte-colony stimulating 
factor (G-CSF). Additionally, these patients are often treated prophylactically with 
antibiotics and undergo surgery to remove HPV-associated warts. Unfortunately, these 
current therapies come at a high cost to the patient and do not prevent recurring infection. 
Given the identified hyperfunctional CXCR4 genetic mutation in the majority of WHIM 
patients, current clinical trials are testing the efficacy of low-dose treatment with the 
CXCR4 antagonist Plerixafor (AMD3100) (McDermott et al., 2014). While directly 
targeting CXCR4 may prove efficacious in WHIM patients, the adverse side effects that 
may be associated with direct CXCR4 antagonism may require the development of 
alternative therapeutic targets to inhibit CXCR4 indirectly. 
  
CXCR4 IN LYMPHOMAS (DLBCLs) 
Aberrant CXCR4 expression has been correlated several hematological 
malignancies that lead to improper trafficking and migration of malignant B cells. While 
CXCR4 has been implicated in several hematological malignancies (Ahn, Seo, Weinberg, 
& Arber, 2013; Burger & Kipps, 2002; Corcione et al., 2006; Trentin et al., 2004; 
Zlotnik, 2006), the significance of CXCR4 in the progression of diffuse large B cell 
lymphomas (DLBCLs) remains unclear. A recent study of 94 biopsies in patients with 
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DLBCLs has demonstrated that CXCR4 expression in these patients can be used as a 
prognostic marker (Moreno et al., 2015). In this study, CXCR4 expression correlated to 
shorter overall survival as well as progression-free survival. Additionally, CXCR4 was 
shown to mediate dissemination of DLBCL cells in a mouse xenograft model. This 
dissemination was inhibited by administration of the CXCR4 antagonist, AMD3100. 
Recently another study of de novo germinal-center B-cell-like (GCB)-DLBCLs has 
demonstrated that an increase in CXCR4 is also associated with increased dissemination 
(Chen et al., 2015). Conversely, a study of gastric extranodal DLBCLs originating from 
mucosa-associated lymphoid tissue (MALT) established that loss of CXCR4 expression 
is a prognostic marker for the development and progression (Deutsch et al., 2013). Thus, 
the expression and role of CXCR4 in DLBCLs varies between different subtypes of 
DLBCLs. Taken together, these studies highlight the therapeutic potential of targeting the 
CXCR4 pathway in DLBCLs. 
 
CXCR4 SIGNALING 
Activation of CXCR4 signaling occurs upon binding to CXCL12. The binding 
region for CXCL12 on CXCR4 lies within the N-terminal domain of CXCR4 (residues 1-
36) (Doranz et al., 1999). Upon activation of CXCR4 by CXCL12, the receptor 
undergoes a conformational change. Ultimately, CXCR4 activation leads to either G 
protein dependent or independent signaling as described in the below sections. 
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CXCR4 SIGNALING: G PROTEIN DEPENDENT  
Following CXCL12 binding to CXCR4, several signaling pathways can be 
activated (Figure 1.6). The majority of signaling that occurs following CXCR4 activation 
is dependent upon the downstream activities of the associated G proteins. CXCR4 
couples canonically to the Pertussis toxin (PTX)-sensitive G"i subunit although coupling 
to Gq, Gs, and G12/13 have also been demonstrated (A. Kumar et al., 2006; Tan, Martin, & 
Gutkind, 2006). Although the vast majority of CXCR4 mediated signaling pathways are 
PTX-sensitive and, therefore, are G"i  dependent. 
 Binding of CXCL12 to CXCR4 results in the exchange of GDP for GTP in the 
G"i subunit and subsequent dissociation of G"i from the !# subunits of the 
heterotrimeric G protein. G"i functions to inhibit adenylyl cyclase and activate the kinase 
Src. Inhibition of adenylyl cyclase inhibits the production of cyclic AMP (cAMP) which 
in turn affects the activity of the PKA (Yang et al., 2007). Activation of Src by G"i 
results in MAPK pathway activation (Ganju et al., 1998; Y. C. Ma, Huang, Ali, Lowry, & 
Huang, 2000) and can regulate the activities of focal adhesion proteins including FAK 
and paxillin (Dutt, Wang, & Groopman, 1998; J. F. Wang, Park, & Groopman, 2000)  
The liberated !# subunits can activate phospholipase C-! (PLC-!) leading to the 
cleavage of inositol-4,5-bisphosphate (PIP2) to form inositol-1,4,5-triphosphate (IP3) and 
diacylglycerol (DAG). IP3 increases the levels of intracellular Calcium (Ca2+) while DAG 
activates protein kinase C (PKC). Additionally, downstream activation of PI3K leads to 
the formation of PIP3 and subsequent activation of the rho family of GTPases, Rac and 
Cdc42. Ultimately, the activation of second messengers downstream of CXCR4 lead to 
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changes in biological processes including migration, adhesion, proliferation and gene 
transcription. 
 
 
Figure 1.6. Signaling pathways activated downstream of CXCR4. Binding of 
CXCL12 to CXCR4 leads to the activation of both G protein dependent and G protein 
independent signaling pathways. The downstream effects of these signaling pathways 
regulate several cellular responses including migration, gene transcription, adhesion and 
proliferation. 
 
A recent study has demonstrated a novel role for AIP4 and ESCRT-0 subunit STAM-1 in 
regulating CXCR4 signaling (Malik, Soh, Trejo, & Marchese, 2012). Using siRNA 
against AIP4 and STAM-1, it was shown that CXCR4 activation of ERK-1/2 signaling 
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was prevented. This phenotype was dependent upon the ability of AIP4 and STAM-1 to 
interact as well as the catalytic activity of AIP4. Thus, ubiquitination activity of AIP4 is 
important in mediating ERK signaling in conjunction with STAM-1. It was further shown 
that AIP4 and STAM-1 activate ERK signaling in microdomains of the caveolar 
compartment. Overall, this study reveals that ubiquitination of STAM-1 by AIP4 is 
important in mediating ERK signaling downstream of CXCR4 activation.  
 
CXCR4 SIGNALING: G PROTEIN INDEPENDENT  
CXCR4 activation can also lead to the activation of signaling pathways 
independent of the G protein. CXCR4 activates Janus kinase (JAK) and signal transducer 
and activator of transcription (STAT) signaling pathway in T cell (MOLT4) lysates. 
Pharmacological inhibition of G"i by PTX treatment does not prevent JAK/STAT 
signaling suggesting this signaling is independent of CXCR4 coupling to G"i (Vila-Coro 
et al., 1999). Furthermore, in this study it was demonstrated that CXCL12 treatment did 
not promote association G"s with CXCR4. Although this study suggest a G protein 
independent mechanism, these studies do not rule out whether JAK/STAT signaling 
downstream of CXCR4 activation can be attributed to coupling to other G proteins 
including Gq or G12/13. 
Non-visual arrestins (!-arrestin-1/2) have also been suggested to mediate CXCR4 
G protein independent signaling. It has been demonstrated that !-arrestin-1and !-arrestin-
2 can increase MAPK signaling downstream of CXCR4 activation through activation of 
ERK and p38. In addition, mice deficient in !-arrestin-2 or GRK6 display defective 
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lymphocyte chemotaxis in response to CXCL12 (Fong et al., 2002). It is thought that the 
defective chemotactic response in these mice is attributed to !-arrestin-2-mediated 
signaling and is independent of G protein activation. Thus, these study suggest that !-
arrestin-2 not only functions in CXCR4 desensitization but may also play a vital role in 
mediating chemotaxis through G protein independent activation of MAPK/p38 signaling 
pathway (Y. Sun, Cheng, Ma, & Pei, 2002). While these study suggest an intriguing role 
for G protein independent signaling, more comprehensive studies will be required to 
determine whether these are truly G protein independent processes. 
 
REGULATION OF CXCR4 SIGNALING 
In order to maintain the proper level of CXCR4 signaling both in magnitude and 
duration, attenuation of CXCR4 signaling is a highly regulated process (Figure 1.7).  
Following activation, CXCR4 signaling is tightly controlled by three processes: 
desensitization, internalization and downregulation as detailed in the following sections.  
 
CXCR4 DESENSITIZATION AND INTERNALIZATION 
Activation of CXCR4 by CXCL12 results in a rapid desensitization process. In 
this process, CXCR4 is first phosphorylated by GRKs on serine and threonine residues 
within the C-terminal tail (Krupnick & Benovic, 1998). In particular GRK2, GRK3 and 
GRK6 have all been implicated in mediating this phosphorylation event (Balabanian et 
al., 2008; Busillo et al., 2010; Jimenez-Sainz et al., 2006). GRK-mediated 
phosphorylation recruits !-arrestin-1/2, which uncouple the receptor from the associated 
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G protein preventing further G protein activation (Gurevich et al., 1995; Lohse et al., 
1990). In addition to uncoupling the receptor from the associated G protein, !-arrestins 
promote proximal degradation of cAMP and DAG through the recruitment of the 
respective phosphodiesterases or DAG enzymes (Nelson et al., 2007; Perry et al., 2002). 
It has also been demonstrated that !-arrestin-1 (a.k.a Arrestin-2) interacts with AIP4 on 
endosomes upon CXCR4 activation, however, siRNA depletion of either !-arrestin-1 or 
AIP4 does not prevent CXCR4 internalization.  This data suggest that the interaction 
between !-arrestin-1 and AIP4 has a role in the post-endocytic sorting of CXCR4 
separate from a function at the plasma membrane (Bhandari, Trejo, Benovic, & 
Marchese, 2007).  
 
CXCR4 UBIQUITIN DEPENDENT DOWNREGULATION 
CXCR4 is rapidly internalized from the plasma membrane onto early endosomes 
upon binding to its cognate ligand CXCL12 (Figure 1.7) (Marchese & Benovic, 2001). 
Prior to internalization, CXCR4 can be ubiquitinated by E3 ubiquitin ligase AIP4. 
Phosphorylation of two serine residues (S324 and S325) within CXCR4 (Bhandari, 
Robia, & Marchese, 2009; Marchese & Benovic, 2001; Marchese, Raiborg, et al., 2003) 
promotes the recruitment of AIP4. This phosphorylation event is mediated by GRK6 
and/or PKC$ (Busillo et al., 2010). AIP4 recruitment to CXCR4 promotes 
monoubiquitination of the CXCR4 at the plasma membrane (Bhandari et al., 2009). 
Interaction studies have highlighted that the interaction between AIP4 and CXCR4 
involves a non-canonical interaction between WW I-II domain of AIP4 with the 
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phosphorylated S324 and S325 within the C-terminal tail of CXCR4 (Bhandari et al., 
2009). Typically, the WW domains of AIP4 interact with proline rich sequences (PPXY 
or PPPY motifs) (Ingham et al., 2005; Sudol, Chen, Bougeret, Einbond, & Bork, 1995), 
however, CXCR4 lacks these sequences. Thus, these studies demonstrate a novel 
interaction between the WW domains of AIP4 with CXCR4.  
Ubiquitin modification of CXCR4 acts as a sorting signal that localizes the 
receptor to early endosomes, however, ubiquitination of CXCR4 is not required for 
internalization. On early endosomes, ubiquitinated CXCR4 is localized to microdomains 
containing ESCRT-0 and sorted for trafficking towards lysosomes where the receptor is 
degraded (Bhandari et al., 2007; Marchese & Benovic, 2001; Marchese, Raiborg, et al., 
2003). Studies have shown that expression of ubiquitination-deficient mutants of CXCR4 
display a significant reduction in agonist-promoted degradation (Marchese & Benovic, 
2001). Agonist-promoted degradation of CXCR4 is a highly efficient process although a 
small amount is recycled back to the plasma membrane via Rab11-positive recycling 
endosomes (A. Kumar, Kremer, Dominguez, Tadi, & Hedin, 2011; Malik & Marchese, 
2010; Marchese & Benovic, 2001). These studies highlight the importance of CXCR4 
ubiquitination in facilitating receptor downregulation. 
Not only does AIP4 mediate ubiquitination of CXCR4 at the plasma membrane, it 
also acts on early endosomes to regulate the sorting machinery, such as ESCRT-0 protein 
HRS, to control CXCR4 sorting to lysosomes (Malik & Marchese, 2010; Marchese, 
Raiborg, et al., 2003). Previous studies have demonstrated that the ESCRT-0 protein 
STAM-1 and Arrestin-2 (!-arrestin-1) act to recruit AIP4 to the endosome where AIP4 
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ubiquitinates HRS (Malik & Marchese, 2010). Ubiquitination of HRS is thought to 
inhibit its ability to target CXCR4 for degradation. Thus AIP4 acts at multiple sites to 
control CXCR4 trafficking, but detailed molecular insight into its function is lacking.  
 
Figure 1.7 Current model of CXCR4 trafficking within the endocytic pathway. Upon 
CXCL12 binding to CXCR4, the receptor is rapidly phosphorylated on serine residues 
324 and 325 within the C-tail by a G protein-coupled receptor kinase (GRK). This 
promotes direct binding to the E3 ubiquitin (Ub) ligase AIP4, which mediates Ub 
conjugation of CXCR4 on nearby lysine residues. The ubiquitin moieties on CXCR4 act 
as a sorting signal recognized by the ESCRT machinery, which is located on endosomes. 
This machinery recognizes and interacts directly with the ubiquitin moieties attached to 
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CXCR4 and acts in a sequential and concerted fashion to deliver ubiquitinated CXCR4 
into ILVs of MVBs. MVBs fuse with lysosomes where their contents are degraded. In 
addition the STAM-1/Arrestin-2 complex on endosomes acts to recruit AIP4 which in 
turn ubiquitinates HRS and limits the extent of CXCR4 that is targeted for degradation.  
 
RATIONALE AND RESEARCH OBJECTIVES 
Despite the fact that dysregulated CXCR4 expression contributes to aberrant 
signaling, very little is known about the molecular processes regulating CXCR4 
expression in cells. Understanding how CXCR4 levels are regulated is critical for two 
reasons. First, understanding CXCR4 regulation will allow future studies to further 
pinpoint the contribution of CXCR4 and its usefulness as a biomarker in disease. 
Secondly, understanding the molecular mechanisms regulating CXCR4 levels will 
provide alternative strategies to target CXCR4. The goal of this dissertation project is to 
understand the molecular mechanisms regulating CXCR4 expression, with a specific 
emphasis on understanding how CXCR4 levels are controlled by membrane trafficking 
within the endocytic pathway.  
CXCL12-activation of CXCR4 results in its rapid ubiquitination and 
internalization from the plasma membrane. Once on endosomes, ubiquitinated CXCR4 is 
sorted for lysosomal degradation through an ubiquitin-dependent pathway (Marchese, 
Raiborg, et al., 2003), although the mechanism remains poorly characterized. CXCR4 is 
ubiquitinated by the HECT-domain E3 ligase AIP4 at the plasma membrane. AIP4 is also 
localized on early endosomes and regulates CXCR4 sorting by modulating the activity of 
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the endosomal sorting complex required for transport (ESCRT) machinery(Malik & 
Marchese, 2010; Marchese, Raiborg, et al., 2003). However, the precise role of AIP4 in 
these processes remains poorly defined. The objective of this project is to gain a greater 
understanding of the mechanisms mediating AIP4 regulation of CXCR4. AIP4 is known 
to interact with other E3 ligases, including DTX1 and Cbl-c (Chastagner et al., 2006; 
Courbard et al., 2002), but whether these E3 ligases or others are involved in CXCR4 
sorting is not known. Our preliminary data indicate that the DTX protein, Deltex-3-like 
(DTX3L) regulates CXCR4 degradation. We hypothesize that the E3 ubiquitin ligase 
DTX3L regulates CXCR4 trafficking within the degradative pathway through an 
interaction with AIP4 and other key proteins involved in the CXCR4 sorting pathway. 
To achieve the overall objective of this project we addressed two specific aims: 
 
AIM # 1. To characterize the role of DTX3L in CXCR4 trafficking to 
lysosomes. Our preliminary data indicates that DTX3L mediates CXCR4 
lysosomal degradation. In this aim we will elucidate the step at which DTX3L 
functions in the endocytic pathway to regulate CXCR4 targeting to lysosomes. 
 
AIM # 2. To elucidate the role of DTX3L on CXCR4-induced ubiquitination. 
In this aim we will test the hypothesis that DTX3L interacts with AIP4 and the 
endocytic machinery on endosomes to modulate CXCR4 lysosomal sorting. 
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The results from this study will further the knowledge on the regulation of CXCR4 
signaling and trafficking. Furthermore, the results of this study can be correlated to 
CXCR4 related pathologies and will provide valuable information that may lead to the 
identification of novel pharmacological targets within the CXCR4 pathway.  
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CHAPTER II 
MATERIALS AND METHODS 
CELL LINES AND TRANSFECTION REAGENTS 
Human cervical cancer (HeLa) cells were obtained from the American Type 
Culture Collection (Manassas, VA) and human embryonic kidney (HEK) 293 cells were 
from Microbix (Toronto, ON, Canada). Cells were maintained in Dulbecco's modified 
Eagle's medium (DMEM; Hyclone Laboratories (Logan, UT)) supplemented with 4 mM 
L-glutamine, 4500 mg/L glucose and 10% fetal bovine serum (FBS; Hyclone 
Laboratories or Fisher Scientific) and incubated in a 37°C humidified chamber containing 
5% CO2.  
 Transfection of cells with plasmid DNA and siRNA were performed using the 
transfection reagents Polyethylenimine (PEI) and Lipofectamine® 2000 or 3000 
(Invitrogen, Carlsbad, CA), respectively.  Transfections with Lipofectamine® 2000 or 
3000 were done per the manufacturers instructions and optimized for experiments 
performed as outline below. Additionally, all transfections were performed within the 
biological safety cabinet to maintain sterility.  
 
TRANSFECTION OF DNA USING POLYETHYLENIMINE (PEI) 
Transfection of cells with DNA was performed on cells cultured in 10-cm, 6-cm 
or 6-well culture dishes using polyethylenimine (PEI). The cells were typically at 70-80% 
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confluency at time of transfection. The protocol was kindly provided by Dr. JoAnn Trejo 
(UCSD) (Grimsey, Lin, & Trejo, 2014). PEI was made as a stock of 1 mg/ml 
(Polysciences, Inc., Warrington, PA) in 30% ethanol (Decon Laboratories, Inc., King of 
Prussia, PA)), as described in Appendix I. PEI was used for DNA transfection at a ratio 
of 2 µl PEI stock: 1 µg of DNA. Specifically, for a 10-cm dish, 10 µg of total plasmid 
DNA was combined with 20 µl of PEI in 1 mL DMEM supplemented with 20 mM 
HEPES pH 7.5. For a 6-cm dish, 5 µg of total plasmid DNA was combined with 10 µl of 
PEI in 1 mL DMEM supplemented with 20 mM HEPES pH 7.5. Lastly, for DNA 
transfections in 6-well dishes, 2.5 µg of total plasmid DNA was incubated with 5 µl of 
PEI in 1 mL DMEM supplemented with 20 mM HEPES pH 7.5.  
The PEI/DMEM mixture was incubated at room temperature for 5 min and then it 
was added drop wise to a second microcentrifuge tube containing the DNA. The 
DNA:PEI mixture was incubated for 20 min at room temperature, during which time the 
media was aspirated and replaced with fresh DMEM plus 10% FBS (10 ml for 10 cm 
dish, 4 ml for 6 cm dish and 1 ml for 6-well plate) prior to adding DNA complexes.  
DNA was then added drop wise to cells. To evenly distribute DNA:PEI complexes, cells 
were gently rocked back and forth several times before placement into a 37°C incubator. 
DNA transfections were allowed to incubate at 37°C for 24-48 h depending on particular 
experiment and amount of DNA transfected.  
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TRANSFECTION OF SMALL INTERFERING RNA (siRNA) USING 
Lipofectamine® 2000 or 3000 REAGENTS 
Transfection of cells with siRNA were performed on cells cultured in 10-cm, 6-
cm and 6-well culture dishes using Lipofectamine® 2000 or 3000 transfection reagents. 
siRNA transfections were performed at a ratio of 2.5 µl Lipofectamine® 2000/3000 to 50 
pmol of siRNA.  
For transfection set up in a biological safety cabinet, the desired amount of siRNA 
was aliquoted into a microcentrifuge tube containing 500 µl of DMEM supplemented 
with 20 mM HEPES pH 7.5. In a second microcentrifuge tube, 500 µl of DMEM 
supplemented with 20 mM HEPES pH 7.5 was aliquoted. The corresponding amount of 
(2.5 – 30 !l) Lipofectamine® was aliquoted directly into this tube. The two 
microcentrifuge tubes were left in the biological safety cabinet at room temperature for 5 
min. After 5 min, the siRNA/DMEM mixture were added drop wise to the tube 
containing the Lipofectamine®/DMEM mixture and incubated for an additional 20 min at 
room temperature. In the mean time, media on 70-80% confluent cells was replaced with 
warm DMEM plus 10% FBS after which siRNA complexes were added drop wise to 
cells. To evenly distribute siRNA:Lipofectamine® complexes, cells were gently rocked 
back and forth several times before placement into a 37°C incubator. Cells were allowed 
to transfect for 24-72 h depending on siRNA used and experiment.  
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ANTIBODIES AND REAGENTS 
Primary antibodies used in this dissertation work are listed in Table 2.1 while 
reagents are listed in Table 2.2. siRNA sequences are listed in Table 2.4. DNA constructs 
and primers used in this work are in Tables 2.5 and 2.6, respectively.  
 
CLONING 
Basic steps used to clone DNA into desired vectors are listed below in Sections 
2.3.1 -2.3.7. Primers used in PCR reactions are listed in Table 2.6 and construct maps of 
each DNA are in Appendix II. 
 
POLYMERASE CHAIN REACTION (PCR) SET UP 
 PCR reactions were set up using the Expand High Fidelity PCR system (Roche) as 
follows. To a sterile PCR tube each of the following ingredients was added: Expand High 
Fidelity Buffer (10") containing 15 mM MgCl2 (2 µl), 10 mM dNTP mixture (1 µl), 
DMSO (2 µl), Forward primer (1 µl), Reverse primer (1 µl), template DNA (1 µg) and 
Expand High Fidelity Enzyme mix (1 µl; 3.5 units/µl) and sterile, autoclaved dH2O to a 
final volume of 50 µl. Tubes were placed in a GeneAMP! PCR system Thermocycler 
(Model 9700; Applied Biosystems) using the following parameters: 94°C for 45 sec- 2.5 
min), 40-55°C for 45 sec – 10 min and 72°C for 2 min for 30 cycles with a 2 min hold 
before the start at 94°C and final elongation hold at 72°C for 7 min. 
 
 
 
60 
GENERATION OF THE FLAG-DTX3L-3C/A MUTANT 
To generate the FLAG-DTX3L-3C/A mutant three conserved cysteine residues 
(561, 596 and 599) within the catalytic RING domain of DTX3L were mutated to 
alanine. Mutation of these residues is predicted to inhibit E2 enzyme binding to the RING 
domain based on previously described RING mutant of DTX1 (Chastagner, Israel, & 
Brou, 2006). These same residues are conserved in the DTX3L sequence as determined 
by manual comparison of the DTX1 and DTX3L sequences. To make this mutant we 
used two-step PCR mutagenesis. Two constructs were generated with the first using 
DTX3L DNA that was PCR amplified and extended with primers designed to incorporate 
one mutation (C561A). The second construct was generated using the C561A DNA as the 
template in our PCR reaction in order to add the second and third mutations (C596A and 
C599A).  
We first generated the single mutant (C561A). Briefly, FLAG-DTX3L-C561A 
was PCR amplified using sequential PCR. Reaction one amplified FLAG-DTX3L 
template DNA using FLAG-DTX3L-Forward and FLAG-DTX3L-C561A-Reverse 
primer in one tube and FLAG-DTX3L-Reverse and FLAG-DTX3L-C561A Forward 
primer in tube two. The product of PCR reaction one was then used as a template to 
anneal the C561A mutant strands. PCR conditions used for this annealing step were: 
denaturation 94°C (2 min), annealing 40°C (10 min) and elongation 72°C (2 min) for 1 
cycle. The annealed product was then extended for 30 cycles using FLAG-DTX3L-
Forward/Reverse primers at the following PCR conditions: denaturation 94°C (45 sec), 
annealing 50°C (45 sec) and elongation 72°C (2 min).  The forward primer carried a NotI 
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restriction site and started at amino acid residue Ala2, in frame with the 3xFLAG epitope. 
The reverse primer carried a XbaI site and an in frame stop codon and ended at E740. 
The PCR fragment was digested with NotI and XbaI and cloned into the NotI and XbaI 
sites of 3xFLAG-CMV10. 
In the second PCR reaction, FLAG-DTX3L-3C/A was amplified by PCR using 
FLAG-DTX3L-C561A (single mutant) template DNA extended with FLAG-DTX3L- 
C596A/C599A-Forward primer in PCR reaction 1. Product of reaction 1 was then 
subjected to a second round of PCR using the FLAG-DTX3L- C596A/C599A-Reverse 
primer in tube two. The product of PCR reaction one was used as a template to anneal the 
DTX3L-3C/A triple mutant strands and extended using FLAG-DTX3L-Forward/Reverse 
primers using the same PCR conditions as above to generate the single mutant. The 
forward primer carried a NotI restriction site and started at amino acid residue Ala2, in 
frame with the 3xFLAG epitope. The reverse primer carried a XbaI site and an in frame 
stop codon and ended at E740. The PCR fragment was digested with the restriction 
enzymes NotI and XbaI and sub-cloned into the NotI and XbaI sites of 3xFLAG-
pCMV10. Incorporation of the three mutations was confirmed by sequencing using the 
FLAG-DTX3L forward and reverse primers, essentially following steps described below 
in Sections 2.3.2-2.3.7. The FLAG-DTX3L-3C/A was also sub-cloned into the His vector 
(pET-21a (+)) and used in binding (Section 2.10.2) and in vitro ubiquitination assays 
(Section 2.13) 
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PCR PRODUCT GEL EXTRACTION 
Amplified products were separated by agarose gel electrophoresis and purified by 
gel extraction. Amplified products diluted in 6X loading dye were loaded onto a pre-
made 1% agarose gel (containing 10 µl of ethidium bromide) along with a 1 kb DNA 
ladder (Promega). Gel was electrophoresed at 130 V for approximately 1-2 h or until dye 
front neared bottom of gel. Samples were viewed under a UV light and the predicted 
product band was cut out using a sterile razor. The gel fragment was placed in a sterile 
1.75 ml microcentrifuge tube. DNA was extracted from the gel using the Qiagen 
QIAquick Gel Extraction kit according to the manufacturer’s protocol. DNA was eluted 
in 30 µl EB buffer (10 mM Tris#Cl, pH 8.5) and amount of DNA eluted was quantified 
using a Nanodrop 8000 spectrophotometer (Thermo Scientific). 
 
RESTRICTION DIGEST 
Both the vector and amplified DNA insert were individually subject to restriction 
enzyme digest using the desired restriction sites that were amplified in the DNA product 
and compatible with the multiple cloning region of the vector. Restriction enzymes used 
in this project are listed in Table 2.7. Digestion reactions were set up as follows: 10" 
BSA (2 µl), 10" NEB buffer 1-3 (2 µl), vector and/or insert DNA, Restriction enzyme 1 
(1 µl), Restriction enzyme 2 (1 µl) and sterile, autoclaved dH2O in a final volume of 20 
µl. Samples were incubated overnight at 37°C. NEB buffers were utilized due to low 
cutting efficiency when using Promega buffers and based on parallel analysis that 
suggested better compatibility of enzymes in a double restriction digest reactions with 
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NEB buffers than Promega buffers. Samples were then run on 1% agarose gel (containing 
10 µl ethidium bromide) and subjected to Gel Extraction using the Qiagen Kit mentioned 
previously. DNA was eluted in 30 µl of EB buffer and the amount of DNA purified was 
quantified using a Nanodrop 8000 spectrophotometer (Thermo Scientific). 
 Specifically to generate DTX3L, the pCMV-SPORT6-DTX3L cDNA (Thermo-
Scientific) purified from bacteria using the Qiagen mini-prep kit per manufacturer’s 
protocol was amplified by PCR and the product was sub-cloned into the Not I and Xba I 
sites of 3"FLAG-pCMV-10 (Sigma-Aldrich, St. Louis, MO), the BamHI and XhoI sites 
of pGEX-6P-1 (GE Healthcare) or the Bam HI and XhoI sites of pET-21a (+).  
To generate the GST-N-terminal (NT) and GST-C-terminal (CT) truncations of 
DTX3L, primers were made based on the DTX3L truncations previously published 
(Takeyama et al., 2003). Briefly, the NT truncation of DTX3L spans amino acids 1-464, 
while the CT truncation covers amino acids 528-740. Full-length GST(pGEX6p1) -
DTX3L was used as a template in the PCR and PCR products were sub-cloned into the 
BamHI and XhoI sites of pGEX-6P-1. 
The DTX3L-3C/A mutant was designed based on the DTX1 mutant previously 
reported (Chastagner et al., 2006), as detailed in Section 2.4.1.1. Briefly, cysteine 
residues 561, 596 and 599 within the RING domain were mutated to alanine residues 
using two-step PCR and sub-cloned into 3"FLAG-pCMV-10 or pET-21a (+) vectors as 
described for wild-type DTX3L.  
 
64 
The 3"FLAG-pCMV-10-AIP4-C830A mutant was made by digesting myc-AIP4-
C830A-pRK5 with XhoI and BamHI and sub-cloning and replacing the equivalent 
fragment in 3"FLAG-pCMV-10-AIP4.  
To make GST-AIP4-C830A, the FLAG-AIP4-C830A cDNA was used as a 
template for PCR and the product was sub-cloned into the BamHI and NotI sites of 
pGEX-6P-1.  
The yellow fluorescent protein tagged 2"FYVE domain (YFP-2"FYVE) was 
made by a previous student, Rohit Malik, by amplifying amino acid residues 147-223 
from HRS by two-step PCR and sub-cloning in tandem into the XhoI and EcoRI sites of 
pEYFP-C1 (Clontech).  
 
LIGATION AND TRANSFORMATION 
Restriction enzyme digested samples were subject to ligation using different 
molar ratios of vector to insert (i.e. 1:1, 1:3, 3:1, etc.). The desired ratios of vector to 
insert DNA were combined in a sterile 0.6 ml microcentrifuge tube with 10" T4 ligase 
buffer (2 µl; Promega), T4 DNA ligase (1 µl; Promega) and sterile, autoclaved dH2O to a 
final volume of 20 µl. As a negative control, a ligation reaction using only the vector but 
no insert (Vector only control) was set up in parallel. The ligation was incubated 
overnight (15 h) at 4°C. The next day, competent DH5#’ bacterial cells (100 µl) were 
combined with ligated DNA (5 µl) in a 1.7 ml sterile, microcentrifuge tube and incubated 
on ice for 30 min. Cells were then placed in a 42°C water bath for 2 min and then back on 
ice for 2 min. Next, 600 µl of LB broth was added to the transformed bacteria and 
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incubated for 40-60 min at 37°C. Transformed cells were then plated onto LB agar plates 
containing 100 µg/mL ampicillin (LB-amp agar). Briefly, transformed cells were 
centrifuged at 4,000 rpm for 1 min. Excess LB broth was aspirated to the 100 µl mark on 
the tube and pelleted bacteria were re-suspended. Cells (25-50 µl) were added to the LB-
amp agar plate. To spread cells onto plate, a metal cell spreader was dipped in 70% 
ethanol and flamed using a Bunsen burner. The spreader was cooled for a 1-2 min and 
then used to spread the bacterial cells back and forth covering the agar dish. Plate was 
then inverted (lid downward) and placed at 37°C overnight.  
 
SELECTION OF COLONIES 
Colonies of transformed bacterial cells plated overnight on LB-amp agar were 
counted manually and compared to vector only control. The amount of colonies selected 
was based on the ratio between vector-only and vector plus insert transformations. 
Briefly, individual colonies were selected and inoculated in 3 ml of LB broth containing 
100 µg/mL ampicillin (LB-amp broth). Samples were allowed to grow overnight in an 
orbital shaker (Forma Scientific, Model 4518) set at 250 rpm and a temperature of 37°C.  
 
SCREENING FOR INSERTS 
Small scale plasmid DNA was isolated from bacterial cultures using the Qiagen 
QIAprep Spin Miniprep kit, according to the manufacturer’s protocol. DNA was eluted in 
a volume of 50 µl EB buffer. Plasmid DNA (500 ng - 1µg) was subjected to a restriction 
enzyme digest using the same restriction enzymes used in the ligation reaction, as 
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described in Section 2.3.3. Following digestion, 2 !l of 6X loading dye was added to 
each sample and loaded onto a 1% agarose gel (containing 10 µl of ethidium bromide) 
along with a 1 kb DNA ladder (Promega). Gel was electrophoresed at 130 V for 
approximately 1 h or until dye front neared bottom of gel. Samples were viewed under a 
UV light box (Fisher Scientific) to determine positive clones for insert incorporation. A 
clone was determined to be positive for the insert if following digestion two bands 
appeared that migrated in the proper kb range determined for both vector and insert.  
 
SEQUENCING 
DNA of positive clones was sent for Single Pass DNA Sequencing off site at 
ACGT, Inc. (Wheeling, IL). Specifically, 5-10 µl of desired mini-prep DNA was 
aliquoted into a 0.6 ml sterile, microcentrifuge tube. In a separate tube, desired primers 
(5-10 µl; forward and reverse) were aliquoted into a 0.6 ml sterile, microcentrifuge tube 
or alternatively banked primers on the ACGT website were indicated to be used in 
sequencing reactions. Typically, data from reactions was uploaded within 2-3 days and 
sequence files were opened in Serial Cloner software (version 1.3-11) to determine 
whether correct insert was cloned into desired vector. Briefly, sequences obtained were 
compared manually to original sequence to determine whether the sequences matched or 
whether a certain mutation was incorporated. Purity of sequence was determined using 
Finch TV software (version 1.4.0, Geospiza Inc.).  
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MAXI PREP 
Following confirmation of sequence, large scale plasmid DNA was isolated using the 
Qiagen HiSpeed Plasmid Maxi kit. Specifically, transformed bacterial cells were 
inoculated in 5 ml of LB-amp broth. Samples were incubated for 8 h in an orbital shaker 
(Forma Scientific, Model 4518) set at 250 rpm and a temperature of 37°C. The 5 ml 
culture was then added to 500 ml of LB-amp broth allowed to grow overnight (18 h) in 
the same orbital shaker set at 250 rpm and a temperature of 37°C.  Bacteria were pelleted 
by centrifugation at 4,000 rpm for 25 min (Beckman Coulter J6-HC centrifuge). DNA 
was then purified from bacterial pellet as per manufacturer’s protocol and eluted in a 
volume of 500-750 µl TE buffer. Concentration of DNA was determined using a 
Nanodrop 8000 spectrophotometer (Thermo Scientific). 
 
SODIUM DODECYL SULFATE POLYACRYLAMIDE GEL (SDS-PAGE) AND 
WESTERN BLOT TRANSFER 
Samples were collected in 2" sample buffer (8% SDS, 10% glycerol, 0.7 M beta-
mercaptoethanol, 37.5 mM Tris HCl, pH 6.5, 0.003% bromophenol blue) as detailed in 
each protocol below. Samples were resolved along with pre-stained molecular weight 
standards (BioRad) on SDS-polyacrylamide gels (containing 7%, 10% or 12% 
acrylamide, as detailed in the Appendix I). Gel was electrophoresed at 150-160 volts in 
1" SDS running buffer (0.25 mM Tris-HCl pH 7.5, 1% SDS and 0.192 M glycine) for 1 h 
-1.5 h. Separated proteins were transferred by Western blot onto nitrocellulose membrane 
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(0.45 !M or 0.20 !M, GE Healthcare or BioRad) for 1 h at 100 volts in 1" transfer buffer 
(0.25 mM Tris-HCl pH 7.5, 0.192 M glycine and 20% (vol/vol) methanol).  
 
IMMUNOBLOT ANALYSIS 
Membranes containing Western blot transferred proteins (immunoblots) were 
incubated in 5% non-fat milk in Tris-buffered saline (20mM Tris pH 7.5, 150 mM NaCl) 
containing 0.05% TWEEN-20 (TBS-T) for 30 min rocking at room temperature on a 
rocking platform (VWR, model 200). Blocked immunoblots were incubated with specific 
primary antibodies (dilution range 1:500 to 1:3000) in the same buffer overnight at 4°C. 
The following morning, primary was saved and frozen at - 20°C for later re-use or 
discarded. Primary incubated immunoblots were washed three times for 5 min with TBS-
T and then incubated with appropriate horseradish peroxidase (HRP) conjugated 
secondary antibody (Vector Labs) at a dilution of 1:10,000 in blocking buffer (5% non-
fat milk dissolved in TBS-T) for 30 min rocking at room temperature. Immunoblots were 
washed five times with TBS-T with one 5 min quick wash and four subsequent 10 min 
longer washes at room temperature. Proteins were visualized using enhanced 
chemiluminescence (ECL) reagents (DURA extended duration substrate, Thermo 
Scientific or homemade short duration substrate). Short duration substrate was made as 
detailed in Appendix I.  DURA was generally used on immunoblots for samples obtained 
from co-immunoprecipitation and degradation experiments for endogenous protein or for 
primary antibodies of low affinity such as DTX3L, HRS and CXCR4. Short duration 
substrate was used on immunoblots of samples with DNA overexpression, for loading 
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controls (Tubulin or Actin), using primary antibodies of high affinity such as AIP4 and 
STAM-1 or obtained from in vitro ubiquitination assays. Immunoblot membranes were 
incubated with 1:1 ratio of ECL for 1-5 min prior to developing. Signal was captured on 
autoradiography film (Dot Scientific high contrast blue or MIDSCI Classic blue 
autoradiography film BX) and exposed films were developed using an automated film 
processor. 
 
LIGAND STIMULATION 
CXCL12 was made as a stock of 10 µM in 0.1% BSA in PBS and stored at - 
20°C. For stimulation with CXCL12, the amount/concentration of desired ligand made in 
0.1% BSA in PBS was diluted in DMEM incomplete supplemented with 20mM HEPES. 
For vehicle stimulation, cells were treated with 0.1% BSA in PBS without ligand. Media 
was removed from cells by aspiration prior to the addition of pre-mixed, diluted ligand in 
DMEM incomplete supplemented with 20mM HEPES. To evenly distribute the ligand, 
plates were gently rocked back and forth twice and placed at 37°C for desired time course 
(15 min-3 h). 
 
CXCR4 DEGRADATION ASSAY 
Agonist promoted degradation of CXCR4 was assessed by immunoblot analysis, 
similar to previously described (Malik & Marchese, 2010; Marchese et al., 2003). 
Specifically, HeLa cells grown to 70-80% confluency in 6-well plates were transfected 
with 50 pmol siRNA directed against DTX family members, c-Cbl, Cbl-b, AIP4 or 
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GAPDH or Luciferase using Lipofectamine® 2000/3000 (Invitrogen, Carlsbad, CA), as 
we have previously described (Marchese et al., 2003). The next day after transfection, 
cells were split 1:2 into 12- well plates and grown for another 24 hours. At the time of 
experiment cells had grown to 90-100% confluency. Cells were washed with DMEM 
complete and then incubated with complete media (500 µl) containing 50 µg/mL 
cyclohexamide to prevent protein synthesis for 15 min at 37°C. Media was aspirated and 
replaced with media containing vehicle (0.1% BSA in PBS) or 10 nM CXCL12 for total 
of 3 h in the continued presence of cyclohexamide. After treatment, media was aspirated 
and replaced with 500 !l PBS at room temperature, followed rapidly by aspiration. Three 
hundred µl of 2" sample buffer was added to each well and cells were removed by gently 
scraping with a rubber policeman and transferred to a 1.7 ml microcentrifuge tube. 
Lysates were sonicated once for 10 sec at 15 % amplitude using a Branson Digital 
Sonifier (Model 450). Equal amounts (10 µl) of samples were analyzed by 10% SDS-
PAGE and immunoblotting with antibodies directed against CXCR4, DTX3L, AIP4, 
actin or tubulin. We were unsuccessful in determining DTX1-3, c-Cbl and Cbl-b 
knockdown by immunoblot due to lack of good reagents that could distinguish these 
proteins. Future study will require qPCR to determine degree of knockdown for these 
proteins. Receptor degradation was determined by densitometric analysis of similar 
enhanced chemiluminescent exposures from multiple experiments and calculated as the 
percent receptor degraded in CXCL12 treated cells compared to vehicle. 
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CONFOCAL FLUORESCENCE MICROSCOPY: SAMPLE PREPARATION 
HeLa cells grown in 6-well plates were transfected with siRNA targeting DTX3L, 
AIP4 or control Luciferase using Lipofectamine® 2000/3000, as described above in 
Section 2.1.2. Alternatively, cells were transfected with 1 µg FLAG-AIP4 DNA using 
PEI, as detailed in Section 2.1.1. Twenty-four hours later cells were plated onto 22 x 22 
mm No. 2 coverslips (Fisher) coated with poly-L-lysine (PLL; 0.1 mg/mL; Sigma-
Aldrich, St. Louis, MO). To coat coverslips, in a biological safety cabinet coverslips were 
placed in 6-well plate and incubated with PLL for 10 min. PLL was aspirated and 
coverslips were incubated in the biological safety cabinet for 40 min at room temperature 
to dry prior to passing cells directly onto coverslips.  
The following day, cells were washed once with DMEM supplemented with 20 
mM HEPES pH 7.5. For serum starvation, media was replaced with 1ml DMEM 
supplemented with 20 mM HEPES pH 7.5 for 3 h at 37 °C before stimulating with 
ligand. To stimulate cells, the desired volume of CXCL12 was pre-diluted in DMEM 
supplemented with 20 mM HEPES pH 7.5 to a final concentration of 10 nM. Media was 
aspirated from cells and media containing vehicle or CXCL12 (10 nM) was added 
directly to cells. Cells were stimulated at 37˚C for various times (15 min-3h). Cells were 
then washed twice on ice with ice-cold 1" PBS (500 !l - 1000 !l; Hyclone Laboratories). 
To fix cells, 1 ml of 3.7% paraformaldehyde-PBS was added to each well followed by 
incubation for 10 min at room temperature. Cells were washed twice again with 1 ml 
1"PBS. To permeabilize cells a solution containing 0.05% (w/v) saponin in 1 ml 1"PBS 
was added for 10 min at room temperature, as described previously (Malik, Soh, Trejo, & 
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Marchese, 2012). To block non-specific binding sites 1000 !l blocking buffer (1"PBS 
plus 1% BSA and 0.05% w/v saponin) was added to each well and incubated for 30 min 
at 37°C. Primary antibodies (1:25 - 1:100 dilution) directed against either CXCR4, 
DTX3L, EEA1, LAMP2, HRS, STAM-1 or FLAG in 100 !l were aliquoted on parafilm 
that was placed on top of moistened filter paper to create a moist chamber. Coverslips 
were inverted onto the aliquoted primary for 1 h at 37 °C and followed by washing with 
0.05% (w/v) saponin in 1 ml 1"PBS. Briefly, coverslips were placed back into the 6 well 
dish (cell side up), washed quickly four times at room temperature and then washed for a 
longer time period for 15 min at 37°C. Samples were then incubated for 30 min at 37°C 
with Alexa-Fluor-conjugated secondary antibodies (1:100) in a similar fashion as the 
primary. Secondary antibodies included: Alexa-Fluor 635-conjugated goat anti-mouse, 
Alexa-Fluor 633-conjugated goat anti-rat, Alexa-Fluor 488-conjugated goat anti-mouse, 
Alexa-Fluor 555-conjugated donkey anti-goat, and Alexa-Fluor 488-conjugated goat anti-
rabbit antibodies (Table 2.3), Molecular Probes (Eugene, OR)).  Controls for staining 
included samples stained with secondary only, primary with opposite (different species) 
secondary or staining sample with single primary and secondary combination followed 
by scanning in opposite channel (i.e. stain with 488 nm conjugated secondary and view in 
555 nm for any bleed-through). Cells were washed as before and mounted on glass slides 
using mounting medium containing DAPI (Vector Laboratories, Burlingame, CA or 
ProLong Gold Invitrogen, Carlsbad, CA). The edges of the slips were sealed using nail 
polish and stored either at room temperature or 4°C in the dark prior to viewing.  
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DTX3L CO-LOCALIZATION WITH EEA1 AND LAMP2  
To examine co-localization between DTX3L and EEA1 or LAMP2, HeLa cells 
plated onto coverslips were serum starved in 1ml DMEM supplemented with 20 mM 
HEPES pH 7.5 for 3 h at 37 °C, treated with 10 nM CXCL12 for 30 min and co-stained 
for DTX3L and EEA1 or LAMP2. 
 
CXCR4 DEGRADATION BY IF 
To characterize the effect of DTX3L silencing on CXCR4 trafficking, HeLa cells 
plated on coverslips were transfected with DTX3L or control siRNA for a total of 48 hrs. 
Cells were then serum starved in 1ml DMEM supplemented with 20 mM HEPES pH 7.5 
for 3 h at 37 °C prior to stimulation with 10 nM CXCL12 or vehicle for 3 h. Cells were 
processed as described above and were co-stained for CXCR4 and EEA1 or LAMP2 or 
DTX3L.  
 
CO-LOCALIZATION OF DTX3L AND AIP4 
To examine co-localization of DTX3L with AIP4, HeLa cells plated on coverslips 
were first transfected with 1 µg of FLAG-AIP4. The following morning cells were serum 
starved in 1ml DMEM supplemented with 20 mM HEPES pH 7.5 for 3 h at 37 °C and 
stimulated with 10nM CXCL12 or vehicle for 0-60 min. Cells were processed essentially 
as stated above and co-stained for DTX3L, FLAG-AIP4 and EEA1. 
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ASSESSING CO-LOCALIZATION WITH ESCRT-0 
To assess the effect of DTX3L on ESCRT-0 components, HeLa cells plated on 
coverslips were transfected with control or DTX3L siRNA for a total of 48 hrs. Cells 
were serum starved in 1ml DMEM supplemented with 20 mM HEPES pH 7.5 for 3 h at 
37 °C and then stimulated with 10 nM CXCL12 or vehicle for 1 h. Cells were processed 
as above and co-stained for HRS or STAM-1 and DTX3L or EEA1. 
 
YFP-FYVE CO-LOCALIZATION STUDIES 
To determine the effect of DTX3L silencing on endosomal phosophoinositol 3-
phosphate (PI-3P) levels, HeLa cells plated on coverslips were co-transfected with 1 µg 
YFP-2"FYVE and control or DTX3L siRNA for 48 hrs. Cells were serum starved in 1ml 
DMEM supplemented with 20 mM HEPES pH 7.5 for 3 h at 37 °C. Cells were then pre-
treated with DMSO or wortmannin (100 nM) for 30 min before stimulation with 10 nM 
CXCL12 for 1 h. Cells were processed as described above, however, cells were 
immunostained for DTX3L and EEA1. 
 
CONFOCAL FLUORESCENCE MICROSCOPY: IMAGE ACQUISITION AND 
PROCESSING 
Slides were viewed using a Zeiss LSM 510 laser-scanning confocal microscope 
equipped with a Plan-Apo " 63/1.4 numerical aperture oil DIC M27 lens objective. 
Images were acquired using a 1.4-megapixel cooled extended spectra range RGB digital 
camera set at 512 " 512 resolution. Specifically, the following parameters detailed below 
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were used to acquire images and did not vary unless stated otherwise. Scan mode was set 
at plane, original data, multitrack, 8 bit. Stack size was set at 512 x 512 x 1. Wavelengths 
used were 633 nm (17%), 561 nm (12%) and 488 nm (4.1%). Channel (Ch) filters were 
as follows: Ch 1 LP650, Ch 2 BP 505-550 and Ch 3 LP 575. Pinhole was set to 134 µM 
for each channel and images were scanned at a speed of 8. The software used to view 
acquired images was Carl Zeiss Laser Scanning System LSM 510. Images were also 
viewed using Zeiss LSM Image Browser version 4.2.0.121. Equal acquisition settings 
were used between parallel samples within each experiment. Specifically, control 
samples were first viewed for each experiment to determine optimal parameters for 
staining with each primary used and those same settings were used to view subsequent 
treated samples during the same sitting on the microscope. Gain and intensity values 
varied based on each primary and secondary combination used, but remained constant 
between each experiment repetition. 
Images were analyzed using ImageJ software (National Institutes of Health, 
version 1.37v) and processed using Adobe Photoshop (CS4). Pearson product-moment 
correlation coefficient was determined using the ImageJ plug-in “Colocalization Finder.” 
Pixels were restrained to the minimum ratio of 75% to reduce noise from channel bleed 
through. Analysis results in values ranging from 0 to 1, where 0 represents ‘no co-
localization’ and 1 represents ‘absolute co-localization’. Puncta analysis was performed 
using the “Analyze Particles” macro in ImageJ. Images (8-bit) were manually thresholded 
to minimum (130-150) and maximum (255) values to exclude background noise. 
Particles counted were restrained to a size of 0.05-1.0 and circularity of 0.5-1.0.  
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GST- AND His-FUSION PROTEIN PURIFICATION  
 Escherichia coli BL21 cells transformed (similar to protocol used in Section 
2.3.4) with cDNA encoding GST-fusion proteins in pGEX-6p1 or His-tagged proteins in 
pET-21a (+) vectors were inoculated in 5 ml LB-amp broth from glycerol stocks. 
Constructs used for GST and His purifications are listed in Table 2.8. Specifically, 10 µl 
of thawed glycerol stock was pipetted into LB-amp using sterile techniques. Sample was 
grown overnight at 37°C in an orbital shaker (Forma Scientific, Model 4518) set at 250 
rpm. The following morning, 30 ml cultures were diluted (3.7% dilution) into a 50 ml 
conical tube and grown to OD600 0.35–0.40 at 37°C in an orbital shaker (1-3 h). Protein 
expression was induced by adding isopropyl-1-thio-$-D-galactopyranoside (IPTG) to a 
final 0.1-0.3 mM concentration (IPTG; Sigma-Aldrich, St. Louis, MO) for 3 h at 18°C. 
Following induction, cells were pelleted by centrifugation (Beckman Coulter J6-HC 
centrifuge set at 4,000 rpm for 20 min at 4°C). Pellets were re-suspended in 0.7 mL lysis 
buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.1% Triton X-100, 1 mM dithiothreitol, 
10 µg/mL each of leupeptin, aprotinin, and pepstatin-A). For purification of His-tagged 
proteins DTT was omitted in the lysis buffer. Cells were lysed by sonication (Branson 
Digital Sonifier Model 450 set at 15% amplitude, 10 sec twice) on ice and clarified by 
centrifugation at 14,000 rpm for 20 min at 4°C (5417r-Eppendorf microcentrifuge). 
 
 
 
77 
EQUILIBRATION OF GLUTATHIONE-SEPHAROSE AND TALON METAL 
AFFINITY BEADS  
For GST-fusion or His-fusion protein purifications, glutathione-Sepharose 4B 
(GE Healthcare) or Talon Metal Affinity Beads (Clontech, Mountain View, CA) resin 
were first equilibrated in lysis buffer. This was done by washing three times with 750 !l 
of lysis buffer. Specifically for each wash, following the addition of wash buffer beads 
were rocked back and forth three times, subject to centrifugation for 15 sec at 10,000 rpm 
and excess buffer was aspirated between washes. The volume of the pelleted resin was 
determined by reading the graduations on the microcentrifuge tube. The resin was re-
suspended in an equal volume of lysis buffer to make a 50% slurry.  
 
IMMOBLIZATION OF GST- AND His-PROTEINS 
Clarified lysates were incubated with 25 !l of a 50% slurry of equilibrated 
glutathione-Sepharose 4B (GE Healthcare) or 20 !l of a 50% slurry of equilibrated Talon 
Metal Affinity Beads (Clontech, Mountain View, CA) resin for His-fusion proteins while 
rocking at 4˚C for 15-17 h. The next day immobilized proteins were washed three times 
with 750 !l of lysis buffer, pelleted by centrifugation at 10,000 rpm for 15 sec and re-
suspended in 100 !l of lysis buffer. For washes, following the addition of wash buffer 
samples were manually rocked back and forth three times, wash buffer was pelleted by 
microcentrifugation for 15 sec at 10,000 rpm (Thermo microcentrifuge 5519, model 120) 
and excess buffer was aspirated between washes. 
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QUANTIFICATION OF IMMOBILIZED GST- AND HIS- FUSION PROTEINS 
To determine the amount of purified protein, the immobilized protein was 
compared to known amounts of BSA. To accomplish this 10 !l of the total immobilized 
sample (100 !l) was combined with 10 !l of 2" sample buffer. Bound protein was eluted 
from the beads by boiling the sample at 100 ˚C for 5 min. Eluted proteins (10 !l) were 
resolved by 7% or 10% SDS-PAGE along with bovine serum albumin (BSA, Roche 
Diagnostics, Indianapolis, IN) standards (0.1 !g- 3 !g). Gel was place in a tray and 
washed in 100 ml distilled water for 30 min. Proteins were stained by incubating gel in 
approximately 50 ml of GelCode Blue stain while rocking at room temperature. GelCode 
Blue was decanted and the gel was then destained by washing with distilled water 2-3 
times for 15-30 min. Protein amounts were estimated by comparing the staining 
intensities of purified proteins to the BSA standards of known concentration. 
Concentration was confirmed by analyzing gel bands using densitometry and comparing 
values of purified proteins to the densities of the BSA standards to determine 
quantitatively the purified protein concentration. An example of typical purification yield 
for GST (0.2 !g/ !l), GST-DTX3L (0.1 !g/ !l) and GST-AIP4 (0.1 !g/ !l) is shown in 
Figure 2.1. 
 
79 
  
Figure 2.1 Example of a gel stained with GelCode Blue used to quantify amounts of 
GST-fusion proteins purified for this study. Representative image of GelCode Blue 
staining of a gel ran for GST-protein purification of GST, GST-DTX3L and GST-AIP4. 
Ten microliters of immobilized protein were eluted in 10 !l of 2" sample buffer. Sample 
was boiled, centrifuged and 10 !l of each eluted protein was subsequently run on 10% 
SDS-PAGE gel along with known BSA standards (0.1 !g, 0.5 !g, 1.0 !g and 3.0 !g). 
The gel was then washed in distilled H2O, stained with GelCode Blue and briefly 
destained with distilled H2O. Fusion protein concentration was then estimated by 
comparing intensities of fusion protein band to the BSA standards. As shown here, the 
protein concentration were estimated to be: GST = 0.2 !g/ !l; GST-DTX3L=0.1 !g/ !l 
and GST-AIP4 = 0.1 !g/ !l. 
 
ELUTION OF HIS-TAGGED PROTEINS 
His-tagged proteins bound to Talon Metal Affinity resin were eluted by 
incubating samples in elution buffer containing 100 mM imidazole. Specifically, 
immobilized proteins (20-50 !l) were eluted in 0.5 mL His purification lysis buffer 
containing 100 mM imidazole, while rocking overnight at 4˚C. The next day, samples 
were centrifuged for 30 sec at 10,000 rpm (Thermo microcentrifuge 5519, model 120) 
and supernatant was then subject to buffer exchange. Eluted proteins were dialyzed in 
10K MWCO, 20mm SnakeSkin dialysis tubing (Life Technologies) in 2 L of dialysis 
buffer (50 mM Tris-HCl, pH 7.4) stirring, overnight and concentrated using Spectra/Gel 
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absorbent (Spectrum Labs, Rancho Dominguez, CA). Twenty !l aliquots were aliquoted 
into microcentrifuge tubes and samples were immediately snap frozen on a mixture of 
dry ice plus methanol for 5 min. Samples were stored at -80˚C until use in experiments. 
Samples were quantified by resolving on 10% SDS-PAGE, followed by staining of gel 
with GelCode Blue. An example of a typical yield for the purification of His-DTX3L (0.1 
!g/ !l) and His-DTX3L-3C/A (0.075 !g/ !l) is shown in Figure 2.2. 
  
Figure 2.2 Example of a gel stained with GelCode Blue used to quantify amounts of 
His-fusion proteins purified for this study. Representative image of GelCode Blue 
staining of a gel ran for His-protein purification of His-DTX3L and His-3C/A. Ten 
microliters of imidazole eluted protein was diluted in 10 !l of 2" sample buffer and 10 !l 
of each sample was subsequently run on 10% SDS-PAGE gel along with known BSA 
standards (0.5 !g, 1.0 !g and 3.0 !g). The gel was then washed in distilled H2O, stained 
with GelCode Blue and briefly destained with distilled H2O. His-fusion protein 
concentration was then estimated by comparing intensities of fusion protein band to the 
BSA standards. Asterisk’s (*) denotes degradation products left over from purification. 
As shown here, the protein concentration were estimated to be: His-DTX3L=0.1 !g/ ! l 
and His-DTX3L-3C/A = 0.075 !g/ !l. 
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LARGE SCALE PURIFICATION AND PreScission PROTEASE CLEAVAGE OF 
GST-AIP4 AND GST-AIP4-C830A 
To generate purified cleaved AIP4 or AIP4-C830A, BL21 E. coli cells 
transformed with GST-AIP4 or GST-AIP4-C830A cDNA were inoculated into 30 ml of 
LB-amp broth at 37˚C overnight. The following morning, cultures were diluted into 500 
mL and grown at 37˚C for 3hr. Protein expression was induced with 0.3 mM IPTG 
(Sigma-Aldrich, St. Louis, MO) for 24 h at 18°C. Cells were then pelleted by 
centrifugation (4000 rpm for 30 min at 4˚C using a Beckman Coulter J6-HC centrifuge) 
and re-suspended in 10 mL of cold GST purification lysis buffer. Lysates were incubated 
for 30 min, while rocking at 4˚C. Samples were sonicated and then pelleted by 
microcentrifugation (4000 rpm for 30 min at 4˚C). To remove any small degradation 
products, supernatants (~10 ml) were placed in a 30 ml syringe and passed through a 0.2 
!M filter and were combined with 600 !l of a 50% slurry of glutathione-Sepharose 4B 
(GE Healthcare) resin overnight at rocking at 4˚C. Samples were washed three times with 
1000 !l lysis buffer. For washes, following the addition of wash buffer samples were 
rocked back and forth three times manually, beads were pelleted by microcentrifugation 
for 15 sec at 10,000 rpm (Thermo microcentrifuge 5519, model 120) and excess buffer 
was aspirated between washes. Samples were re-suspended in 1000 !l of lysis buffer.  
To cleave the GST (pGEX6P1) tag from GST-AIP4 and GST-C830A, 
immobilized proteins in lysis buffer (1000 !l) were directly incubated with 10 units of 
PreScission Protease (GE Life Sciences) for 12 h, while rocking at 4˚C. Eluted samples 
were dialyzed in 10K MWCO, 20mm SnakeSkin dialysis tubing (Life Technologies) in 2 
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L of dialysis buffer (50 mM Tris-HCl, pH 7.4) stirring, overnight and concentrated using 
Spectra/Gel absorbent (Spectrum Labs, Rancho Dominguez, CA). Samples were 
quantified by resolving on 10% SDS-PAGE, followed by staining of gel with GelCode 
Blue, similar to sections 2.9.3 and 2.9.4. An example of typical purification yield for 
cleaved AIP4 (0.2!g/ !l) and cleaved AIP4-C830A (0.2!g/ !l) is shown in Figure 2.3. 
Twenty-five !l aliquots were made into microcentrifuge tubes and samples were 
immediately snap frozen on a mixture of dry ice plus methanol for 5 min. Samples were 
stored at -80˚C until used in experiments.  
 
 
Figure 2.3 Example of a gel stained with GelCode Blue for cleaved AIP4 and AIP4-
C830A purification. Representative image of GelCode Blue staining of a gel ran for the 
purification and PreScission protease cleavage of (A.) GST-AIP4 and (B.) GST-AIP4-
C830A. Five microliters of each sample was diluted in 6 !l of 2" sample buffer and 5 !l 
of each sample was subsequently run on 10% SDS-PAGE gel along with known BSA 
standards (0.1 !g, 0.5 !g, 1.0 !g and 3.0 !g). ‘Cleaved’ sample represents GST-fusion 
protein that was cleaved with PreScission Protease and ‘Bound’ sample represents GST-
fusion protein that remain in bead volume after cleavage. The gel was then washed in 
distilled H2O, stained with GelCode Blue and briefly destained with distilled H2O. 
Protein concentration was then estimated by comparing intensities of fusion protein band 
to the BSA standards. Asterisk’s (*) denotes degradation products left over from 
purification. As shown here, the protein concentration of cleaved proteins was estimated 
to be: AIP4=0.2 !g/ !l and AIP4-C830A= 0.2!g/ !l. 
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GST- AND HIS-FUSION BINDING ASSAYS 
Binding assays were used to determine protein-protein interactions by affinity 
purification. 
 
GST- AND HIS-FUSION BINDING ASSAYS : LYSATE COLLECTION 
Typically for a binding reaction using HeLa cell lysates, HeLa cells were first 
plated onto 6-cm dishes. HeLa cells were either left untransfected or transfected with 
empty vector or desired DNA constructs for 24 h. Cells were washed two times with 3 ml 
1"PBS on ice and collected by gently scraping cells in 0.4 ml of binding buffer (20 mM 
Tris-HCl pH 7.4, 150 mM NaCl, 0.1% Triton X-100, 1 mM dithiothreitol, 20 mM N-
ethylmaleimide (NEM) and 10 µg/mL each of leupeptin, aprotinin, and pepstatin-A).  
Samples were rocked for 30 min at 4˚C and lysed by sonication (15 % amplitude, 10 sec) 
on ice. Lysates were cleared by microcentrifugation at 14,000 rpm for 20 min at 4°C 
(5417r-Eppendorf microcentrifuge). Protein concentrations of supernatants were 
determined using the BCA Protein Assay Kit (Pierce, Rockford, IL). A total of 100-500 
!g of supernatant was incubated with immobilized protein overnight while rocking at 4 
˚C. 
 
GST- AND HIS-FUSION BINDING ASSAYS : BINDING ASSAYS 
For GST-binding assays, immobilized fusion proteins were incubated with cleared 
HeLa lysates either transiently transfected without or with 1!g of FLAG-AIP4. Between 
100 !g -500 !g of cleared lysate was used in binding assays as detailed below. Samples 
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were incubated at 4˚C for 15-17 h while gently rocking. Samples were washed three 
times with 750 !1 of lysis buffer. Specifically, following the addition of wash buffer 
samples were manually rocked back and forth three times, beads were pelleted by 
microcentrifugation for 15 sec at 10,000 rpm (Thermo microcentrifuge 5519, model 120) 
and excess buffer was aspirated between washes. Samples were eluted with 25 !1 2" 
sample buffer and followed by immunoblot analysis. 
 
 
GST-DTX3L TRUCATIONS 
For binding reaction involving the GST-DTX3L N-terminal and C-terminal 
truncation mutants, equimolar amounts of GST, GST-DTX3L-full length, -NT or –CT 
(100 nmol) were incubated with cleared HeLa lysates (100 !g) transiently transfected to 
express FLAG-AIP4 or empty vector. Samples were incubated overnight and collected as 
described above. Lysates were subjected to immunoblot analysis for anti-FLAG-HRP 
(AIP4) and blot was stained with Ponceau to show amount of purified protein used the 
reaction.  
 
GST-AIP4 TRUNCATIONS 
For binding reaction involving the GST-AIP4 truncation mutants, equimolar 
amounts of GST, GST-AIP4, GST-C2, GST-WWI-IV or GST-HECT (200 nmol) were 
incubated with His-DTX3L (5nM). Samples were incubated overnight and collected as 
described above. Lysates were subjected to immunoblot analysis for DTX3L and GST.  
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AIP4 AND DTX3L BINDING 
To determine binding between GST-AIP4 and endogenous DTX3L, HeLa lysates 
(500 µg) were collected as described above and incubated overnight with immobilized 
GST or GST-AIP4 (100 nmols). DTX3L binding was determined by immunoblot 
analysis. To determine direct binding between AIP4 and DTX3L, increasing amounts of 
purified, eluted His-DTX3L (1-10 nM final concentration) were incubated with equal 
amounts of immobilized GST-AIP4 (100 nmol) in a volume of 100 !l for 1 h while 
gently rocking at 4˚C. Samples were washed three times with 750 !1 lysis buffer. 
Specifically, following the addition of wash buffer samples were manually rocked back 
and forth three times, beads were pelleted by microcentrifugation for 15 sec at 10,000 
rpm (Thermo microcentrifuge 5519, model 120) and excess buffer was aspirated between 
washes. Samples were eluted with 25 !1 2" sample buffer and followed by immunoblot 
analysis to determine His-DTX3L binding to GST-AIP4. 
 
GST- AND HIS-FUSION BINDING ASSAYS : DATA QUANTIFICAITON 
Data were quantified by densitometric analysis for each experiment. Values were 
averaged between experiments and represented as a fraction of GST or empty vector 
control.  
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CO-IMMUNOPRECIPITATION 
Co-immunoprecipitation assays were utilized to determine protein-protein 
interactions in cells using specific antibodies to capture target proteins as detailed in the 
following sections. 
 
TIME COURSE CO-IMMUNOPRECIPITATOIN  
To determine whether the interaction between DTX3L and AIP4 is dependent on 
CXCL12 treatment, we performed a time course co-immunoprecipitation. Specifically, 
HeLa cells plated in 10-cm dishes were serum starved for 4 h and then treated for 0-60 
min with 10 nM CXCL12 at 37°C. Cells were placed on ice, washed once with ice-cold 
PBS and lysed in immunoprecipitation buffer [20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 
1% Triton X-100, 20 mM N-ethylmaleimide (NEM), protease inhibitors (10 !g/mL each 
of aprotinin, leupeptin and pepstatin A (Roche))]. Lysates were cleared by centrifugation 
at 14,000 rpm for 20 min in a 5417r-Eppendorf microcentrifuge. Clarified lysates (500 
!g) were incubated with an antibody (2 !g) directed against DTX3L or goat IgG control 
for 16 h at 4 ˚C. Twenty !l of a 50% slurry of protein A agarose was then added and 
samples were incubated for an additional 1 h. Samples were then washed three times as 
follows: following the addition of wash buffer samples were rocked back and forth three 
times, beads were pelleted by microcentrifugation for 15 sec at 10,000 rpm (Thermo 
microcentrifuge 5519, model 120) and excess buffer was aspirated between washes. 
Immunoprecipitated proteins were denatured by the addition of 25 !l 2" sample buffer, 
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resolved by 7% SDS-PAGE and analyzed by immunoblotting using antibodies directed 
against AIP4, DTX3L, and actin.  
 
CO-IMMUNOPRECIPITATION OF ENDOGENOUS PROTEINS 
For the immunoprecipitation of endogenous proteins, lysates were collected in a 
similar fashion as Section 2.10.1, however, left untreated. Specifically, to determine the 
effect of DTX3L depletion on the binding between ESCRT-0 components HRS and 
STAM-1, HeLa cells were transfected with control siRNA or DTX3L siRNA (25 nM 
final concentration) for 24 h before immunoprecipitation of cleared lysates (300 !g) with 
2 !g of either anti-HRS or mouse IgG control and anti-STAM-1 or rabbit IgG control for 
1 h at 4 ˚C. Twenty !l of a 50% slurry of protein A agarose was then added and samples 
were incubated for an additional 1 h. Immunoblots were probed with antibodies against 
AIP4, DTX3L, HRS, STAM1 or actin.  
For endogenous DTX3L co-immunopecipitation experiments lysates were 
collected as stated above, however, cleared lysates (500!g) were immunoprecipitated 
with 3 !g of anti-DTX3L or goat IgG control. Samples were resolved by 7% SDS-PAGE 
and immunoblots were probed with antibodies against AIP4, DTX3L, HRS, STAM1 or 
actin.  
 
CO-IMMUNOPRECIPITATION DATA QUANTIFICATION 
Data were quantified by densitometric analysis for each experiment. For the time 
course co-immunoprecipitation analysis, values were averaged between experiments and 
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vehicle values were set to 1 and treatment times were represented as a fraction of vehicle. 
In the ESCRT-0 co-immunoprecipitations, the average of control siRNA values were set 
to 1 and DTX3L siRNA samples were calculated as a fraction of the control siRNA.  
 
UBIQUITINATION ASSAYS  
Ubiquitination assays were used to determine the ubiquitination of substrates in 
cells or in purified in vitro systems. 
 
HRS AND STAM UBIQUITINATION 
HeLa cells grown on 6-cm dishes were transfected with 1 !g FLAG-ubiquitin, 4 
!g T7-HRS or T7-STAM-1 and control siRNA or siRNA directed against DTX3L, AIP4 
or a combination (25 nM final concentration for each siRNA) using Lipofectamine® 3000 
(Invitrogen, Carlsbad, CA), as described in Section 2.1.2. Specifically, cells were first 
transfected with siRNA in the morning and then transfected with DNA seven hours later. 
The following morning, cells were placed on ice, washed twice with ice-cold PBS and 
collected into 2 mL microcentrifuge tubes with 200 !l of denaturing ubiquitination buffer 
[20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% SDS, 1% Triton X-100, 5 mM EDTA, 20 
mM N-ethylmaleimide (NEM), and protease inhibitors [10 !g/mL each of aprotinin, 
leupeptin and pepstatin A (Roche, Indianapolis, IN)] by gently scraping with a rubber 
policeman. Collected samples were boiled for 5 min at 100˚C on a heat block, sonicated 
(15%, 10 sec) on ice and diluted with 1.8 mL dilution buffer [20 mM Tris-HCl, pH 7.5, 
150 mM NaCl, 1% Triton X-100, 5 mM EDTA]. Cells were allowed to lyse for 1 h while 
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rocking at 4 ˚C. Samples were cleared by centrifugation (14,000 rpm, 25 min at 4 ˚C) and 
protein concentrations of supernatants were determined using the BCA Protein Assay Kit 
(Pierce, Rockford, IL). A total of 300 !g of supernatant was incubated with 2 !g of an 
anti-T7 goat polyclonal antibody overnight while rocking at 4 ˚C. The next day, samples 
were then incubated with 20 !l of a 50% slurry of Protein G agarose (Roche) for 1 h 
while rocking at 4 ˚C. Samples were washed twice with 500 !l dilution buffer as follows. 
Following the addition of wash buffer samples were rocked back and forth three times, 
beads were pelleted by microcentrifugation for 15 sec at 10,000 rpm (Thermo 
microcentrifuge 5519, model 120) and excess buffer was aspirated between washes. 
Bound proteins were eluted in 25 !l of 2" sample buffer, resolved by 7% or 12% SDS-
PAGE and then analyzed by immunoblotting with antibodies directed against the FLAG 
and T7 epitopes, DTX3L AIP4 or actin. 
 
CXCR4 UBIQUITINATION 
To examine CXCR4 ubiquitination, HEK293 cells grown on 10-cm dishes were 
first transfected with siRNA against control, DTX3L or AIP4 (25 nM final concentration) 
using Lipofectamine® 3000 as described in Section 2.1.2. Seven hours later cells were 
transfected with 3 !g FLAG-ubiquitin and 7 !g HA-CXCR4. The next morning cells 
were split 1:2 into 6-cm dishes. Twenty-four hours later cells were serum starved in 
DMEM incomplete plus 20 mM HEPES for 3 h at 37 ˚C, followed by stimulation with 30 
nM CXCL12 or vehicle for 30 min.  Cells were placed on ice and washed twice with 3 ml 
ice-cold 1"PBS. Samples were collected with 200 !l of denaturing ubiquitination buffer 
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by gently scraping with a rubber policeman. Samples were then boiled for 5 min at 100˚C 
on a heat block, sonicated (15%, 10 sec) on ice and diluted with 1.8 mL dilution buffer. 
Cells were allowed to lyse for 1 h while rocking at 4 ˚C. Samples were cleared by 
centrifugation (14,000 rpm, 25 min at 4 ˚C) and protein concentrations of supernatants 
were determined using the BCA Protein Assay Kit (Pierce, Rockford, IL). Supernatants 
(300 !g) were incubated with 2 !g of an anti-HA rabbit polyclonal antibody 
(Covance/Biolegend) while rocking overnight at 4 ˚C. Samples were then incubated with 
20 !l of a 50% slurry of Protein A agarose (Roche) for 1 h while rocking at 4 ˚C. 
Samples were washed twice with 500 !l dilution buffer. Bound proteins were eluted in 25 
!l of 2" sample buffer, resolved by 10%, 7% or 12% SDS-PAGE and then analyzed by 
immunoblotting with antibodies directed against the FLAG and HA epitopes, DTX3L, 
AIP4 or tubulin.  
 
IN VITRO UBIQUITINATION ASSAYS 
AIP4 AND DTX3L IN VITRO UBIQUITINATION 
To determine effect of DTX3L on AIP4 ubiquitination, in vitro ubiquitination 
assays were performed using 500 ng of GST-purified/cleaved AIP4 or AIP4-C830A-
HECT mutant and 1 !g His-DTX3L or DTX3L-3C/A RING mutant alone or in 
combination. Briefly, purified E3s were incubated alone or together with a master mix of 
E1 (0.5 !g), E2 (UbcH5c, 0.5 !g), and ubiquitin (2.5 !g) and ATP in a final volume of 
20 !l for 1 h 30 min at room temperature. Reactions were stopped by the addition of 20 
!l of 2" sample buffer. Samples were resolved by 7% or 12% SDS-PAGE and then 
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analyzed by immunoblotting with antibodies directed against the AIP4, DTX3L, 
ubiquitin or GST. 
 
AIP4, DTX3L AND PARKIN IN VITRO UBIQUITINATION 
To examine the effect of AIP4, DTX3L and Parkin ubiquitination alone and in 
combination, purified MBP-Parkin (500 ng), AIP4 (500 ng) and His-DTX3L (1 !g) were 
allowed to react alone and in combination for 1 h 30 min at room temperature similar to 
previous section. Samples were separated by 7% SDS-PAGE and analyzed by 
immunoblotting with antibodies directed against DTX3L, AIP4, Parkin and ubiquitin. 
 
STATISTICAL ANALYSIS AND FINAL FIGURE PREPARATION  
Data were analyzed by Student's t-test, one-way analysis of variance (ANOVA) 
using GraphPad Prism 4.0 for Macintosh (GraphPad Software, San Diego, CA). Figures 
were created using Adobe! Illustrator CS4. 
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Table 2.1 List of Primary Antibodies used in this project 
Antibody 
Name 
Clone/N
ame 
Type Vendor Catalog 
Number 
Anti-T7   goat polyclonal Abcam ab9138 
Anti-T7    mouse monoclonal  Novagen 69522-3 
Anti-HA.11 16B12 mouse monoclonal BioLegend/Covance mms-101p 
Anti-HA  101R rabbit polyclonal BioLegend/Covance prb-101p 
Anti-FLAG-
HRP 
M2 mouse monoclonal Sigma A8592-1MG 
Anti-FLAG M2 mouse monoclonal Sigma F3165-1MG 
Anti-FLAG   rabbit polyclonal Sigma F7425 
Anti-FLAG M1 mouse monoclonal Sigma F3040-1MG 
Anti-LAMP2  H4B1 mouse monoclonal Developmental 
Studies Hybridoma 
Bank at the University 
of Iowa 
H4B4 
Anti-EEA1   mouse monoclonal BD 610457 
Anti-tubulin   mouse monoclonal Developmental 
Studies Hybridoma 
Bank at the University 
of Iowa 
12G10 
Anti-actin   mouse monoclonal Developmental 
Studies Hybridoma 
Bank at the University 
of Iowa 
JLA20 
Anti-DTX3L N-16 goat polyclonal Santa Cruz sc-102497 
Anti-UbcH5c   mouse monoclonal Abcam ab58251 
Anti-UbcH5c   rabbit monoclonal Cell Signaling 
Technologies 
#4330 
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Anti-UbcH7   rabbit monoclonal Abcam ab108936 
Anti-Itch 
(AIP4) 
  rabbit monoclonal Abcam ab108515 
Anti-Itch 
(AIP4) 
  rabbit monoclonal Abcam ab109018 
Anti-Itch 
(AIP4) 
  mouse monoclonal BD 611198 
  
Anti-HRS C-7 mouse monoclonal Santa Cruz sc-271455 
Anti-HRS   rabbit polyclonal Proteintech 10390-1-AP 
Anti-STAM-1   rabbit polyclonal Proteintech 12434-1-AP 
Anti-Ubiquitin P4D1 mouse monoclonal Santa Cruz sc-8017 
Anti-CXCR4 2B11 rat BD 558644 
 
Table 2.2 List of reagents used in this dissertation work 
Reagent Vendor 
Dulbecco's modified Eagle's medium 
(DMEM) Hyclone Laboratories  
Phosphate Buffered Saline (1"PBS) Hyclone Laboratories 
Trypsin EDTA 1" Gibco by Life Technologies 
HEPES, pH 7.5 Hyclone Laboratories  
paraformaldehyde (PFA) Sigma-Aldrich 
Poly-L-lysine (PLL) Sigma-Aldrich 
Lipofectamine$ 2000 Invitrogen 
Lipofectamine$ 3000 Invitrogen 
Polyethylenimine (PEI) Polysciences, Inc. 
DEPC RNAase/DNAase free water Invitrogen 
Ethanol, 200 proof Decon Laboratories Inc. 
Methanol Fisher Scientific 
Isopropanol Sigma-Aldrich 
Talon Metal Affinity Resin Clontech 
Glutathione Sepharose 4B GE Healthcare 
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Sodium chloride (NaCl) Sigma-Aldrich 
Tris Base Fisher Scientific 
Tween-20 Sigma-Aldrich 
Glycine Sigma-Aldrich 
D-Dithiothreitol (DTT) Roche 
Triton X-100 Sigma-Aldrich 
N-Ethylmalemide (NEM) Sigma-Aldrich 
Hydrochloric acid (HCl) Acros 
Isopropyl-B-D-1-thiogalactopyranoside 
(IPTG) Sigma-Aldrich 
Ampicillin Sigma-Aldrich 
Kanamycin Sigma-Aldrich 
Sodium Dodecyl Sulfate (SDS) Roche 
Dimethyl Sulfate (DMSO) Sigma-Aldrich 
DURA extended duration substrate Thermo Scientific 
luminal (3-aminophathalhydrazide)  Sigma-Aldrich 
p-coumaric acid  Sigma-Aldrich 
hydrogen peroxide  Sigma-Aldrich 
Imidazole Sigma-Aldrich 
CXCL12 PeproTech 
EGF PeproTech 
AMD3100 Sigma-Aldrich 
Leupeptin (for IF-M) Sigma-Aldrich 
VECTASHIELD Mounting Media with DAPI Vector Labs 
ProLong GOLD Mounting Media with DAPI Invitrogen 
Protein A agarose Roche 
Protein G agarose Roche 
Saponin Sigma-Aldrich 
Bovine serum albumin fraction V Roche 
Non Fat Dry Milk Baker's Corner, ALDI 
Acrylamide/Bisacrylamide, 37.5:1 Roche 
TEMED Thermo Scientific 
Ammonia persulfate (APS) Sigma-Aldrich 
Nitrocellulose, 0.45 µm BioRad; GE Healthcare 
Nitrocellulose, 0.2 µm BioRad 
Ponceau-S Sigma-Aldrich 
Aprotinin Roche 
Pepstatin-A Roche 
Leupeptin Roche 
Gel Code® Blue Stain Reagent Thermo Scientific 
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X-ray Film, high contrast blue  Dot Scientific  
X-ray Film, Classic blue autoradiography film 
BX MIDSCI 
Microscope coverglass 22x22 mm No. 2 Fisher Scientific 
Premium microscope slides, frosted Fisher Scientific 
Mini-prep kit Qiagen  
Maxi-prep kit Qiagen  
NEB Buffer 3 NEB 
Agarose dot scientific Inc. 
beta-mercaptoethanol Sigma-Aldrich 
bromophenol blue Fisher Scientific 
T4-DNA ligase and buffer Promega 
Fetal bovine serum (FBS) 
Hyclone Laboratories ; Fisher 
Scientific 
PreScission Protease GE Healthcare 
Wortmannin   
Luria Broth Fisher Scientific 
Agar Fisher Scientific 
Glycerol  Sigma-Aldrich 
10K MWCO, 20mm SnakeSkin dialysis 
tubing  Life Technologies 
Spectra/Gel absorbent  
Spectrum Labs, Rancho Dominguez, 
CA 
BCA Protein Assay Kit Pierce, Rockford, IL 
EDTA Sigma-Aldrich 
E1 Boston Biochem 
E2, UbcH5c Boston Biochem 
Mg-ATP Activating Solution Boston Biochem 
10" ubiquitination buffer Boston Biochem 
ubiquitin Boston Biochem 
Expand High Fidelity PCR System Roche 
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Table 2.3 List of secondary antibodies used in this project 
Secondary Anti-
body Species Vendor 
Catalog 
Number 
anti-goat-HRP horse Vector Labs PI-95000 
anti-mouse-HRP goat Vector Labs PI-2000 
anti-rabbit-HRP goat Vector Labs PI-1000 
anti-rat-HRP goat Calbiochem DC01L 
Alexa-Fluor-488 rabbit Invitrogen A11070 
Alexa-Fluor-488 mouse Invitrogen A11029 
Alexa-Fluor-488 rat Invitrogen A11006 
Alexa-Fluor-555 goat Invitrogen A21432 
Alexa-Fluor-555 mouse Invitrogen A21424 
Alexa-Fluor-568 rabbit Invitrogen A11036 
Alexa-Fluor-635 mouse Invitrogen A31575 
Alexa-Fluor-633 rat Invitrogen A21094 
Alexa-Fluor-633 rabbit Invitrogen A21071 
Alexa Fluor-EGF-488   Invitrogen E13345 
 
Table 2.4 List of siRNA used for this dissertation work 
Name Sequence Source 
AIP4 GGUGACAAAGAGCCAACAGAG Dharmacon RNA 
Technologies (Lafayette, 
CO) Cat. No. MARAD-
000018 
DTX3L 1. GGAGAAAGGAGGCGAAUUA 
2. GGAGUUGAAUCACCAGUUU 
3. GAAAGAGGGUCAUGAAACA 
4. CAAGAUACCUGUGAAACUA 
SMARTpool, Dharmacon 
RNA Technologies 
(Lafayette, CO) 
Cat. No. M-007143-01-003 
DTX1 1. GAAGAUACAUGCAGAAGGU 
2. GAUAUGGACAUCUGCAUCA 
3. GAAGAAGUUCACCGCAAGA 
4. CCAAGAAGAAGCACCUUAA 
SMARTpool, Dharmacon 
RNA Technologies 
(Lafayette, CO) 
Cat. No. M-006525-00-003 
DTX2 1. GGACCAUCCUCAUAGUUUA 
2. CAACUACACUGUCAACUAC 
3. CAGGACCGCUUCUGUGUUU 
4. GAUACAGCGAUGUGACUGA 
SMARTpool, Dharmacon 
RNA Technologies 
(Lafayette, CO) 
Cat. No. M-007114-02-003 
DTX3 1. GCACCAUUGUCAUCCAGUA 
2. GGCGGAUGCUGGUCUCUAA 
3. UCAAGGGGCUGCUAAAAGA 
4. CCUCAUAGAUGGCGAGACU 
SMARTpool, Dharmacon 
RNA Technologies 
(Lafayette, CO) 
Cat. No. M-007156-01-003 
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Cbl 1. GGAGACACAUUUCGGAUUA 
2. GAUCUGACCUGCAAUGAUU 
3. GACAAUCCCUCACAAUAAA 
4. CCAGAAAGCUUUGGUCAUU 
SMARTpool, Dharmacon 
RNA Technologies 
(Lafayette, CO) 
Cat. No. M-003003-02-0003 
Cbl-b 1. GACCAUACCUCAUAACAAG 
2. UGAAAGACCUCCACCAAUC 
3. GAUGAAGGCUCCAGGUGUU 
4. UAUCAGCAUUUACGACUUA 
SMARTpool, Dharmacon 
RNA Technologies 
(Lafayette, CO) 
Cat. No. M-003004-02-0003 
UbcH5a GGUGUAGUCAUUAGCAAA Integrated DNA 
Technologies (Coralville, 
Iowa) Cat. No. 87294301 
UbcH5b GGAUAACCUCUACAAAUA Integrated DNA 
Technologies (Coralville, 
Iowa) Cat. No. 87294304 
UbcH5c UGCAUGUCAAUAAAGGAAUGACCTG Integrated DNA 
Technologies (Coralville, 
Iowa) Cat. No. 121392347 
UbcH7 ACUAGAUCCUGUGGAGAAGAUGACT 
 
 
Integrated DNA 
Technologies (Coralville, 
Iowa) Cat. No. 121392344 
UbcH9 1. GCAUAGCCACUCAGUAUUU 
2. GCUAAGUUAUCCACUAGUG 
3. AUAUGAAGGUGGUGUGUUU 
4. GGAGCUAGCUGAAAUAACC 
SMARTpool, Dharmacon 
RNA Technologies 
(Lafayette, CO)  
Cat. No. M-008845-00 
 
Table 2.5 DNA constructs used for this dissertation work  
Construct Name Vector Reference 
 
AIP4 constructs 
FLAG-AIP4 pCMV10 Marchese and Benovic, 2001 
GST-AIP4 pGEX-4T2 Bhandari et al., 2007 
GST-AIP4-C830A pGEX-6P1 Holleman and Marchese, 2014 
GST-AIP4-C2 pGEX-4T2 Bhandari et al., 2007 
GST-AIP4-dPRR pGEX-4T2 Malik et al., 2011 
GST-AIP4-WWI-IV pGEX-4T2 Bhandari et al., 2007 
GST-AIP4-dWWI-IV pGEX-4T2 Bhandari et al., 2007 
GST-AIP4-HECT pGEX-4T2 Bhandari et al., 2007 
Myc-AIP4 pRK5 Marchese et al., 2003 
 
CXCR4 constructs 
HA-CXCR4 pcDNA3.0 Marchese and Benovic, 2001 
FLAG-CXCR4 pCMV-10 Malik and Marchese, 2010 
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DTX3L constructs 
DTX3L pCMV-
SPORT6 
Thermo Scientific 
FLAG-DTX3L pCMV-10 Holleman and Marchese, 2014 
GST-DTX3L pGEX6p1 Holleman and Marchese, 2014 
GST-DTX3L-NT pGEX6p1 Holleman and Marchese, 2014 
GST-DTX3L-CT pGEX6p1 Holleman and Marchese, 2014 
His-DTX3L pET-21a(+) Holleman and Marchese, 2014 
His-DTX3L-3C/A pET-21a(+) Holleman and Marchese, 2014 
 
Other constructs 
HA-Ubiquitin pcDNA3.0 Bhandari et al. 2007 
FLAG-Ubiquitin pCMV-10 Marchese and Benovic, 2001 
FLAG-HRS pCMV-10 Malik and Marchese, 2010 
FLAG-STAM-1 pCMV-10 Malik and Marchese, 2010 
FLAG-Arrestin-1 pCMV-10 Source unknown  
FLAG-Arrestin-2 pCMV-10 Source unknown  
FLAG-UbcH5c pcDNA3 Gift from Dr. Noriyuki Matsuda 
FLAG-UbcH7 pcDNA3 Gift from Dr. Noriyuki Matsuda 
GST-STAM-1 pGEX-4T2 Malik and Marchese, 2010 
T7-HRS Unknown Marchese et al., 2003 
T7-STAM-1 Unknown Malik and Marchese, 2010 
YFP-HRS-2"FYVE pEYFP-C1 Holleman and Marchese, 2014 
His pET-21a(+) Gift from Katherine L. Knight 
 
 
Table 2.6 Primers used to generate constructs for this dissertation  
Construct 
Name 
Primers (5’ to 3’) 
FLAG-
DTX3L  
(1-740) 
F: 5’ATATGCGGCCGCGCCTCCCACCTGCGCCCGCCGTC 
R: 5’ATATTCTAGATTACTCAATTCCTTTGGCTTTC 
FLAG-
DTX1 
(1-620) 
F: 5’ATAT AAGCTTTCACGGCCAGGCCACGGTGGGC 
R: 5’ATAT TCTAGATCAAGCCTGGTGTCGACTCCGGC 
FLAG-
DTX2 
(1-622) 
F: 5’ATAT AAGCTTGCCATGGCCCCAAGCCCTTCCC 
R: 5’ ATAT TCTAGACTGCTGCTCCAGGCAGTC 
FLAG-
DTX3L-
F: 5’ GAAGGAAAAGGGCATCGCTGTCATCTGTATGGACACC 
R: 5’ GGTGTCCATACAGATGACAGCGATGCCCTTTTCCTTC 
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C561A 
FLAG-
DTX3L-
C596/599A 
F: 5’CATGTCATATAAGCCAATGCTCCCACAGCCCAGACTTCCTATGGTATTC 
R: 
5’GAATACCATAGGAAGTCTGGGCTGTGGGAGCGATTGGCTTATATGACATG  
 
GST-
DTX3L 
(1-740) 
F: 5’ATATGGATCCGCCTCCCACCTGCGCCCGCCGTC 
R: 5’ATATCTCGAGTTACTCAATTCCTTTGGCTTTC 
GST-
DTX3L-
3C/A 
F: 5’ATATGGATCCGCCTCCCACCTGCGCCCGCCGTC 
R: 5’ATATCTCGAGTCAGATGCCCTTTTCCTTCTTGTCCAGTTCAAAGC 
 
GST-
DTX3L-
NT 
(1-464) 
F: 5’ATATGGATCCGCCTCCCACCTGCGCCCGCCGTC  
R: 5’ATATCTCGAGTCAGATGCCCTTTTCCTTCTTGTCCAGTTCAAAGC 
 
GST-
DTX3L-CT  
(528-740) 
F: 5’ATATGGATCCGACATTGATAGCGATGATTCC 
R: 5’ATATCTCGAGTTACTCAATTCCTTTGGCTTTC 
  
His-
DTX3L 
(1-740) 
F: 5’ATATGGATCCGCCTCCCACCTGCGCCCGCCGTC 
R: 5’ATATCTCGAGCTCAATTCCTTTGGCTTTCAGCTC 
 
His-
DTX3L-
3C/A 
F: 5’ATATGGATCCGCCTCCCACCTGCGCCCGCCGTC 
R: 5’ATATCTCGAGCTCAATTCCTTTGGCTTTCAGCTC 
 
GST-AIP4-
C830A 
F: ATATGGATCCGGTAGTCTGACCATGAAATCTCAACTTCAG 
R: ATATGCGGCCGCTTACTCTTGTCCAAATCCTTCTGTTTCTTCTAG 
 
Table 2.7 Restriction enzymes used for cloning in this dissertation 
Enzyme 
 
Recognition 
Sequence 
Vendor Cat. No. 
NotI GC%GGCC  GC 
CG  CCGG&CG 
Promega R643A 
XbaI T%CTAG  A 
A  GATC&T 
Promega R618A 
BamHI G%GATC  C 
C   CTAG&G 
Promega R602A 
XhoI C%TCGA  G 
G  AGCT&C 
Promega R6161 
EcoRI G%AATT   C 
C   TTAA&G 
Promega R6011 
ApaI G  GGCC%C 
C&CCGG  G 
Promega R636A 
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Table 2.8 GST- and His-fusion proteins used in this study 
Number Fusion protein 
1. GST 
2. GST-AIP4 
3. GST-AIP4-C830A 
4. GST-AIP4-C2 
5. GST-AIP4-dC2/dPRR 
6. GST-AIP4-WWI-IV 
7. GST-AIP4-dWWI-IV 
8. GST-AIP4-HECT 
9. GST-DTX3L 
10. GST-DTX3L-NT 
11. GST-DTX3L-CT 
12. GST-STAM-1 
13. His-DTX3L 
14. His-DTX3L-3C/A 
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CHAPTER III 
RESULTS 
ROLE OF DTX3L IN CXCR4 DEGRADATION 
Endosomal sorting of the chemokine receptor 4 (CXCR4) into the degradative 
pathway is important for controlling both the duration and magnitude of CXCR4 
signaling (Malik, Soh, Trejo, & Marchese, 2012; Marchese et al., 2003). Ubiquitin is 
known to regulate CXCR4 sorting into the degradative pathway, however, the precise 
mechanisms by which this occurs remains poorly understood (Bhandari, Trejo, Benovic, 
& Marchese, 2007; Malik & Marchese, 2010; Marchese & Benovic, 2001; Marchese et 
al., 2003). Agonist activated CXCR4 is rapidly ubiquitinated at the plasma membrane by 
the E3 ligase AIP4 and once internalized onto endosomes is sorted towards lysosomes by 
the endosomal sorting complex required for transport (ESCRT) machinery. AIP4 also 
ubiquitinates ESCRT-0, negatively impacting its sorting function to control the amount of 
CXCR4 that is targeted for lysosomal degradation (Malik & Marchese, 2010; Marchese 
et al., 2003). These data indicate that AIP4 is a central player in governing CXCR4 
degradation and yet the mechanism regulating AIP4 remains poorly understood.  
Given previous literature that suggest that AIP4 can interact with RING domain E3 
ligases including Cbl-c and deltex-1 (DTX1), we tested the hypothesis that the DTX 
and/or Cbl ligases are involved in CXCR4 trafficking (Chastagner, Israel, & Brou, 2006; 
Courbard et al., 2002). Initially, we performed a preliminary small interfering RNA 
(siRNA) screen to determine the role of deltex (DTX) and Casita B-lineage Lymphoma 
(Cbl) proteins in regulating agonist promoted degradation of CXCR4. To determine this 
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we examined agonist promoted degradation of endogenous CXCR4 in HeLa cells by 
immunoblot analysis, similar to previously described (Bhandari et al., 2007; Malik & 
Marchese, 2010; Marchese et al., 2003). HeLa cells were transfected with siRNA against 
control, AIP4, DTX1-3, DTX3L, c-Cbl or Cbl-b. Twenty-four hours later cells were split 
into single wells of a 24 well plate and grown overnight at 37˚C. The following day, cells 
were treated with vehicle (0.1% BSA + PBS) or 10 nM CXCL12 for 3 h in the presence 
of the protein synthesis inhibitor cyclohexamide. Cyclohexamide is used in order to 
prevent de novo CXCR4 synthesis during the 3 h treatment period. Cells were harvested 
in 2x sample buffer and subjected to SDS-PAGE followed by immunoblot analysis for 
CXCR4. As shown in Figure 3.1, siRNA against AIP4 and DTX3L results in depletion of 
AIP4 and DTX3L, respectively. Similar to our previously published results, siRNA 
mediated knockdown of AIP4 significantly attenuates CXCR4 agonist-promoted 
degradation when compared to control (Marchese et al., 2003). (Figures 3.1, 3.2 and 3.3).  
Additionally, agonist-promoted degradation of CXCR4 was significantly inhibited in 
cells transfected with siRNA against DTX3L as compared to cells transfected with 
control siRNA (Figure 3.1).  
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Figure 3.1 DTX3L regulates CXCR4 degradation. A. HeLa were transiently transfected with control 
(Ctrl), AIP4 or DTX3L siRNA and treated with vehicle (0.1% BSA + PBS) or 10 nM CXCL12 for 3 h. 
Whole cell lysates were collected and analyzed for the level of endogenous CXCR4, AIP4, DTX3L or actin 
by immunoblot (IB) analysis. B.  The percent of CXCR4 levels normalized to actin were determined by 
densitometric analysis. Data are representative of the average percent of CXCR4 degradation following 
CXCL12 treatment from 8 independent experiments. Data were analyzed by one-way ANOVA (p<0.001), 
followed by Bonferroni’s post-hoc test for multiple comparison amongst the groups. Compared to control 
siRNA-treated cells, AIP4 (p<0.001) and DTX3L (p<0.001) siRNA depletion significantly attenuated 
CXCR4 degradation. 
 
In contrast, depletion of Cbl and DTX1-3 proteins had no effect on CXCR4 degradation 
(Figures 3.2 and 3.3). Although no phenotype was displayed, we were unable to 
determine knockdown of DTX1-4 and Cbl proteins due to lack of suitable reagents. 
Future studies will be required to confirm knockdown either of protein or mRNA by 
immunoblot or qPCR analysis, respectively.  Overall, these data suggest a novel role for 
the DTX protein DTX3L in mediating CXCR4 degradation. 
 
   CXCL12 (10 nM): - +
IB
52
101
101
 72
siD
TX
3LsiC
trl
siA
IP4
0
50
   100
75
P<0.001
%
 C
XC
R
4 
D
eg
ra
de
d
50
DTX3L
Actin
AIP4
CXCR4
Ctrl DTX3LAIP4    siRNA: 
25
P<0.001
***
***
- + - +
Figure 1. Holleman and Marchese
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Figure 1. A role for DTX3L in CXCR4 degradation. (A) HeLa cells transfected with siRNA directed  against  GAPDH, 
AIP4 or DTX3L were treat  with vehicl  (PBS + 0.1% BSA) or 10 nM CXCL12 for  3 h. Whole cell  lysates were analyzed 
for the levels of endogenous CXCR4 and the indicated proteins by immunoblotting (IB). (B) CXCR4 levels normalized to 
actin were determined by densitometric analysis. Data represent the average percent CXCR4 degraded in CXCL12 
treated cells as compared to vehicle treated cells from 8 independent experiments. Error bars represent the standard error 
of the mean. Data were analyzed by a on -way ANOVA(p < 0.0001), followed by Bonferroni's post-hoc test. CXCR4 degradation in 
AIP4 (p < 0.001) and DTX3L (p < 0.001) siRNA treated cells was significantly different from siRNA control (siCtrl). 
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Figure 3.2 Cbl proteins in CXCR4 degradation. A. HeLa were transiently transfected with Ctrl, AIP4, c-
Cbl or Cbl-b siRNA and treated with vehicle or 10 nM CXCL12 for 3 h. Whole cell lysates were collected 
and analyzed for the level of endogenous CXCR4 and tubulin by IB analysis. B.  The percent of CXCR4 
levels normalized to actin were determined by densitomeric analysis. Data are representative of the average 
percent of CXCR4 degradation following CXCL12 treatment from two independent experiments. Data 
were quantified by densitomeric analysis and analyzed by one-way ANOVA (**p = 0.0067) followed by 
Bonferroni’s post-hoc test. Error bars represent the standard deviation. 
 
 
Figure 3.3 DTX proteins in CXCR4 degradation.  
A. HeLa were transiently transfected with Ctrl, AIP4, DTX3L or DTX1-3 siRNA and treated with vehicle 
or 10 nM CXCL12 for 3 h. Whole cell lysates were collected and analyzed for the level of endogenous 
CXCR4 and tubulin by IB analysis. B.  The percent of CXCR4 levels normalized to actin were determined 
by densitometric analysis. Data are representative of the average percent of CXCR4 degradation following 
CXCL12 treatment. Data were quantified by densitomeric analysis and analyzed by one-way ANOVA 
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(***p = 0.0004). Data represent three independent experiments for Ctrl, AIP4 and DTX3L or two 
independent experiments for DTX1-3. Error bars represent the standard deviation.  
 
CXCR4 ACTIVATION PROMOTES DTX3L DISTRIBUTION TO THE 
SURFACE OF EARLY ENDOSOMES 
Given the novel role identified for DTX3L in regulating CXCR4 degradation, we 
next assessed the subcellular distribution of endogenous DTX3L in HeLa cells following 
CXCL12 treatment. To determine whether CXCL12 could regulate DTX3L localization 
to either early endosomes or late endosomes/lysosomes, we employed fixed cell 
confocal immunofluorescence microscopy. HeLa cells plated onto coverslips were 
serum starved for 3 h and treated with CXCL12 or vehicle for 30 min. Cells were then 
co-stained for endogenous DTX3L along with early endosomal and lysosomal markers 
EEA1 and LAMP2, respectively. As shown in Figure 3.4, endogenous DTX3L staining 
appears mostly diffuse in vehicle-treated cells with some punctate staining that co-
localizes little with the early endosomal marker EEA1 and the lysosomal marker 
LAMP2 (Figure 3.4C). In contrast, upon CXCL12 treatment, DTX3L puncta were 
significantly increased (Figures 3.4A and B). Additionally, in contrast to vehicle, 
CXCL12 treatment significantly increased the degree of co-localization of DTX3L with 
EEA1-positive early endosomes (Figures 3.4A and C) compared to control whereas 
DTX3L co-localization to LAMP2-positive lysosomes was only modestly increased 
(Figures 3.4A and D). 
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Figure 3.4 CXCR4 activation promotes DTX3L distribution on early endosomes. A. HeLa cells grown 
on coverslips were serum starved for 3hrs. Media was replaced with media containing vehicle or 10 nM 
CXCL12 for 30 min placed at 37˚C. HeLa cells were treated with vehicle or 10 nM CXCL12 for 30 min. 
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Cells were fixed, permeabilized and immunostained for endogenous DTX3L and EEA1 or LAMP2. Yellow 
in the “merge” panel indicates co-localization between DTX3L and EEA1 or LAMP2. Differential 
interference (DIC) contrast images are shown. B. Quantification of DTX3L puncta in vehicle or CXCL12 
treated cells using the ImageJ Function “Analyze Particles.” Threshold was set at a minimum of 130 and 
maximum of 255. CXCR4 activation significantly increases DTX3L puncta. C,D. Quantification of 
average co-localization between DTX3L and EEA1 (C) or LAMP2 (D) using the Pearson product moment 
correlation co-efficient. Correlation was determined using the ImageJ plug-in “Colocalization Finder.” 
Error bars represent the standard error of the mean. Data are representative of four independent 
experiments and analyzed by a Student’s t test.  
 
DTX3L REGULATES CXCR4 TRAFFICKING 
Because CXCR4 is sorted for degradation by trafficking from early endosomes to 
lysosomes (Bhandari et al., 2007; Marchese & Benovic, 2001; Marchese et al., 2003) and 
since CXCL12 treatment promotes DTX3L localization on to early endosomes (Figures 
3.4A and C), we next sought to determine whether DTX3L regulates the trafficking of 
CXCR4 from early endosomes to lysosomes. In order to address this question, we used 
confocal immunofluorescence microscopy to monitor the distribution of CXCR4 in HeLa 
transiently transfected with control or DTX3L siRNA. Images were acquired under equal 
acquisition settings between parallel experiments as detailed in Methods Section 2.7.  In 
control siRNA cells, treatment with CXCL12 significantly increased CXCR4 localization 
to LAMP2-labeled lysosomes with little CXCR4 co-localizing to the early endosomal 
marker EEA1 (Figures 3.5A and 3.6A) indicating that CXCR4 has trafficked from early 
endosome to lysosomes. In contrast to control, depletion of DTX3L significantly 
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increased the amount CXCR4 puncta (Figures 3.5A and 3.6B) and the co-localization of 
CXCR4 with EEA1-positive early endosomes (Figures 3.5A and 3.6A), indicating that 
CXCR4 sorting to lysosome is impaired. Overall, these data indicate that DTX3L is 
important in mediating CXCR4 sorting from early endosomes to lysosomes. 
 
 
Figure 3.5 DTX3L promotes CXCR4 endosomal to lysosomal degradation. A. HeLa cells grown on 
coverslips transiently transfected with either control or DTX3L siRNA were serum starved for 3hrs. Media 
was replaced with media containing vehicle (PBS + 0.1% BSA) or 10 nM CXCL12 for 30 min placed at 
37˚C. Cells were fixed, permeabilized and co-stained for endogenous CXCR4, DTX3L and EEA1 or 
LAMP2. CXCR4 is shown in green, DTX3L is shown in blue and EEA1 or LAMP2 are shown in red. 
Yellow puncta in the “merge” image indicate co-localization between CXCR4 and EEA1 or LAMP2. 
Images represent four independent experiments, 45-60 cells. Differential interference (DIC) contrast 
images are shown.   
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Figure 3.6 DTX3L is required for CXCR4 localization to and degradation in lysosomes. A. 
Quantification of average co-localization between CXCR4 and EEA1 or LAMP2 using the Pearson product 
moment correlation co-efficient. Correlation was determined using the ImageJ plug-in “Colocalization 
Finder.” Data were analyzed by one-way ANOVA (p<0.001), followed by Bonferroni’s post-hoc test. B. 
Quantification of CXCR4 puncta in control and DTX3L siRNA-treated cells. Puncta were analyzed using 
the ImageJ function “Analyze Particles.” Data are representative of the average puncta from four 
independent experiments, 45-60 cells. Threshold was set at a minimum of 130 and maximum of 255.  Error 
bars represent the standard error of the mean. Data were analyzed by a Student’s t test.   
 
AIP4 AND DTX3L DIRECTLY INTERACT 
Since DTX3L not only co-localizes with CXCR4 upon activation, but also 
regulates the extent to which CXCR4 degrades, we next wanted to determine the 
mechanism by which DTX3L controls CXCR4 endosomal sorting. Given the role of 
DTX3L in CXCR4 degradation (Figures 3.1 and 3.5) we hypothesize that DTX3L may 
interact with key CXCR4 regulators, including AIP4 and ESCRT-0. In particular, prior 
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studies have shown that AIP4 interacts with other E3 ligases including DTX1 and Cbl-c 
(Chastagner et al., 2006; Courbard et al., 2002). Therefore, we tested whether DTX3L 
could interact with AIP4 and the ESCRT-0 subunits, HRS and STAM-1 by co-
immunoprecipitation. We immunoprecipitated endogenous DTX3L from HeLa cells and 
assessed whether endogenous AIP4 or ESCRT-0 were present in the immunoprecipitates 
by immunoblot analysis. As seen in Figure 3.7A, endogenous AIP4 and ESCRT-0 
subunits, HRS and STAM-1 immunoprecipitated with DTX3L, but not immunoglobulin 
G (IgG), used here as an isotype control. These data indicate that DTX3L can interact 
with AIP4 and ESCRT-0, suggesting that potentially through these interactions DTX3L 
may regulate endosomal sorting of CXCR4. 
In order to determine the mechanism by which DTX3L controls CXCR4 
endosomal sorting, we first focused on the interaction between AIP4 and DTX3L. First, 
we determined whether AIP4 and DTX3L directly interact by performing binding 
experiments using purified proteins. As shown in Figure 3.7B, recombinant His-DTX3L 
interacts directly with recombinant GST-AIP4 in a concentration-dependent manner. 
Second, we tested whether the interaction of AIP4 and DTX3L is promoted by CXCL12 
treatment. HeLa cells were treated with or without CXCL12 for various times (0 - 60 
min) and endogenous DTX3L was immunoprecipitated, followed by immunoblot 
analysis using an anti-AIP4 antibody. As shown in Figure 3.7C, AIP4 co-
immunoprecipitates with DTX3L at all time-points, with a significant increase in this 
interaction at 15 min. 
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Figure 3.7 AIP4 and DTX3L directly interact. A. HeLa cells lysates (500 µg) were subject to 
immunoprecipitation for endogenous DTX3L or immunoglobulin G (IgG) isotype control and co-
immunoprecipitation of proteins was determined by immunoblot analysis. Data represent three independent 
experiments. B. Equimolar amounts of purified recombinant GST-AIP4 (100 nmols) were incubated with 
increasing concentrations of His-DTX3L (1-10 nM). Samples were analyzed by 10% SDS-PAGE and 
immunoblotting for DTX3L and GST. Bands in the GST-AIP4 purification lower than 100 kDa represent 
degradation products from the purification. Data were quantified as the fold change in binding to AIP4 
using densitometric analysis. Specifically, average values were subtracted from the GST only values and 
then normalized to the 1 nM His-DTX3L sample.  Data show a significant increase in His-DTX3L to AIP4 
with increasing concentration. Data represent three independent experiments. Data were analyzed by one-
way ANOVA, followed by Bonferroni’s post-hoc test. C. HeLa cells were serum starved for 3 h, followed 
by treatment with 10 nM CXCL12 for 0-60 min. Cleared lysates (500 µg) were subject to 
immunoprecipitation using the goat polyclonal anti-DTX3L and isotype control antibodies. 
!"#$%&
!"'()
!*+,
!,-"./
'&
01
$!2
34
5 '(!6
7-
89
:
';
<
/=/
/=/
>3
)>
!7-89:>3
/=/
'?
"@
7-89:
!"#$%&
= /A 9= B= = /A 9= B=';
<
'(6!7-89:
'&01$!
2/@A45
!"'()
>A
/==
/==
A=
C8C:/3!/=!&.
'?
C@
=@A
!!!/@A
!!=
/@=
DE
FG
!"
'(
)!
?
%&
G%
&;
= /A 9= B=
-HIJ$KI&$!-%KI!2K%&5
0L=@=A
M
7-89:
<,-
'&
01
$!
<,
-
<,
-N
"'
()
/=/
/=/
>3
>3
93
/ A /=/ A /==@A
<,-N"'()
7-89:!2&.5
'?
B=
!!!/3=
!!=
/==
O=
)=
3=
/!&. A!&. /=!&.
4
!7
-8
9:
!?
%&
G%
&;
*%PN7-89:6
<,-N"'()
0L=@=A
M
?@
 
 
112 
Immunoprecipitates and inputs were resolved by SDS-PAGE and immunoblotting to detect endogenous 
AIP4, DTX3L or actin. AIP4 binding to DTX3L was significantly increased at 15 min of CXCL12 
treatment. Immunoblots from four independent experiments were subject to densitomeric analysis and the 
bar graph represents average AIP4 binding. Data were analyzed by one-way ANOVA followed by 
Bonferroni’s post-hoc test (p<0.05). Error bars represent the standard error of the mean.  
 
Third, we examined the localization of endogenous DTX3L and FLAG-AIP4 
upon CXCR4 activation by fixed cell confocal immunofluorescence microscopy. Images 
were acquired under equal acquisition settings between parallel experiments as detailed 
in Methods Section 2.7.  Overexpression of AIP4 was required in these experiments due 
to a lack of suitable antibodies directed against AIP4 that could detect endogenous AIP4 
by confocal microscopy. As seen in Figure 3.8, FLAG-AIP4 and DTX3L co-localize 
upon CXCL12 treatment. Pearson analysis for co-localization reveals that AIP4 and 
DTX3L significantly co-localizes at 15 - 60 min time points compared to cells treated 
with vehicle (Figure 3.8B). This co-localization persisted up to the 60 min at which time 
point there was a slight reduction in DTX3L and AIP4 co-localization (Figures 3.8A and 
B). Additionally, the average amount of FLAG-AIP4 puncta increased upon CXCL12 
treatment and decreased back towards vehicle by 60 min time point. (Figure 3.8C). In 
contrast, DTX3L puncta levels increased upon CXCL12 treatment and persisted above 
vehicle levels up to the 60 min time point (Figures 3.8D). The return of AIP4 puncta to 
baseline at 60 min may be due to AIP4 cytosolic re-distribution rather than degradation 
given that AIP4 levels in inputs at 60 min are not reduced (Figure 3.7C). Altogether these 
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data indicate that DTX3L and AIP4 directly interact and CXCR4 activation promotes this 
interaction. 
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Figure 3.8 CXCL12 promotes DTX3L co-localization with AIP4. A. HeLa transfected with 1 µg FLAG-
AIP4 were serum starved for 3 h and stimulated with vehicle or 10 nM CXCL12 for 15-60 min. Cells were 
fixed, permeabilized and co-stained for FLAG epitope, endogenous DTX3L and EEA1. FLAG-AIP4 is 
shown in green, DTX3L is shown in red and EEA1 in blue. White puncta in the “merge” image represent 
co-localization between AIP4, DTX3L and EEA1. Differential interference (DIC) contrast images are 
shown. B. Quantification of average co-localization between DTX3L and FLAG-AIP4 using the Pearson 
product moment correlation co-efficient. Correlation was determined using the ImageJ plug-in 
“Colocalization Finder.” Data were analyzed by a Student’s t test and error bars represent the standard error 
of the mean. (C, D). Quantification of FLAG-AIP4 (C) and DTX3L (D) puncta. Puncta were analyzed 
using the ImageJ function “Analyze Particles.” Threshold was set at a minimum of 130 and maximum of 
255. Data are representative of the average puncta from four independent. Error bars represent the standard 
error of the mean. Data were analyzed by a Student’s t test. E. Immunoblot depicting the level of FLAG-
AIP4 overexpression in lysates from IF in (A).  
 
MAPPING THE AIP4 BINDING SITE ON DTX3L 
We have shown so far that DTX3L regulates the lysosomal degradation of 
CXCR4 at the level of the endosome and that DTX3L interacts directly with AIP4. To 
gain insight into the role of DTX3L interaction with AIP4 on CXCR4 trafficking, we 
performed interaction studies to determine the binding regions.  First, we performed 
GST-pull down experiments using GST-AIP4 and HeLa cell lysates endogenously 
expressing DTX3L. Endogenous DTX3L is able to bind to full-length recombinant GST-
AIP4, but not GST-only control (Figure 3.9A).  
In order to determine the binding region through which DTX3L binds to AIP4, we 
generated GST-fusion proteins of the N-terminal (NT) and C-terminal (CT) regions of 
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DTX3L based on the DTX3L truncation mutants previously characterized by Takeyama 
et al. 2003. The NT truncation of DTX3L spans amino acids 1-464 of the unique region, 
while the CT truncation covers amino acids 528-740 which includes the CT RING 
domain (Figure 3.9B). These truncation mutants were compared along with GST-
DTX3L-Full length (FL) for binding to FLAG-AIP4 expressed in HeLa cells. As shown 
in Figure 3.9, FLAG-AIP4, but not empty vector binds strongly to GST-DTX3L-FL as 
compared to GST alone. In addition, FLAG-AIP4 binds to a lesser degree to the NT and 
CT DTX3L truncations when compared to FL DTX3L (Figure 3.9C). However, 
densitomeric analysis demonstrates that FLAG-AIP4 binds stronger to DTX3L-NT and 
weakly to the DTX3L-CT truncation (Figure 3.9B and D). Altogether these data 
demonstrate that DTX3L and AIP4 bind and that the N-terminal unique region of DTX3L 
binds strongly to AIP4. 
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Figure 3.9 DTX3L binds AIP4 via the N-terminal domain. A. Equimolar amounts (100 nmols) of 
immobilized GST or GST-AIP4 were incubated with HeLa lysates (500 µg). Binding of endogenous 
DTX3L was determined by immunoblot analysis. Ponceau staining of blot depicts the loading of GST and 
GST-AIP4 used in the binding reactions. B. Schematic representing the DTX3L truncation constructs used 
in binding experiments described in panels C and D. Summary of AIP4 binding to each truncation mutant 
is indicated. +++ = high binding; ++ = intermediate binding; + = low binding. C. Equimolar amounts (100 
nmol) of immobilized GST, GST-DTX3L-Full length (FL), GST-DTX3L-N-term (NT) or GST-DTX3L-C-
term (CT) were incubated with HeLa lysates (100 µg) transiently transfected with FLAG-AIP4 or empty 
vector control. Binding of FLAG-AIP4 was detected by immunoblotting with the anti-FLAG-HRP 
antibody. Amount of FLAG-AIP4 binding was determined by densitomeric analysis and normalized to FL. 
Ponceau staining depicts the loading of the GST-fusion proteins. D. Shown are representative data analyzed 
from a total of three independent experiments. Data is represents fold AIP4 binding to each DTX3L 
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construct normalized to control (empty vector). Data were analyzed by one-way ANOVA and error bars 
represent the standard error of the mean.  
 
MAPPING THE DTX3L BINDING SITE ON AIP4 
In order to gain further insight into the interaction between DTX3L and AIP4, we 
next sought to determine the region on AIP4 that could be binding to DTX3L. In order to 
do this, we performed binding experiments using immobilized GST-AIP4-full length 
(FL) as well as several GST-AIP4 truncation mutants (Figure 3.10C). Equimolar amounts 
of the GST fusion proteins were incubated with HeLa lysates to determine binding to 
endogenous DTX3L. As shown in Figure 3.10, endogenous DTX3L bound strongly to 
GST-AIP4-FL and to a lesser extent to GST-C2 and GST-HECT truncations relative to 
GST only control. Little to no binding was detected for GST-WW I-IV samples. These 
data suggest that DTX3L is able to bind strongly to both the N-terminal C2 domain as 
well as the C-terminal HECT domain of AIP4 and potentially to regions containing the 
PRR domain. However, future experiments will need to be performed to determine 
importance of the two AIP4 binding regions in mediating the interaction with DTX3L.  
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Figure 3.10 AIP4 binding to DTX3L involves the C2 and HECT domains. A. Equimolar amounts (200 
nmols) of immobilized GST, GST-AIP4, GST-C2, GST-WW I-IV or GST-HECT were incubated with His-
DTX3L (5 nM) overnight. Binding of His-DTX3L was determined by immunoblotting with the anti-T7 
monoclonal antibody. His-DTX3L binds strongly to GST-AIP4 and weaker to GST-C2 and GST-HECT. B. 
Data from two independent experiments were quantified by densitometry. Data represents fold DTX3L 
binding to each AIP4 construct as a fraction of control (GST). Error bars represent the standard deviation.  
D. Cartoon depicting the recombinant GST-AIP4 constructs used in binding reactions and summary of the 
relative binding of His-DTX3L to each construct denoted as follows: +++ = high binding; ++ = 
intermediate binding; + = low binding. Data represent two independent experiments.  
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DTX3L REGULATES ESCRT-0 UBIQUITINATION 
Previous work from our lab has shown that the extent to which CXCR4 is 
degraded is dependent on both CXCR4 and ESCRT-0 ubiquitination mediated by AIP4. 
Agonist-stimulation of CXCR4 promotes ubiquitination of both ESCRT-0 components, 
HRS and STAM-1 (Malik & Marchese, 2010; Marchese et al., 2003). Recent data from 
our lab has also highlighted that the interaction of STAM-1 with the adaptor arrestin-2 
(a.k.a. !–arrestin-1) on early endosomes acts to potentially regulate the ubiquitination 
status and sorting function of HRS (Malik & Marchese, 2010). In this complex, Arrestin-
2 is thought to recruit AIP4 to endosomes where it ubiquitinates HRS and, thereby, 
triggers a conformational change in HRS structure that prevents its sorting function with 
STAM-1. Importantly, CXCR4 degradation is enhanced when HRS ubiquitination is 
inhibited (Malik & Marchese, 2010). Essentially, the extent of CXCR4 degradation is 
dependent upon the ubiquitination status of ESCRT-0 (Malik & Marchese, 2010; 
Marchese et al., 2003). We sought to determine whether DTX3L also has an effect on 
ESCRT-0 ubiquitination. We examined the degree of ubiquitination of ESCRT-0 
subunits HRS and STAM in HeLa cells following DTX3L or control siRNA depletion. 
As seen in Figure 3.11, in DTX3L siRNA-treated cells there was significantly increased 
amounts of ubiquitinated HRS (Figure 3.11A) and STAM-1 (Figure 3.11B) compared to 
control. There was also an increase in total ubiquitination in lysates treated with DTX3L 
siRNA compared to control, indicating that depletion of DTX3L may result in a global 
accumulation of ubiquitinated proteins and does not result in a reduction in the protein 
stability of either HRS or STAM-1. Based on these experiments this data suggest that 
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DTX3L negatively regulates the ubiquitination process. This is surprising given the role 
that ubiquitin ligases often have in promoting substrate ubiquitination. To the best of our 
knowledge, this is first study to show that depletion of a particular E3 ubiquitin ligase 
actually promotes global ubiquitination of substrates and opens the door to idea that E3 
ubiquitin ligases may have both positive as well as negative roles in mediating 
ubiquitination. Taken together, these data suggest that DTX3L regulates CXCR4 
degradation through regulation of ESCRT-0 ubiquitination.  
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Figure 3.11 DTX3L regulates ESCRT-0 ubiquitination and complex formation. A, B. HeLa cells were 
first transfected with control or DTX3L siRNA, followed by co-transfection with FLAG-ubiquitin and T7-
HRS (A) or T7-STAM-1 (B). Lysates were collected under denaturing conditions and subject (300 µg) to 
immunoprecipitation using the anti-T7 polyclonal antibody. Immunoprecipitates and lysates were resolved 
by 7% SDS-PAGE and immunoblotted with the indicated antibodies. Data are representative of 3 
independent experiments and were quantified by densitomeric analysis. Asterisks (*) indicate HRS or 
STAM attached to a single or multi-mono ubiquitin. The amount of ubiquitination in control siRNA-treated 
cells was normalized to one and ubiquitination in DTX3L siRNA-treated cells was represented as a fold 
over control. Data were analyzed by a Student’s t test and error bars represent the standard error of the 
mean. Data were analyzed by a Student’s t test. 
 
DTX3L REGULATES ESCRT-0 COMPLEX STABILITY  
Previous studies have suggested that ubiquitination of HRS can regulate the 
ability of ESCRT-0 to form a stable complex on early endosomes due to the inability of 
HRS to adopt an active conformation and be recruited to early endosomes (Hoeller et al., 
2006; Malik & Marchese, 2010; Marchese et al., 2003). Specifically, the sorting activity 
of HRS is predicted to be inhibited upon ubiquitination due to the adoption of an auto-
inhibitory conformation in which the ubiquitin moiety on HRS binds to its own ubiquitin 
binding domain (UBD). This conformation inhibits HRS from binding to STAM-1 and, 
thus, prevents ESCRT-0 from sorting ubiquitinated cargo on the endosome (Hoeller et 
al., 2006). In support of this idea, recent data from our lab has demonstrated that when 
HRS poly-ubiquitination is inhibited, the amount of CXCR4 sorted to lysosomes is 
increased (Malik & Marchese, 2010). Having determined that DTX3L functions to 
regulate ESCRT-0 ubiquitination, we next examined the effect that DTX3L has on the 
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ability of HRS and STAM-1 to form an active sorting complex on early endosomes. In 
HeLa cells immunoprecipitated for endogenous HRS or STAM-1, DTX3L siRNA 
depletion resulted in a significant reduction in co-immunoprecipitation of STAM-1 or 
HRS, respectively, compared to control (Figures 3.12A and B). Therefore, DTX3L 
positively regulates ESCRT-0 complex integrity. Overall, these data indicate that DTX3L 
is an important regulator of ESCRT-0 ubiquitination and complex formation as means to 
regulate the extent of CXCR4 sorting into the degradative pathway. 
 
 
Figure 3.12 DTX3L regulates ESCRT-0 ubiquitination and complex formation. A, B. HeLa lysates 
transfected with control or DTX3L siRNA were subject to immunoprecipitation for endogenous HRS (A) 
or STAM-1 (B). Immunoprecipitates and lysates were subject to SDS-PAGE and immunoblotting for 
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indicated antibodies. Data represent 3-4 independent experiments. The amount of co-immunoprecipitation 
was determined by densitomeric analysis. Briefly, the amount of the associated protein was calculated as a 
fraction of the total immunoprecipitated protein for each respective siRNA sample. Average control values 
were normalized to one and then compared to DTX3L siRNA-treated samples. Data were analyzed by a 
Student’s t test. 
 
DTX3L PROMOTES ESCRT-0 ACTIVITY ON EARLY ENDOSOMES 
Given that ubiquitin modification of ESCRT-0 may prevent the formation of 
active complex, we hypothesize that DTX3L through regulating the degree of ESCRT-0 
ubiquitination could, therefore, also regulate the ability of ESCRT-0 to be recruited to 
endosomes (Hoeller et al., 2006; Marchese et al., 2003). In order to address this question, 
we used confocal immunofluorescence microscopy to monitor the distribution of HRS 
and STAM-1. HeLa cells grown on coverslips transiently transfected with either control 
or DTX3L siRNA were serum starved for 3h. Media was replaced with media containing 
vehicle (PBS + 0.1% BSA) or 10 nM CXCL12 for 30 min placed at 37˚C. Cells were 
then fixed, permeabilized and immunostained for DTX3L and HRS or STAM-1. Images 
were acquired under equal acquisition settings between parallel experiments as detailed 
in Methods Section 2.7. In control siRNA-treated cells, DTX3L co-localizes with both 
HRS (Figures 3.13A and 3.14B) and STAM-1 (Figures 3.13B and 3.14D). Furthermore, 
siRNA depletion of DTX3L resulted in a reduction in the level of both HRS (Figures 
3.13A and 3.14A) and STAM-1 (Figures 3.13B and 3.14C) puncta compared to control. 
These data indicate that DTX3L modulates the ability of ESCRT-0 to localize onto 
endocytic structures following CXCR4 activation and, therefore, the degree of CXCR4 
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endosomal to lysosomal sorting into the degradative pathway. Taken together, these data 
provide mechanistic insight into DTX3L regulation of CXCR4 degradation through 
positively regulating ESCRT-0 complex formation and integrity.  
 
 
Figure 3.13 DTX3L promotes ESCRT-0 aggregation on early endosomes. A, B. HeLa cells were 
transiently transfected with control or DTX3L siRNA. Cells were serum starved for 3hr and then stimulated 
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with 10 nM CXCL12 for 1 h and then fixed, permeabilized and co-stained for HRS (A) or STAM-1 (D) 
and DTX3L. HRS or STAM are shown in green and DTX3L is shown in red. Yellow in the “merge” image 
represents co-localization of HRS or STAM with DTX3L. Differential interference (DIC) contrast images 
are shown. Data represent 4 and 3 independent experiments, respectively. For HRS 110-145 cells were 
analyzed whereas 45-50 cells were analyzed for STAM-1. Data were analyzed by a Student’s t test. 
 
 
Figure 3.14 DTX3L localizes with and regulates the aggregation of ESCRT-0 on endosomes.  A, C. 
Quantification of the average HRS (A) and STAM-1 (C) puncta per cell using the ImageJ function 
“Analyze Particles.” Threshold was set at a minimum of 150 and maximum of 255. Data were analyzed by 
a Student’s t test and error bars represent the standard error of the mean. B, D. Quantification of average 
co-localization between DTX3L and HRS (B) or STAM-1 (D) using the Pearson product moment 
correlation co-efficient. Correlation was determined using the ImageJ plug-in “Colocalization Finder.” Data 
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represent 4 and 3 independent experiments, respectively. For HRS 110-145 cells were analyzed whereas 
45-50 cells were analyzed for STAM-1. Data were analyzed by a Student’s t test.  
 
PHOSPHATIDYLINOSITOL 3-PHOSPHATE IS NOT REGULATED BY DTX3L 
The localization of ESCRT-0 to the surface of early endosomes is dependent 
partly on the interaction of the FYVE (Fab1, YOTB, Vac1 and early endosome antigen-
1) -domain of HRS with phosphoinositide 3-phosphate (PI-3P), an endosomally enriched 
phospholipid localized to the cytosolic surface (Raiborg et al., 2001; Stenmark, Aasland, 
& Driscoll, 2002). The FYVE domain contains a cysteine rich zinc finger that binds 
directly with high selectivity to PI-3P compared to other phospholipids. The FYVE-
domain is named after four proteins in which it was originally discovered: Fab1, YOTB, 
Vac1 and early endosome antigen-1 EEA1 (Burd & Emr, 1998; He et al., 2009). We 
explored the possibility that DTX3L modulates the steady state levels of PI-3P as a 
mechanism for controlling ESCRT-0 localization to endosomes. In order to determine 
this, we employed fixed cell confocal immunofluorescence microscopy in HeLa cells 
transfected with the fluorescent-tagged FYVE domain fusion (YFP-2"FYVE) construct 
as a means to monitor PI-3P levels similar to published approaches (Gillooly et al., 
2000).  In particular, we examined the effect DTX3L depletion has on YFP-2"FYVE 
localization to early endosomes following CXCR4 activation. Images were acquired 
under equal acquisition settings between parallel experiments as detailed in Methods 
Section 2.7. To control for binding to endosomes, we utilized wortmannin a potent 
inhibitor of phosphoinositide (PI) 3-kinase. Wortmannin is a non-selective PI-3K 
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inhibitor that disrupts the synthesis of PI-3Ps and, therefore, can disrupt the binding of 
proteins on endosomes that depend on the interaction with endosomally enriched PI-3Ps 
(Wymann et al., 1996).  
In both control and DTX3L siRNA-treated cells, YFP-2"FYVE was highly co-
localized to early endosomes following CXCL12 stimulation as determined by Pearson 
analysis (Figures 3.15A and 3.16B). However, pre-treatment of both control and DTX3L 
depleted cells with the PI-3P inhibitor, wortmannin, prevented YFP-2"FYVE localization 
to early endosomes. Additionally, there was a reduction in EEA1 staining upon 
wortmannin pre-treatment indicating a disruption of EEA1 binding to PI 3-P enriched 
endosomes (Figures 3.15A). This coincides with previously published literature that 
demonstrated that wortmannin treatment disrupts EEA1 binding to PI-3P membranes 
(Patki et al., 1997). Together, these data demonstrate that DTX3L ability to regulate the 
endosomal localization of ESCRT-0 is not due to a change in steady-state levels of 
endosomally localized PI-3P. 
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Figure 3.15 DTX3L does not reduce phosphatidylinositol 3-phosphate levels. A. HeLa cells were 
transiently co-transfected with YFP-2"FYVE and either control or DTX3L siRNA. Media was aspirated 
and cells were serum starved for 3h, followed by pre-treatment with either DMSO or wortmannin (100 nM) 
for 30 min prior to stimulation with CXCL12 (10 nM) for 1 h. Cells were fixed, permeabilized and co-
stained for EEA1 and DTX3L. YFP-2"FYVE is in green, EEA1 is in red and DTX3L is in blue. White in 
the “merge” panel indicates co-localization between YFP-2"FYVE, EEA1 and DTX3L whereas yellow 
indicates co-localization between YFP-2"FYVE and EEA1. Differential interference (DIC) contrast images 
are shown.  
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Figure 3.16 YFP-FYVE puncta and localization to endosomes is reduced upon reduction in 
phosphatidylinositol 3-phosphate by wortmannin. A. Quantification of the average YFP-2"FYVE 
puncta per cell using the ImageJ Function “Analyze Particles.” Data represent 3 independent experiments, 
35-40 cells. Threshold was set at a minimum of 130 and maximum of 255. Wortmannin treatment 
significantly prevents YFP-2"FYVE localization to early endosomes in both control and DTX3L siRNA-
treated cells in contrast to DMSO control. Data were analyzed by one-way ANOVA (p < 0.0001) and error 
bars represent the standard error of the mean. B. Quantification of average co-localization between YFP-
FYVE and EEA1 using the Pearson product moment correlation co-efficient. Correlation was determined 
using the ImageJ plug-in “Colocalization Finder.” Data represent 3 independent experiments. Data were 
analyzed by one-way ANOVA (p < 0.0001) and error bars represent the standard error of the mean. 
 
DTX3L PREVENTS AIP4 SELF-UBIQUITINATION IN VITRO 
Given that DTX3L and AIP4 interact directly and have opposing effects on 
ESCRT-0 ubiquitination (Figures 3.7 and 3.11) (Holleman & Marchese, 2014; Malik & 
Marchese, 2010; Marchese et al., 2003), we hypothesized that DTX3L may modulate 
AIP4 E3 ligase activity. In order to determine this, we performed in vitro ubiquitination 
assays using purified AIP4, His-DTX3L and their catalytically inactive mutants (AIP4-
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C830A; His-3C/A). In general, E3 ubiquitin ligases including AIP4 and DTX3L are 
activated through self-ubiquitination (Takeyama et al., 2003 Scialpi et al., 2008). Thus, 
these reactions were designed to examine AIP4 and DTX3L self-ubiquitination alone and 
in combination. The catalytically inactive mutants are mutated within their active site 
HECT (AIP4-C830A) or RING (His-3C/A) domain and are unable to mediate direct or 
indirect transfer of ubiquitin to substrates (Chastagner et al., 2006; Marchese & Benovic, 
2001). Specifically, the DTX3L-RING-3C/A mutant was designed based on the DTX1 
mutant previously reported in which cysteine residues 561, 596 and 599 within the RING 
domain were mutated to alanine residues. This mutation prevents E2 enzyme mediated 
transfer of ubiquitin by disrupting the E2 binding site (Chastagner et al., 2006). 
Therefore, these ‘ligase-dead’ mutants serve as negative controls since they are unable to 
promote ubiquitination. Incubation of AIP4 and DTX3L alone results in self-
ubiquitination, which is common among E3 ubiquitin ligases (Scialpi et al., 2008; 
Takeyama et al., 2003). Briefly, reactions were performed at room temperature for 1 h 30 
min. Reaction conditions were based on previously described in vitro ubiquitin reactions 
and optimized by titrating amount of ligase used in the reaction as well as performing 
reactions at different temperatures (RT and 37˚C) and/or times (15, 30 or 60 min) in order 
to determine optimal activity of either ligase (Laney & Hochstrasser, 2011). 
Ubiquitination of substrates is determined by immunoblot analysis and is represented by 
either the accumulation or smearing of higher molecular weight bands above the 
predicted molecular weight of the unmodified substrate as compared to input. 
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  As seen in Figure 3.17, AIP4 self-ubiquitination is more robust than DTX3L with 
AIP4 accumulating higher molecular species (Figure 3.17, lane 6 vs. 8). In contrast, 
incubation of either catalytically inactive mutant (AIP4-C830A or His-3C/A) did not 
exhibit self-ubiquitination (Figure 3.17, lane 7 and 9). Combination of AIP4 and DTX3L 
resulted in a robust decrease in the level of AIP4 self-ubiquitination when compared to 
AIP4 alone, indicating that the co-incubation of DTX3L with AIP4 inhibits AIP4 self-
ubiquitination (Figure 3.17, lane 10). A small decrease in DTX3L ubiquitination was also 
apparent in these reactions as seen in the DTX3L immunoblot (Figure 3.17, lane 10). In 
addition, co-incubation of AIP4 with the catalytically inactive mutant of DTX3L 
(DTX3L-3C/A) also resulted in a decrease in AIP4 self-ubiquitination demonstrating that 
the catalytic integrity of the DTX3L RING domain is not necessary to inhibit AIP4 self-
ubiquitination (Figure 3.17, lane 11). In contrast, neither co-incubation of AIP4-C830A 
with DTX3L nor AIP4-C830A with DTX3L-3C/A resulted in AIP4-C830A 
ubiquitination due to the inability of AIP4-C830A mutant to load ubiquitin (Figure 3.17, 
lane 12 and 13). Thus, DTX3L-3C/A and AIP4-C830A mutants both act as negative 
controls since both are unable to mediate ubiquitination. Altogether, these data show that 
DTX3L, independent of the RING domain activity, inhibits AIP4 self-ubiquitination.  
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Figure 3.17 DTX3L inhibits AIP4 ligase activity. A. Ubiquitination reactions containing purified AIP4, 
AIP4-C830A, His-DTX3L or His-3C/A alone or in combination were incubated with ATP, E1, E2 
(UbcH5c) and ubiquitin for 1 ! h at room temperature in a total volume of 20 µl. Following completion of 
the reaction, samples were diluted with 20 µl of 2x sample buffer. Samples were resolved by 7% SDS-
PAGE followed by immunoblotting for AIP4, DTX3L or ubiquitin. Asterisks indicate residual uncleaved, 
degraded GST-AIP4-C830A left in purified, cleaved sample. This was confirmed using an anti-GST 
antibody (unpublished results). Data represent six independent experiments. B. Ubiquitination reactions 
containing purified AIP4, His-DTX3L or MBP-Parkin alone or in combination were incubated with ATP, 
E1, E2 (UbcH5c) and ubiquitin for 1 ! h at room temperature in a total volume of 20 µl. Reactions were 
terminated by the addition of 20 µl 2x sample buffer and samples were resolved by 7% SDS-PAGE. 
Samples were analyzed by immunoblot analysis for indicated proteins. Data represent four independent 
experiments.  
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To further confirm that the inhibition of AIP4 self-ubiquitination is specific to DTX3L 
acting upon AIP4 and not due simply to non-specific sequestration of ubiquitin by 
DTX3L, we examined the effect of the E3 ubiquitin ligase Parkin on AIP4 self-
ubiquitination. Parkin belongs to the RING-between-RING (RBR) E3 ligases, which 
possess features of both HECT and RING domain ligases and are termed RING-HECT 
hybrids. In addition, Parkin shows self-ubiquitination activity with the E2 enzymes 
UbcH7 and UbcH5c (Wenzel, Lissounov, Brzovic, & Klevit, 2011). As shown in Figure 
17B, co-incubation of AIP4 with Parkin robustly promoted AIP4 self-ubiquitination 
when compared to AIP4 alone (Figure 3.17B, lanes 5 vs. 9). As expected co-incubation 
of AIP4 and DTX3L reduced AIP4 self-ubiquitination (Figure 3.17B, lanes 5 vs. 8). 
Parkin co-incubation with AIP4 promoted a different pattern of AIP4 ubiquitination than 
seen with AIP4 alone indicating that either the presence of Parkin increases the ability of 
AIP4 to self-ubiquitinate or that Parkin may mediate AIP4 ubiquitination (Figure 3.17B, 
lane 5 vs. 9). Furthermore, DTX3L self-ubiquitination was robustly reduced in the 
presence of Parkin, whereas co-incubation with AIP4 slightly reduced DTX3L self-
ubiquitination consistent with the previous panel (Figures 3.17B, lane 10 and 8, and 
3.17A, lane 10). Moreover, co-incubation of AIP4 or DTX3L with Parkin did not prevent 
Parkin self-ubiquitination (Figure 3.18B, lane 9 and 10). These results indicate that the 
decrease in AIP4 ubiquitination in the presence of DTX3L in these reactions is specific. 
Although both DTX3L and Parkin belong to the RING-type ligase family, either ligase 
differentially regulates AIP4 self-ubiquitination in vitro. The importance of Parkin in 
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mediating differential changes in both AIP4 and DTX3L self-ubiquitination will remain 
to be investigated by future studies.  
 
DTX3L ANTAGONIZES AIP4-MEDIATED UBIQUITINATION OF HRS 
Given that DTX3L inhibits AIP4 self-ubiquitination in vitro, we next wanted to 
determine whether DTX3L could prevent AIP4 ligase activity toward its substrates. To 
this end, we examined the effect of DTX3L on inhibiting the ubiquitination of a known 
AIP4 substrate, HRS, in HeLa cells (Malik & Marchese, 2010; Marchese et al., 2003). 
HeLa cells were depleted of DTX3L, AIP4 or the combination and the level of HRS 
ubiquitination was determined by immunoprecipitation followed by immunoblot analysis. 
As seen in Figure 3.18, depletion of DTX3L results in hyper-ubiquitination of HRS 
confirming results shown in Figure 3.11A. In contrast, either AIP4 depletion alone or the 
combination of AIP4 and DTX3L siRNA resulted in a reduction in HRS ubiquitination. 
Although in these experiments we noted that AIP4 knockdown efficiency was not as 
great when co-transfected with DTX3L siRNA as seen with AIP4 knockdown alone. 
Nonetheless given that the degree of HRS hyper-ubiquitination was reduced in the 
combined lanes than with DTX3L knockdown alone, these data indicate that DTX3L 
counteracts AIP4 activity in cells namely the hyper-ubiquitination of HRS. Thus, we have 
defined that not only does DTX3L regulate CXCR4 endosomal to lysosomal degradation 
but also DTX3L does so by promoting ESCRT-0 activity while counteracting AIP4 
activity on early endosomes. 
 
 
136 
 
Figure 3.18 DTX3L counteracts AIP4-mediated HRS ubiquitination. A. HeLa cells were first 
transfected with siRNA against control, DTX3L, AIP4 or the combination, followed by co-transfected with 
FLAG-ubiquitin and T7-HRS. Lysates were collected under denaturing conditions and subject (300 µg) to 
immunoprecipitation using the anti-T7 polyclonal antibody. Immunoprecipitates and lysates were resolved 
by 7% SDS-PAGE and immunoblotted with the indicated antibodies. Data are representative of 4 
independent experiments. 
 
DTX3L DOES NOT PREVENT AGONIST-PROMOTED CXCR4 
UBIQUITINATION 
AIP4 mediates CXCR4 agonist-promoted ubiquitination at the plasma membrane 
(Marchese et al., 2003). Given that DTX3L counteracts AIP4 mediated ubiquitination of 
HRS, we next assessed the effect DTX3L depletion has on AIP4 agonist-promoted 
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ubiquitination of CXCR4. To examine this, HeLa cells were depleted of DTX3L and the 
level of agonist-promoted ubiquitination of CXCR4 was determined by 
immunoprecipitation followed by immunoblot analysis. As shown in Figure 3.19, 
depletion of DTX3L did not prevent CXCR4 ubiquitination. The level of CXCR4 
ubiquitination in DTX3L siRNA-treated cells was even greater than in control. These 
data indicate that DTX3L counters AIP4 agonist-promoted ubiquitination of CXCR4 
such that depletion of DTX3L increases AIP4-mediated ubiquitination of CXCR4. 
Altogether, we have established that DTX3L is a bona fide inhibitor of AIP4 
modification of CXCR4 and ESCRT-0 in the context of CXCR4 trafficking and 
degradation. 
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Figure 3.19 DTX3L does not prevent agonist-promoted CXCR4 ubiquitination. A. HeLa lysates were 
co-transfected with FLAG-ubiquitin and HA-CXCR4 plus control or DTX3L siRNA. Serum starved cells 
were treated with 10 nM CXCL12 for 30 min followed by immunoprecipitation with the anti-HA 
polyclonal antibody under denaturing conditions. Samples were resolved by 7% SDS-PAGE followed by 
immunoblotting for indicated proteins. Data represent 7 independent experiments.  
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CHAPTER IV 
DISCUSSION 
The findings in this current study have provided further mechanistic insight into the 
regulation of CXCR4 signaling and trafficking. Our study highlights a novel role for the 
E3 ubiquitin ligase DTX3L in regulating the extent of CXCR4 degradation. We 
demonstrate that silencing of DTX3L results in accumulation of CXCR4 on early 
endosomes preventing its lysosomal degradation. We also show that AIP4 interacts with 
the RING domain ligase Deltex-3L (DTX3L) upon CXCR4 activation. Furthermore, 
DTX3L interacts directly with AIP4 and inhibits AIP4 self-ubiquitination in vitro. 
Additionally, DTX3L interacts with the ESCRT-0 components HRS and STAM and 
regulates ESCRT-0 complex integrity. Our data show that DTX3L regulates AIP4-
mediated ubiquitination of ESCRT-0 to regulate the extent of CXCR4 degradation 
(Holleman & Marchese, 2014). Altogether this study has provided conceptual advances 
in understanding both the regulation of CXCR4 signaling as well as expands upon current 
knowledge into GPCR regulation in general. 
 
ROLE OF DTX3L IN CXCR4 DEGRADATION 
Deltex-3-like (DTX3L; also known as B lymphoma and BAL associated protein, 
BBAP) belongs to the RING domain ligase family of Deltex proteins (Takeyama et al., 
2003). While DTX1 and DTX2 have been widely studied as regulators of Notch 
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signaling, the function of DTX3 and DTX3L are less defined in the literature (Mazaleyrat 
et al., 2003; Takeyama et al., 2003).  DTX3L was first identified in a subset of DLBCLs 
as a binding partner to the gene BAL (B aggressive lymphoma). The interaction of BAL 
with DTX3L enables BAL nuclear localization and is implicated in regulating the DNA 
damage response through DTX3L-mediated monoubiquitination of histone H4 (Yan et 
al., 2009; Yan et al., 2013). Here in this work, we have defined a novel role for DTX3L 
in regulating the membrane trafficking of CXCR4 (Figure 4.1). We show that siRNA-
mediated knockdown of DTX3L significantly prevented CXCR4 degradation, revealing a 
novel function of DTX3L as a positive regulator of CXCR4 degradation (Figure 3.1). To 
our knowledge, this present study is the first to define a role for DTX3L in membrane 
trafficking of a GPCR. 
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Figure 4.1 Proposed model for the role of DTX3L in CXCR4 trafficking.  Upon CXCR4 activation, 
endogenous DTX3L is recruited to early endosomes where it interacts directly with AIP4.  On early 
endosomes, DTX3L antagonizes AIP4 ubiquitin ligase activity and ability to bridge to the ESCRT-0 
subunits through binding to Arrestin-2. This limits the extent to which ESCRT-0 subunits (HRS and 
STAM-1) are ubiquitinated (green arrows). This promotes ESCRT-0 function on early endosomes such that 
it is able to interact with ubiquitinated CXCR4 and sort it for lysosomal degradation. Taken together our 
data are consistent with a model whereby DTX3L acts as a inhibitor of AIP4 activity to promote CXCR4 
downregulation. 
 
 
!"!#$%
GRK
&'()
!"!#$%
( (
!"!#$%
?*+,,-./01
!"!#$%
Degradation
!"#$%&!'()*)+,
-".,&!'()*)+,/&012 &-%*)*)+,
23/,+4-5565+,
'1/,+4-5565+,
!5+/7,01
&(%
89
Recycling
3,4%4$5'6
!'()*)+, 2:!;<
=;:
:<&>*$
'*'''
89( ( ( (
&'()
Desentization
?8@ ?8@
!"!;)
?<"A#
89
89
!"!#$%
Internalization
Arrestin-2
!
142 
DTX3L REGULATES CXCR4 TRAFFICKING INTO THE DEGRADATIVE 
PATHWAY 
Our study highlights that DTX3L subcellular distribution to early endosomes is 
influenced upon CXCR4 activation. The distribution of endogenous DTX3L in HeLa 
cells is mostly diffuse in the cytosol with few puncta aggregating on early endosomes and 
lysosomes (Figure 3. 4). Following CXCR4 activation, DTX3L co-localization onto early 
endosomes increases significantly whereas DTX3L localization to lysosomes remains 
relatively unchanged (Figure 3.4A,C and D). The precise mechanisms governing DTX3L 
recruitment onto endosomes and lysosomes remain to be determined. Yet given the 
uncharacterized unique N-terminal region of DTX3L, we speculate that perhaps a non-
canonical motif within this N-terminal region may be required for recruitment to 
endosomes and lysosomes. Alternatively, DTX3L through binding to such proteins as 
AIP4 or ESCRT-0 may act to recruit DTX3L to these structures.  
Moreover, we have demonstrated that DTX3L functions to regulate the endosomal 
to lysosomal trafficking of CXCR4 since siRNA depletion of DTX3L increases the 
number of CXCR4 puncta that localize to early endosomes following 3 h of CXCL12 
treatment in contrast to control (Figure 3.4A and B). Since DTX3L knockdown prevents 
CXCR4 degradation, we can speculate that in DTX3L CXCR4 may be trafficked through 
recycling pathways. Preliminary CXCR4 recycling experiments suggest that indeed 
DTX3L knockdown promotes CXCR4 recycling back to the plasma membrane. 
Additionally, the receptor that recycles back to the plasma membrane is able to evoke 
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agonist-promoted signaling responses. Overall the findings in this study and preliminary 
data suggest that DTX3L functions to promote ESCRT-dependent trafficking of CXCR4 
into the degradative pathway and the removal of DTX3L antagonizes CXCR4 
degradation in favor of recycling. 
Given that a small subset of endogenous DTX3L does localize to early endosomes 
and lysosomes prior to CXCL12 stimulation, it is plausible that DTX3L may have 
additional roles in regulating membrane trafficking not exclusive to ESCRT-0. For 
instance, DTX3L may regulate the recruitment and ubiquitin modification of the other 
ESCRT proteins to facilitate the concentration of receptors into the limiting membrane of 
the endosome to form the MVBs. Preliminary binding experiments demonstrated that 
GST-DTX3L not only interacts with the endosomally localized ESCRT-0 components 
HRS and STAM-1 but in addition DTX3L can bind to the ESCRT-I component Tsg101, 
ESCRT-II component EAP45 as well as Arrestin-2 (!-Arrestin-1). Given that previous 
literature suggests that the STAM1/Arrestin-2 complex may recruit AIP4 to endosomes 
where it can bind ESCRT-0 and ubiquitinate the subunit HRS, it is plausible that DTX3L 
may inhibit AIP4 from interacting with STAM-1/Arrestin-2 to promote ESCRT-
dependent targeting of CXCR4 for degradation (Malik & Marchese, 2010). Preliminary 
data demonstrate that DTX3L can in fact bind to Arrestin-2 directly albeit at a lower 
affinity than that of DTX3L with AIP4 when compared in parallel binding experiments. 
Thus, DTX3L may antagonize AIP4 activity by inhibiting AIP4 interaction with STAM-
1/Arrestin-2 complex. DTX3L may play a general role in endosomal to lysosomal 
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targeting of other ESCRT-dependent GPCRs through general regulation of the ESCRT 
machinery or function of Arrestin-2. To this end, whether other GPCR ligands can 
promote increased DTX3L localization to endosomes remains to be determined. 
 
INTERACTION OF DTX3L AND AIP4 
Previously our lab demonstrated that siRNA mediated knockdown of AIP4 
significantly inhibits CXCR4 degradation to a similar degree seen with DTX3L siRNA 
treatment in the current study (Marchese et al., 2003). Given the propensity of AIP4 to 
interact with RING domain ligases (Chastagner, Israel, & Brou, 2006; Courbard et al., 
2002; Kitching et al., 2003), we found in the present study that AIP4 could interact with 
DTX3L by several complementary approaches (Figure 3.7-3.10). Domain mapping 
studies also reveal that the N-terminal unique region of DTX3L binds stronger than the 
C-terminal RING domain to AIP4. In addition, the C2 and HECT domains of AIP4 bind 
strongly to DTX3L. However, it will be important in future studies to further determine 
the precise amino acid binding regions between DTX3L and AIP4. This information 
could provide insight into creating a mini-gene to inhibit or mimic this interaction and 
help establish more precisely the importance of this interaction in cells.  
Given that AIP4 belongs to the Nedd4 family of HECT domain ligases that are 
highly homologous within their HECT domain sequences, it is intriguing to speculate that 
DTX3L may bind to and regulate the ligase activity of other members of the Nedd4 
family. In line with this, preliminary interaction studies reveal that DTX3L can bind to 
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the Nedd4 family members AIP2, AIP5 and Nedd4L in addition to AIP4 (data not 
shown). Future studies will be necessary to establish the general importance of DTX3L 
interactions with Nedd4 ligases. 
 
DTX3L PREVENTS AIP4 E3 LIGASE ACTIVITY 
Our lab has demonstrated that AIP4 spatially regulates CXCR4 both at the plasma 
membrane as well as on early endosomes.  Given that DTX3L directly interacts and 
localizes onto early endosomes with AIP4, we hypothesized that the DTX3L and AIP4 
interaction could regulate ligase activity. Indeed, we show that DTX3L inhibits AIP4 
self-ubiquitination activity in vitro independent of its RING domain activity (Figure 
3.17). We did not determine in our experiments the predominant ubiquitin linkage be 
formed on AIP4. However, based on previous literature which demonstrated that AIP4 
self-ubiquitination reactions predominately form K63 poly-ubiquitin chains and that this 
had a non-degradative role in regulating AIP4 function, we can speculate that K63 poly-
ubiquitination may be the predominate linkage form in our in vitro ubiquitin reactions 
(Scialpi et al., 2008). Overall, we have defined DTX3L as an inhibitor of AIP4 ubiquitin 
dependent self-activation.  
The mechanism of this interaction is in contrast to previously published 
interactions of AIP4 with RING domain ligases whereby AIP4 could act as a positive or 
negative regulator of RING ligase activity. In the case of DTX1, it was shown that AIP4 
could mediate K29-polyubiquitination of DTX1 leading to DTX1 lysosomal degradation 
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(Chastagner et al., 2006). Therefore, it was concluded that AIP4 acts to inhibit DTX1 
function in ligand-independent Notch signaling (Chastagner et al., 2006). Interestingly, 
DTX3L has also been shown to interact with DTX1, however, the function of this 
interaction in cells remains to be determined. The interaction of AIP4 with RING domain 
ligase Cbl-c was demonstrated to act synergistically to regulate ubiquitination and 
lysosomal degradation of the epidermal growth factor receptor (EGFR) (Courbard et al., 
2002). To our knowledge, our study is the first to demonstrate that a RING ligase 
(DTX3L) is an inhibitor of HECT domain ligase (AIP4) self-ubiquitination. Whether the 
effect DTX3L has on AIP4 activity regulates other AIP4 substrates remains to be 
established. For instance, DTX3L by inihibiting AIP4 may also prevent AIP4-mediated 
ubiquitination of DTX1 in the context of Notch signaling or Cbl-c in the context of 
EGFR. Thus, the importance of DTX3L in other receptor pathways will be important to 
address. 
 
DTX3L ANTAGONIZES AIP4-MEDIATED UBIQUITINATION OF ESCRT-0 
It has previously been shown that CXCR4 is degraded via ESCRT dependent 
sorting on early endosomes. Following CXCR4 activation, the ESCRT-0 subunits HRS 
and STAM-1 are ubiquitinated by AIP4 (Malik & Marchese, 2010; Marchese et al., 
2003). It was further defined that Arrestin-2 has a role in this AIP4-mediated 
ubiquitination of HRS. Specifically, AIP4 is recruited by the STAM-1/Arrestin-2 
complex to endosomes and, thereby, ubiquitinates HRS. HRS ubiquitination regulates the 
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extent of receptor degradation. Importantly, recent work from our lab has demonstrated 
that CXCR4 sorting to lysosomes is enhanced when HRS ubiquitination is blocked 
(Malik & Marchese, 2010). However, the precise mechanism underlying CXCR4 
ESCRT-dependent sorting remains poorly defined. In addition, previous studies have 
shown that the DUBs USP8 and AMSH indirectly promote the trafficking of CXCR4 by 
counteracting the AIP4-mediated ubiquitination of ESCRT-0 "#$%&'()! *'++'(,-./01)!2'3$)!4'$%%0)!5!603/)!7898:.  
Our current study provides further insight into AIP4 mediated ubiquitination of 
ESCRT-0 and its implications in targeting CXCR4 for degradation. We show that 
DTX3L negatively regulates ESCRT-0 ubiquitination by antagonizing AIP4  (Figure 
3.11; 4.2). We also show that DTX3L is also an important regulator of ESCRT-0 
complex formation on early endosomes following CXCR4 activation (3.12-3.14). Taken 
into account previous studies, it could be the case that DTX3L also has effects on the 
function or localization of DUBs, like USP8 and AMSH, to facilitate CXCR4 
downregulation. Future studies aimed at characterizing the effect DTX3L has on DUBs 
will be important to address. Furthermore whether DTX3L inhibits the ability of the 
STAM-1/Arrestin-2 to recruit AIP4 remains to be determined. Preliminary studies have 
revealed that DTX3L can bind to both Arrestin-2 and STAM-1. In addition, DTX3L 
binds to Arrestin-2 directly in a purified binding assay. Thus DTX3L not only counteracts 
AIP4 activity itself, but may also interact with the STAM-1/Arretin-2 complex 
preventing the interaction of AIP4 and, hence, promoting CXCR4 downregulation. This 
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idea will be important to address in the future. Altogether this current study expands our 
knowledge on the regulation of CXCR4 downregulation by demonstrating that DTX3L 
by antagonizing AIP4 function promotes ESCRT activity on early endosomes and, hence, 
sorting of CXCR4 for degradation (Figure 4.2).  
 
Figure 4.2 Proposed model for DTX3L antagonism of AIP4-mediated ubiquitination of ESCRT-0. In 
model one (1), AIP4 undergoes self-ubiquitination through its interaction with its cognate E2 conjugating 
enzyme. This self-ubiquitination is required for AIP4 activation and results in the hyperubiquitination of 
ESCRT-0, which prevents CXCR4 lysosomal degradation. In model two (2), activation of DTX3L by its 
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cognate E2 promotes DTX3L binding to AIP4, thereby, preventing AIP4 E2-mediated self-ubiquitination. 
As a result, ESCRT-0 is moderately ubiquitinated and, therefore, functions to sort CXCR4 for lysosomal 
degradation. 
 
 Although ubiquitin modification of ESCRT-0 seems to regulate ESCRT-
dependent sorting of CXCR4, the cellular relevance of ESCRT-0 ubiquitination in 
mediating receptor sorting remains to be confirmed. In yeast, fusion of ESCRT-0 or 
ESCRT-I to a DUB was shown to prevent their ubiquitination, but does not effect their 
sorting of ubiquitinated cargoes into the intraluminal vesicles (ILVs) (Stringer & Piper, 
2011). These data demonstrate that receptor ubiquitination is required to promote ESCRT 
activity on endosomes leading to concentration of receptors into ILVs, however, ESCRT 
modification by ubiquitination is not necessary to the sorting process. Thus, ubiquitin 
modified cargos play an essential role in ILV formation and cooperation between 
ubiquitin cargo and ESCRTs help facilitate ILV formation (Shields & Piper, 2011). In 
contrast to yeast, in mammalian cells ESCRT ubiquitination has been proposed to play a 
role in receptor trafficking. CXCR4 trafficking for degradation is proposed to be 
dependent upon ubiquitination of ESCRT-0. AIP4 counteracts ESCRT-0 activity via 
poly-ubiquitination (Marchese et al., 2003). This is thought to displace HRS and STAM 
from early endosomes and perhaps result in an auto-inhibitory conformation. In this study 
we have further identified that the E3 ligase DTX3L antagonizes the effect AIP4 has on 
ESCRT-0 ubiquitination by preventing AIP4 self-ubiquitination activity (Holleman & 
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Marchese, 2014). Although there seems to be a clear effect on ESCRT-0 ubiquitination 
downstream of CXCR4 activation, whether this plays a direct role in receptor trafficking 
remains to be determined. Moreover, it has yet to be proven that poly-ubiquitination of 
HRS or STAM1 leads to either protein being placed in an auto-inhibitory conformation. 
This could be address by fusing either ESCRT-0 protein to a DUB similar to a published 
approach used in yeast (Stringer & Piper, 2011). Expression of a fusion of ESCRT-0 to a 
DUB in cells should remove any ubiquitin modification of the fusion and, therefore based 
on our study, should promote ESCRT-dependent downregulation opposite to that seen 
with DTX3L knockdown. This will be important to establish in future studies. Although 
previous data highlight that monoubiquitination of ESCRT-0 is predicted to place HRS in 
auto-inhibitory conformation, thereby, preventing HRS interaction with STAM1 and the 
ability to sort ubiquitinated receptors (Hoeller et al., 2006). Another recent study suggests 
that HRS ubiquitination also effects the extent by which the RTK receptor EGFR is 
degraded (Sun, Hedman, Tan, Schill, & Anderson, 2013).  
One reason for this difference between yeast and mammalian cells may be due to 
that fact that mammalian cells have evolved to be more complex than yeast. For example 
mammalian cells are more compartmentalized with mammalian cells requiring both 
endosomes and lysosomes to sort cargo, whereas in yeast cargos are sorted into the 
vacuole (the homolog to the mammalian lysosome). Another reason for the difference 
between yeast and mammalian cells could be due to the necessity of additional adaptor 
proteins in facilitating the downregulation of mammalian GPCRs. For example, the 
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downregulation of mammalian CXCR4 is dependent upon the adaptor protein Arrestin-2 
(Bhandari, Trejo, Benovic, & Marchese, 2007; Malik & Marchese, 2010). Arrestin-2 can 
form a complex with STAM-1, negatively regulating the ESCRT-dependent 
downregulation CXCR4. Additionally, the STAM-1/Arrestin-2 complex binds and 
localizes AIP4 on early endosomes enabling AIP4 to mediate ubiquitination the ESCRT-
0 component HRS, thereby, modulating ESCRT-0 function. Thus, Arrestin-2 may act to 
bridge AIP4 with ESCRT-0 to regulate the extent of ESCRT-0 ubiquitination and, hence, 
targeting of CXCR4 for degradation. Given the vast complexity of mammalian cells, it is 
not surprising that perhaps ESCRT ubiquitination may have a direct role on GPCR 
trafficking distinct from yeast. 
 
DTX3L NEGATIVELY REGULATES CXCR4 UBIQUITINATION 
It has been previously demonstrated that AIP4 mediates agonist-promoted 
ubiquitination of CXCR4 at the plasma membrane to facilitate downstream sorting and 
degradation (Marchese & Benovic, 2001; Marchese et al., 2003). In this study, we also 
demonstrate that silencing of DTX3L enhances both basal and agonist promoted CXCR4 
ubiquitination (Figure 3.19). These data are consistent with the observation that DTX3L 
inhibits AIP4 ligase activity. Thus, DTX3L inhibition of AIP4 may not be restricted to 
early endosome although preliminary data demonstrate that DTX3L is not localized to the 
plasma membrane at early time points following CXCR4 activation (data not shown). 
Given that DTX3L and AIP4 complex basally and optimally at 15 min of CXCL12 
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treatment (Figures 3.7C and 3.8), it is possible DTX3L may sequester a fraction of AIP4 
early on from mediating CXCR4 ubiquitination at the plasma membrane. Future studies 
will be required to determine whether this is indeed the case. 
 
SUMMARY AND FIGURE DIRECTIONS 
The findings of this present study are summarized in Figures 4.1 and 4.2. We 
have identified a novel role for the E3 ubiquitin ligase DTX3L in regulating CXCR4 
degradation through inhibition of the activity of AIP4 on early endosomes. Our findings 
demonstrate that upon CXCR4 activation, DTX3L displays enhanced localization to early 
endosomes where it directly interacts with AIP4. Through its interaction with AIP4, 
DTX3L inhibits the ubiquitination of ESCRT-0 and, therefore, promotes ESCRT sorting 
function on early endosomes. We believe this mechanism serves to regulate the extent to 
which CXCR4 is sorted for degradation in lysosomes. 
 
DTX3L AS A GENERAL REGULATOR OF RECEPTOR DOWNREGULATION  
In this study we found that DTX3L regulates CXCR4 downregulation, however, 
whether DTX3L also regulates the ESCRT-dependent downregulation of other GPCRs or 
RTKs remains unknown. However, preliminary data suggest that DTX3L does not seem 
to regulate the ESCRT-dependent sorting of the receptor tyrosine kinase receptor EGFR 
(data not shown). Even though DTX3L may not have role in EGFR degradation, this 
could be due to the fact that EGFR sorting by ESCRTs is mediated by a different 
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mechanism. Recently, it has been shown that EGFR trafficking is dependent upon both 
Smad anchor for receptor activation (SARA) an endocytically enriched FYVE-domain 
containing protein as well as the RING domain ligase RNF11 (Kostaras et al., 2013). 
This study demonstrated that both SARA and RNF11 interact with ESCRT-0 to regulate 
the extent by which EGFR is degraded. In particular, SARA was shown to interact with 
clathrin and the ESCRT-I subunit Tsg101 similar to HRS indicating that SARA may 
function with or is a part of an alternative ESCRT-0 in the EGFR pathway. Whether 
SARA plays a role in GPCR trafficking remains to be studied. However to the best of our 
knowledge, the need for additional ESCRT adaptors seen for EGFR degradation such as 
Eps15b appears to be specific to EGFR. EGFR ubiquitination upon EGF stimulation is 
also dependent upon the RING ligase Cbl-c. Interestingly, AIP4 has been shown to act 
synergistically to promote Cbl-c mediated ubiquitination and degradation of EGFR 
(Courbard et al., 2002). Our study demonstrates that CXCL12 activation of CXCR4 
promotes DTX3L localization to early endosomes where we believe that DTX3L inhibits 
AIP4 activity to promote ESCRT function. Although DTX3L does not regulate 
downregulation of EGFR, DTX3L localization to early endosomes and the effect on 
AIP4 as well as ESCRT function may be dependent on a specific a ligand (i.e. CXCL12) 
or additional yet to be identified ligands. Altogether, whether DTX3L plays a role in the 
ESCRT-dependent sorting of other GPCRs remains to be determined, however, it 
plausible to suggest that DTX3L may have a general role in GPCR sorting. 
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MECHANISM OF DTX3L INHIBITION OF AIP4 SELF-UBIQUITINATION  
While this study demonstrates that DTX3L antagonizes AIP4 activity in the 
context of CXCR4 downregulation, the precise mechanism by which DTX3L prevents 
AIP4 self-ubiquitination remains unclear. Our data show DTX3L inhibition of AIP4 
ubiquitination is independent of its ability to bind to the E2 since the RING mutant of 
DTX3L still prevents AIP4 ubiquitination in vitro (Figure 3.17). Moreover, interaction 
studies suggest that DTX3L binds to the HECT domain of AIP4 (Figure 3.10) and 
preliminary competition assays suggest DTX3L does not compete with E2 for binding to 
AIP4. Therefore based on these observations, we can speculate that DTX3L occludes E2-
mediated transfer of ubiquitin to AIP4, but not the ability of the E2 to bind to AIP4. 
Additionally, it is conceivable that the inability of AIP4 to self-ubiquitinate in the 
presence of DTX3L may be due to an inability to adopt an active conformation 
structurally. To confirm this will require further and more rigorous study. Nonetheless, 
this study establishes DTX3L as a bona fide antagonist of AIP4 activity in the context of 
CXCR4 trafficking.  
 
TARGETING THE DTX3L/AIP4 INTERACTION IN CXCR4 PATHOLOGIES 
The findings from this study leave the possibility of further exploring the DTX3L 
and AIP4 interaction as a potential therapeutic option in treating CXCR4 pathologies. For 
instance, the progression of many cancers is correlated to a high expression of CXCR4. 
Specifically in HER2/neu positive breast cancers, CXCR4 levels are increased due in part  
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to inhibition of receptor ubiquitination and downregulation (Li et al., 2004). 
Overexpression of AIP4, but not the catalytically inactive mutant of AIP4 (C830A), 
could promote downregulation in these cancer cells. However, the status of DTX3L in 
the HER2/neu subtype of breast has yet to be determined. Based on this study, one 
strategy to promote AIP4 activity is to increase AIP4 levels in these cells to promote 
CXCR4 ubiquitination at the plasma membrane. Yet given the dual functions of AIP4 at 
both the plasma and early endosome, it would important to promote CXCR4 
ubiquitination at the plasma membrane while also ensuring a level of endosomal 
downregulation.  Based on our data if DTX3L is overexpressed in these cancers, it should 
prevent AIP4 activity on endosomes and, thereby, promote CXCR4 downregulation. 
However if DTX3L is expressed at a low levels, a combinational therapy that promotes a 
balance of AIP4 as well as DTX3L function may be efficacious. Therapies that could 
promote function could include gene therapy or delivery (i.e. PEGylation, PLGA 
microspheres, nanoparticle) of a drug that promotes activity. A recent study described the 
creation of small bicyclic peptides that could target the E2 binding site that is crucial for 
ubiquitin transfer within the HECT domains of Nedd4, Smurf2, WWP1 and Mule/Huwe1 
(Mund, T. et al. 2014). This approach could inhibit the auto-ubiquitination of these 
ligases as well as prevent transfer of ubiquitin to substrates. An approach similar to this 
could be utilized to target the catalytic HECT domain of AIP4, however, it would be 
necessary to ensure that endosomally localized AIP4 would be specifically targeted in 
order to promote CXCR4 downregulation. More detailed analysis in the future will be 
!
156 
required to determine whether these strategies would be useful in order to promote 
CXCR4 downregulation in HER2/neu cancers.  
Whether altered CXCR4 ubiquitination is implicated in other cancers where 
CXCR4 is overexpressed or whether this is specific to HER2/neu cancers remains to be 
investigated. Though one could speculate, given the importance of CXCR4 ubiquitination 
in CXCR4 endosomal to lysosomal downregulation, that defective CXCR4 ubiquitination 
could underlie other CXCR4 related pathologies. Additionally, a defect in ESCRT-
dependent targeting of CXCR4 for degradation may promote increased CXCR4 
expression. For instanced, increased ubiquitination of ESCRT-0 by AIP4 prevents 
CXCR4 targeting for degradation and, thereby, may promote CXCR4 recycling (Malik & 
Marchese, 2010; Marchese et al., 2003). Thus, targeting key regulators in the CXCR4 
degradative pathway, including those interactions defined in this dissertation, may prove 
efficacious in treating this subtype of breast cancer where CXCR4 is overexpressed. 
In terms of hematological malignancies, both DTX3L and CXCR4 have 
prominent roles in DLCBLs. Analysis of the gene expression profile from the Brune 
Lymphoma Dataset (Oncomine database) reveals that the increased expression of DTX3L 
(fold change above 0) is correlated with a decrease in AIP4 levels (fold change below 0) 
in 10 out of 11 samples from DLBCLs (Brune et al., 2008). The reduction in AIP4 levels 
may be attributed to the DTX3L-mediated inhibition of AIP4. However, whether DTX3L 
also regulates AIP4 expression remains to be defined. Interestingly, in all of these 
samples HRS levels were increased (fold change between 0.79 – 1.81) while STAM-1 
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levels were elevated in 9 out of the 11 samples (fold change between 0.07 – 1.7). The 
increase in both ESCRT-0 components HRS and STAM-1 seen in these DLBCLs could 
be correlated to high levels of DTX3L, which we believe promotes ESCRT-0 function. 
Consistent with our study, this data reveals that high expression of DTX3L may be 
correlated to increased ESCRT-0 activity possibly through a reduction in AIP4 levels. 
More variation is seen in the levels of CXCR4 in these DLBCLs samples ranging from a 
fold change between -0.54 to 0.63. This variation may reflect differential functions of 
CXCR4 in DLBCLs subtypes. 
 A recent study has established that loss of CXCR4 expression is a prognostic 
marker for the development and progression of gastric extranodal DLBCLs originating 
from mucosa-associated lymphoid tissue (MALT) (Deutsch et al., 2013). While decrease 
expression of CXCR4 has been implicated in progression of gastric extranodal DLBCLs, 
an increase in CXCR4 has been associated with increased dissemination in de novo 
germinal-center B-cell-like (GCB)-DLBCLs (Chen et al., 2015). The latter study assessed 
CXCR4 expression in 743 patient biopsies. Another study demonstrated that in cell lines 
derived from 94 DLBCL biopsies, high levels of CXCR4 correlated to increased 
migration and increased engraftment as well as dissemination in a NOD/SCID xenograft 
mouse model (Moreno et al., 2015). Treatment of these mice with the CXCR4 antagonist 
AMD3100 significantly reduced dissemination. Thus, CXCR4 expression and role in 
progression varies between different DLBCLs sub-types. 
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Overexpression of DTX3L and B-aggressive lymphoma 1 (BAL1) are a risk 
factor for the host response (HR) subtype of DLBCLs signified by increased IFN- ! 
production and immune/inflammatory infiltrate (Juszczynski et al., 2006). In particular, 
DTX3L has been shown to bind to the nuclear protein BAL1. The DTX3L/BAL complex 
shuttles from the cytoplasm to nucleus where DTX3L mediates monoubiquitination of 
Histone H4 to modulate the DNA damage response (Yan et al., 2009). It will be 
interesting to establish within different subtypes of DLBCLs whether CXCR4 expression 
correlates to DTX3L levels. For example in line with our study, high levels of DTX3L 
should correlate to an overall reduction in CXCR4 levels due to increased receptor 
downregulation. Therefore, in DLBCL subtypes where low levels of CXCR4 drive 
disease progression, reducing DTX3L activity to promote CXCR4 recycling may prove 
advantageous. One strategy to reduce DTX3L levels therapeutically could be to prevent 
DTX3L interaction with AIP4 using a mini-gene that would mimic the minimal binding 
region on AIP4 to occlude DTX3L binding. Based on the present study by preventing 
DTX3L interaction with AIP4, this should prevent ESCRT-dependent sorting of CXCR4 
for degradation and instead promote CXCR4 recycling and resensitization at the plasma 
membrane. Conversely, in DLBCLs where high levels of CXCR4 are implicated as a 
prognostic marker, promoting DTX3L activity by gene therapy to drive CXCR4 
downregulation could be an ideal therapeutic strategy. Although our study did not focus 
on the role DTX3L may have on CXCR4-mediated signaling and migration, it will be 
important in future studies to establish whether DTX3L regulates these processes in 
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addition to receptor downregulation. Altogether understanding the molecular mechanisms 
regulating CXCR4 downregulation and signaling may provide insight into treating 
different sub-types of DLBCLs.  
In addition to studying the therapeutic potential of targeting the DTX3L/AIP4 
interaction in the context of CXCR4 related pathologies, future studies may highlight 
DTX3L as general regulator of ESCRT-dependent sorting of GPCRs (i.e. B2AR, PAR2, 
DOR) providing further implications for studying DTX3L in the context of a therapeutic 
treatment. Given that preliminary data (not shown) demonstrate that DTX3L can interact 
with other Nedd4 E3 ligases in addition to AIP4 raises the possibility that DTX3L may 
regulate these ligases in the context of other GPCR trafficking pathways. 
 
E2 ENZYMES IN CXCR4 DOWNREGULATION 
Ubiquitination plays a major role in the lysosomal downregulation of CXCR4. It 
has been established here and in previous work that the E3 ligases AIP4 and DTX3L are 
key regulators of this process (Holleman & Marchese, 2014; Marchese et al., 2003). AIP4 
mediates agonist-induced ubiquitination of CXCR4 at the plasma membrane (Marchese 
et al., 2003). However on early endosomes, AIP4 acts to limit the extent of CXCR4 
sorted for degradation by ubiquitin modification of ESCRT-0 subunits HRS and STAM-1 
(Bhandari, Trejo, Benovic, & Marchese, 2007; Malik & Marchese, 2010; Marchese et al., 
2003). Work from this dissertation has demonstrated that DTX3L acts to antagonize 
AIP4 activity on early endosomes to promote CXCR4 downregulation. Given that 
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ubiquitination of substrates is dependent upon three enzymes (E1, E2 and E3), whether 
specific E2 conjugating enzymes regulate CXCR4 degradation through their interactions 
with the E3 ligases AIP4 and DTX3L remains unknown. The function of the E2 enzyme 
is to link the ATP-dependent activation of ubiquitin by the E1 activating enzyme to the 
final covalent modification of protein substrates through the activities of E3 ubiquitin 
ligases. Based on phylogenetic analyses, the E2 enzymes are sub-grouped into 17 
families (Wenzel, Stoll, & Klevit, 2011). In contrast, there are over 600 E3 ubiquitin 
ligases sub-grouped into the RING and HECT domain families (Metzger, Hristova, & 
Weissman, 2012; Metzger & Weissman, 2010; Pickart, 2001). Given the ratio of E2:E3 
enzymes, it is often the case that one particular E3 ligase can work with several E2 
enzymes and conversely one particular E2 can interact with several E3 ligases.  
The role of specific E2 enzymes in conjunction with their E3 ligases in regulating 
GPCR downregulation remains unknown. Prior data on the downregulation of the RTK 
receptor EGFR demonstrated that the E2 enzymes UbcH5b and UbcH5c could regulate 
EGFR ubiquitin-dependent downregulation. This ubiquitination event is mediated 
through the interaction of UbcH5b and UbcH5c with the RING domain ligase Cbl-c 
(Umebayashi, Stenmark, & Yoshimori, 2008). This was the first study to our knowledge 
that provided insight into the specificity of E2 enzymes in the regulation of receptor 
trafficking. The precise role for specific subsets of E2 enzymes in GPCR regulation 
remains elusive.  
!
161 
Previous studies have demonstrated that DTX3L activity is dependent upon UbcH5 
members (Takeyama et al., 2003) while AIP4 activity is mediated through either UbcH5 
or UbcH7 (Kim & Huibregtse, 2009; Schwarz, Rosa, & Scheffner, 1998; Scialpi et al., 
2008; Wenzel et al., 2011).  Whether CXCR4 activation promotes the binding of 
particular E2 enzymes to either DTX3L or AIP4 remain to be determined. Future studies 
aimed at assessing the subcellular localization of these E2 enzymes with AIP4 and 
DTX3L upon CXCR4 activation can provide further mechanistic insight into E2 and E3 
regulation of CXCR4 trafficking. Although previous literature has shown that UbcH5c 
can localize to both the plasma membrane as well as the early endosome with the E3 
ligase Cbl-c following EGF stimulation (Umebayashi et al., 2008). Whether this 
localization pattern is true following CXCR4 activation remains to be determined. 
Though given the E2 specificities for DTX3L and AIP4 defined in the literature, we can 
speculate that UbcH5c and UbcH7 can localize to similar compartments as AIP4 and 
DTX3L such as the plasma membrane and early endosome. Understanding the particular 
E2:E3 interactions in the CXCR4 trafficking pathway may help determine differential 
specificities of these enzymes in regulating ubiquitination of CXCR4, ESCRT-0 as well 
as the self-ubiqutination of AIP4 and DTX3L, thereby, providing further mechanistic 
insight into CXCR4 ubiquitin dependent regulation. 
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ROLE OF UbcH5c IN DTX3L-MEDIATED INHIBITION OF AIP4 SELF 
UBIQUITINATION 
It has been well documented that self-ubiquitination of some ubiquitin ligases like 
AIP4 is essential to their function and this may also be the case for DTX3L in CXCR4 
trafficking (Scialpi et al., 2008). In particular, our in vitro ubiquitination assays utilized 
the E2 enzyme UbcH5c. Whether UbcH5c has a functional role in the cellular context in 
mediating DTX3L inhibition of AIP4 self-ubiquitination will be interesting to address in 
future study. One could speculate that UbcH5c may influence both the activity and  
subcellular distribution of either AIP4 or DTX3L to promote endosomal trafficking of 
CXCR4. 
A recent study of the E3 ligase Parkin has demonstrated that specific E2 enzymes 
(UbcH5b, UbcH5c, UbcH7 and UbcH13) are important regulators of Parkin translocation 
from the cytoplasm to the mitochondria upon mitochondrial stress (Fiesel, Moussaud-
Lamodiere, Ando, & Springer, 2014). Depletion of the identified E2 enzymes reduced 
Parkin localization to the damaged mitochondria and prevented Parkin mediated 
ubiquitination of substrates at the mitochondria. Additionally, in the Parkin study it was 
demonstrated that E2 enzymes UbcH5b, UbcH5c and UbcH7 function redundantly to 
activate and charge Parkin with ubiquitin. However, whether these E2 enzymes regulate 
Parkin stability and degradation was not assessed. Based on these studies, it is intriguing 
to speculate that particular E2 enzymes may also regulate the activation and localization 
of AIP4 and/or DTX3L within the CXCR4 degradation pathway. Yet given the broad role 
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of E2 enzymes in the ubiquitination process, whether we may see effects attributed 
directly or indirectly to AIP4-mediated ubiquitination may be one caveat. 
 
CONCLUSION 
Overall, this study provides increased knowledge on the ubiquitin-dependent 
regulation of CXCR4 signaling and downregulation (Figure 4.1). We have discovered the 
RING domain ligase DTX3L as a novel endogenous antagonist of AIP4 in the context of 
CXCR4 trafficking. This interaction may prove beneficial in developing strategies in 
modulating CXCR4 expression. Furthermore, the details of this study can be used in 
future studies aimed at creating potential therapies for CXCR4 pathologies, such as breast 
cancer and DLBCLs, and may even be broadly applicable to other GPCRs. 
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Polyethylenimine (1mg/ml PEI) 
In a 50 mL conical tube, dissolve 0.01 grams of PEI (Sigma-Aldrich) in 3 ml of 100% 
ethanol. Vortex solution and heat in 37°C water bath for 5 -10 min (vortex 2-3 times) 
until PEI is dissolved. Dilute PEI solution in 7 ml of DEPC treated (RNAase/DNAase 
free) H2O (Invitrogen; final volume of 30% ethanol). In a biological safety cabinet, 
syringe filter the solution with a 0.2 µm filter and make 100 µl aliquots. Store aliquots at 
-80°C.  
 
Short-duration ECL solution 
Solution 1      Solution 2 
2.5 mM luminol     0.02% Hydrogen Peroxide 
0.45 mM p-Coumaric Acid    0.1 M Tris pH 8.8 
0.1 M Tris pH 8.8 
 
To make Solution 1, dissolve 112.5 mg of luminol in 2.5 ml of DMSO. Dissolve 18.5 mg 
p-Coumaric acid in 1.25 ml DMSO. Add 0.1 M Tris-HCl pH 8.8 in final volume of 250 
ml.  To make Solution 2, combine 167 µl of Hydrogen peroxide to 250 ml of 0.1 M Tris-
HCl pH 8.8. Store each solution at 4°C. To use, combine equal volumes of solution 1 and 
solution 2. Incubate with immunoblot for 1 min before exposure.  
 
Protease Inhibitor Cocktail 
 [166] 
Make 10 mg/ml stocks of aprotinin, leupeptin and pepstatin. To 50 mg of aprotinin 
and leupeptin, add 5 ml of dH2O on ice and vortex. Make 1 mL aliquots. Add 1 mL 
DMSO to 10 mg of pepstatin. Aliquot 50 µl of each protease inhibitor into a sterile 
microcentrifuge tube. Store at -20°C.  
 
Acrylamide Running Gels 
10 % Acrylamide Running Gel Volume for 2 gels 
Sterile, filtered dH2O 1.54 ml 
0.75 M Tris-HCl, pH 8.8 5.0 ml 
10 % SDS 100 µl 
30 % Acrylamide 3.3 ml 
10% APS 60 µl 
TEMED 10 µl 
 
7 % Acrylamide Running Gel Volume for 2 gels 
Sterile, filtered dH2O 2.5 ml 
0.75 M Tris-HCl, pH 8.8 5 ml 
10 % SDS 100 µl 
30 % Acrylamide 2.33 ml 
10% APS 60 µl 
TEMED 10 µl 
 
12 % Acrylamide Running Gel Volume for 2 gels 
Sterile, filtered dH2O 830 µl 
0.75 M Tris-HCl, pH 8.8 5 ml 
10 % SDS 100 µl 
30 % Acrylamide 4.0 ml 
10% APS 60 µl 
TEMED 10 µl 
 
3 % Acrylamide Stacking Gel Volume for 2 gels 
Sterile, filtered dH2O 2.0 ml 
0.75 M Tris-HCl, pH 8.8 500 µl 
10 % SDS 45 µl 
30 % Acrylamide 400 µl 
10% APS 50 µl 
TEMED 5 µl 
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Mix together desired percentage of resolving acrylamide gel ingredients in a 50 ml 
conical tube (add Acrylamide, APS and TEMED last). Vortex and pipet into glass plates 
leaving about a ! inch space from top of short plate. Fill remaining space with 
isopropanol. Let resolving gel solidify at room temperature for about 20 min. To pour the 
stacking gel, first rinse away isopropanol from resolving gel with dH2O and then combine 
stacking ingredients in a 50 ml conical tube (add Acrylamide, APS and TEMED last). 
Vortex and pipet into remaining space between glass plates. Place comb of desired size 
(i.e. 10 sample or 15 sample comb) into stacking liquid. Let solidify at room temperature 
for about 10 min. To load gel, remove comb and place gel into running apparatus (Bio-
Rad). Fill tank with 1! SDS Running Buffer prior to loading samples. 
 
SDS Running Buffer (10!) 
0.25 mM Tris Base   
0.192 M Glycine   
1% (w/v) SDS    
dH2O  4 L to final volume 
 
To 3 L dH2O, combine Tris Base and Glycine. Once dissolved, add SDS and dH2O to 4 L 
final volume. To make 1! Running Buffer, dilute 400 ml of 10 X SDS Running Buffer 
with 3.6 L of dH2O. 
 
Transfer Buffer (10!) 
0.25 mM  Tris Base   
 [168] 
0.192 M  Glycine   
dH2O  4 L to final volume 
 
To 3 L dH2O, combine Tris Base and Glycine. Once dissolved, add dH2O to 4 L final 
volume. To make 1!Transfer Buffer, combine 400 ml of 10 X Transfer Buffer with 800 
ml of methanol (20% vol/vol) and 2.8 L of dH2O. Store at 4°C. 
 
Western Blot Stripping Buffer 
10% SDS   200 ml 
0.75 M Tris-HCl, pH 6.5 83.4 ml 
14.3 M "-mercaptoethanol  7 ml 
dH2O    709.6 ml 
 
Combine SDS, Tris HCl and dH2O. Add "-mercaptoethanol in biological safety cabinet. 
Store at room temperature. To strip immunoblots, incubate immunoblots with ~100 ml of 
Stripping Buffer for 30 min at 60°C. After stripping, wash blots 10 X with d dH2O. Block 
immunoblots with 5% TBST-milk for 30 min at room temperature and add primary 
overnight at 4°C. Develop blots as described above.  
 
0.75 M Tris-HCl pH 8.8 or 6.5 
0.75 M Tris Base 45.41 g 
Concentrated HCl Drop-wise to desired pH 
dH2O   500 ml final volume 
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Stir together Tris Base with 300 ml dH2O in glass beaker. Add pH monitor (calibrate if 
necessary). Once Tris Base is dissolved, add HCl drop-wise until desired pH obtained. 
Add dH2O to final volume of 500 ml. 
 
1 M Tris-HCl pH 7.5 
1 M Tris Base  193.76 g 
Concentrated HCl Drop-wise to pH 7.5 
dH2O   1.6 L 
 
In a 2 L beaker with a stir bar, dissolve Tris Base in 1.2 L of dH2O. Add pH monitor to 
beaker (calibrate if necessary). Add HCl drop-wise until pH 7.5 is achieved. Bring 
solution to final volume of 1.6 L with dH2O. 
 
TBS-T (20X) 
3 M NaCl  2.4 L 
1 M Tris-HCl, pH 7.5 1.6 L 
Tween   40 ml 
dH2O   4L final volume 
 
In a 4 L beaker with a stir bar, combine NaCl, Tris-HCl and Tween in 4 L of dH2O (final 
volume). Store at 4°C. To make 1! TBS-T, combine 200 ml 10! TBS-T with 3.8 L of 
dH2O. Store at 4°C until use. 
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2! Sample Buffer (8% SDS) 
8% SDS    
10% glycerol    
0.7 M "-mercaptoethanol    
37.5 mM Tris-HCl, pH 6.5  
0.003% bromophenol blue  
 
To a 500 ml flask with a stir bar, combine SDS, Tris-HCl and glycerol. In a biological 
safety cabinet, add the "-mercaptoethanol. Lastly, add the bromophenol blue. Once 
dissolved, make aliquots and store at -20°C. 
 
Co-immunoprecipitation Buffer 
50 mM Tris-HCl 
150 mM NaCl 
2 mM EDTA 
1% Triton-X 100 
20 mM NEM 
10 µg/ml Protease Inhibitor cocktail 
dH2O to final volume 
 
Combine all ingredients except protease inhibitor cocktail.  Place at 4°C and let NEM 
dissolve for 30 min. Then add protease inhibitor cocktail on ice before adding to cells. 
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GST-fusion Purification Lysis Buffer 
50 mM Tris-HCl, pH 7.5 
300 mM NaCl 
1% Triton X 100 
1 mM DTT 
10 µg/ml Protease Inhibitor cocktail 
dH2O to final volume 
 
Combine all ingredients except protease inhibitor cocktail. Store at 4°C. Then add 
protease inhibitor cocktail on ice before adding to bacterial pellets. 
 
His-fusion Purification Buffer 
50 mM Tris-HCl, pH 7.5 
300 mM NaCl 
1% Triton X 100 
10 µg/ml Protease Inhibitor cocktail 
dH2O to final volume 
 
Combine all ingredients except protease inhibitor cocktail. Store at 4°C. Then add 
protease inhibitor cocktail on ice before adding to bacterial pellets. 
 
Binding Buffer 
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50 mM Tris-HCl, pH 7.5 
300 mM NaCl 
1% Triton X 100 
20 mM NEM 
10 µg/ml Protease Inhibitor cocktail 
dH2O to final volume 
 
Combine all ingredients except protease inhibitor cocktail.  Place at 4°C and let NEM 
dissolve for 30 min. Then add protease inhibitor cocktail on ice before adding to cells. 
 
Ubiquitination Buffer 
150 mM NaCl 
50 mM Tris-HCl, pH 7.5 
1% SDS 
5 mM EDTA 
1% Triton X 100 
20 mM NEM 
10 µg/ml Protease Inhibitor cocktail 
dH2O to final volume 
 
Combine all ingredients except protease inhibitor cocktail.  Place at 4°C and let NEM 
dissolve for 30 min. Then add protease inhibitor cocktail on ice before adding to cells. 
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Ubiquitin Dilution Buffer 
150 mM NaCl 
50 mM Tris-HCl, pH 7.5 
5 mM EDTA 
1% Triton X 100 
dH2O to final volume 
 
Combine all ingredients and place at 4°C until use. 
 
Immunofluorescence Reagents: 
3.7% Paraformaldehyde (PFA) Fixing solution 
Dilute 1 ml of 37 % PFA (Sigma-Aldrich) into 9 ml of cold, 1!PBS 
 
Permeabilization Buffer 
Combine 1!PBS plus 0.05% w/v saponin 
 
Blocking Buffer 
Combine 1!PBS plus 1% BSA and 0.05% w/v saponin 
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Plasmid Name: FLAG-DTX3L-Full Length 
Vector Backbone: p3xFLAG-CMV-10 (Product No. E4401; Sigma) 
Insert Size: ~2.0 kb  Vector Size: 6.4 kb 
Constructed by: Justine Holleman 
Construction Date: 10-12-2011 
Location: Maxi Prep DNA Box 1 (4ºC); Glycerol Stock -80C 
IMAGE clone ID: 4339554 
GenBank No.: BC042191.1 
 
Construction Details: 
FLAG-Deltex-3-Like (DTX3L) was PCR amplified from pCMV-SPORT6-DTX3L 
template (Thermo Scientific). Primers used are listed below. Briefly, the forward primer 
carried a NotI restriction site and started at amino acid residue Ala2, in frame with the 
3xFLAG epitope. The reverse primer carried a XbaI site and an in frame stop codon and 
ended at E740. The PCR fragment was digested with NotI and XbaI and cloned into the 
NotI and XbaI sites of p3xFLAG-CMV10. 
 
                              
 DTX3L-pCMV10 F: 5’ATATGCGGCCGCG GCC TCC CAC CTG CGC CCG CCG TC  
                                           NotI               A      S       H      L      R       P       P 
 DTX3L-pCMV10 R: 5’ ATATTCTAGA TTA CTC AAT TCC TTT GGC TTT C  
                                       XbaI       stop   E       I         G      K      A     K        
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Plasmid Name: FLAG-DTX3L-C561A 
Vector Backbone: p3xFLAG-CMV-10 (Product No. E4401; Sigma) 
Insert Size: ~2.2 kb  Vector Size: 6.4 kb 
Constructed by: Justine Holleman 
Construction Date: 03-12-2012 
Location: Mini Prep DNA Box 1 (4ºC); Glycerol Stock -80C 
 
Construction Details: 
To generate the single mutant FLAG-DTX3L-C561A we first amplified FLAG-DTX3L 
template DNA using FLAG-DTX3L-Forward and FLAG-DTX3L-C561A-Reverse 
primer in one tube and FLAG-DTX3L-Reverse and FLAG-DTX3L-C561A Forward 
primer in tube two. The product of PCR reaction one was then used as a template to 
anneal the C561A mutant strands. The forward primer carried a NotI restriction site and 
started at amino acid residue Ala2, in frame with the 3xFLAG epitope. The reverse 
primer carried a XbaI site and an in frame stop codon and ended at E740. The PCR 
fragment was digested with NotI and XbaI and cloned into the NotI and XbaI sites of 
3xFLAG-CMV10. 
 
 
DTX3L-C561A-F: 5’ GAAGGAAAAGGGCATCGCTGTCATCTGTATGGACACC 
                                     C561A 
 
DTX3L-C561A-R: 5’ GGTGTCCATACAGATGACAGCGATGCCCTTTTCCTTC 
                                                C561A 
 
DTX3L-pCMV10 R: 5’ ATATTCTAGATTACTCAATTCCTTTGGCTTTC  
                               XbaI      
 
 DTX3L-pCMV10 F: 5’ATATGCGGCCGCGGCCTCCCACCTGCGCCCGCCGTC  
                                     NotI 
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Plasmid Name: FLAG-DTX3L-3C/A 
Vector Backbone: p3xFLAG-CMV-10 (Product No. E4401; Sigma) 
Insert Size: ~2.2 kb  Vector Size: 6.4 kb 
Constructed by: Justine Holleman 
Construction Date: 03-12-2012 
Location: Maxi Prep DNA Box 1 (4ºC); Glycerol Stock -80C 
 
Construction Details: 
FLAG-DTX3L-3C/A was PCR amplified using FLAG-DTX3L-C561A (single mutant) 
template DNA extended with DTX3L- C596/599A -Forward oligo in PCR reaction 1. 
Product of reaction 1 was then subjected to a second round of PCR using the DTX3L- 
C596/599A -Reverse/pcmv10-R in tube two. The product of PCR reaction one was used 
as a template to anneal the DTX3L-3C/A triple mutant strands and extended using 
pcmv10-DTX3L-Forward/Reverse primers. The forward primer carried a NotI restriction 
site and started at amino acid residue Ala2, in frame with the 3xFLAG epitope. The 
reverse primer carried a XbaI site and an in frame stop codon and ended at E740. The 
PCR fragment was digested with NotI and XbaI and cloned into the NotI and XbaI sites 
of 3xFLAG-CMV10.  
 
DTX3L-C596/599A-Forward: 
 5’ CATGTCATATAAGCCAATCGCTCCCACAGCCCAGACTTCCTATGGTATTC 
                                     C596A               C599A 
 
DTX3L-C596/599A-Reverse: 
5’GAATACCATAGGAAGTCTGGGCTGTGGGAGCGATTGGCTTATATGACATG 
                   C599A              C596A 
 
DTX3L-pCMV10 R: 5’ ATATTCTAGATTACTCAATTCCTTTGGCTTTC  
                               XbaI      
 
 DTX3L-pCMV10 F: 5’ATATGCGGCCGCGGCCTCCCACCTGCGCCCGCCGTC  
                                     NotI 
 
 [178] 
Plasmid Name:GST-DTX3L 
Vector Backbone: pGEX-6p-1 
Insert Size: ~2 kb  Vector Size: 5 kb 
Constructed by: Justine Holleman 
Construction Date: 10-24-2011 
Location: Maxi Prep DNA Box 1 (4ºC); Glycerol Stock -80C 
 
Construction Details: 
GST-DTX3L was PCR amplified from pCMV-SPORT6-DTX3L template (Thermo). The 
forward primer carried a BamHI restriction site and started at amino acid residue Ala2, in 
frame with the pGEX6p1 epitope. The reverse primer carried a XhoI site and an in frame 
stop codon and ended at E740. The PCR fragment was digested with BamHI and XhoI 
and cloned into the BamHI and XbaI sites of pGEX6p1. 
 
F: 5’-ATAT GGA TCC GCC TCC CAC CTG CGC CCG CCG TC 
                          Bam HI 
 
R: 5’-ATAT CTC GAG TTA CTC AAT TCC TTT GGC TTT C  
                           XhoI 
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Plasmid Name:GST-DTX3L-N-term 
Vector Backbone: pGEX-6p-1 
Insert Size: ~1.68 kb   Vector Size: 5 kb 
Constructed by: Justine Holleman 
Construction Date: 10-24-2011 
Location: Maxi Prep DNA Box 1 (4ºC); Glycerol Stock -80C 
 
Construction Details: 
GST-DTX3L was PCR amplified from pCMV-SPORT6-DTX3L template (Thermo). The 
forward primer carried a BamHI restriction site and started at amino acid residue Ala2, in 
frame with the pGEX6p1 epitope. The reverse primer carried a XhoI site and an in frame 
stop codon and ended at I560. The PCR fragment was digested with BamHI and XhoI 
and cloned into the BamHI and XbaI sites of pGEX6p1. 
 
DTX3L-pGEX- F: 5’ ATATGGATCCGCCTCCCACCTGCGCCCGCCGTC  
                                            BamHI 
 
DTX3L-Nterm-GEX- R: 
5’ ATATCTCGAGTCAGATGCCCTTTTCCTTCTTGTCCAGTTCAAAGC 
                   XhoI     STOP 
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Plasmid Name:GST-DTX3L-N-term 
Vector Backbone: pGEX-6p-1 
Insert Size: ~0.6 kb  Vector Size: 5 kb 
Constructed by: Justine Holleman 
Construction Date: 10-24-2011 
Location: Maxi Prep DNA Box 1 (4ºC); Glycerol Stock -80C 
 
Construction Details: 
GST-DTX3L was PCR amplified from pCMV10- DTX3L template. The forward primer 
carried a BamHI restriction site and started at amino acid residue D529, in frame with the 
3xFLAG epitope. The reverse primer carried a XhoI site and an in frame stop codon and 
ended at E740. The PCR fragment was digested with BamHI and XhoI and cloned into 
the BamHI and XbaI sites of pGEX6p1. 
 
DTX3L-Cterm-GEX- F: 5’ ATATGGATCCGACATTGATAGCGATGATTCC 
                            BamHI 
 
DTX3L-pGEX- R: 5’ ATATCTCGAGTTACTCAATTCCTTTGGCTTTC  
                    XhoI      
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Plasmid name: His-DTX3L 
Vector Backbone: pET-21a(+) (Katherine Knight lab) 
Insert size: ~2.1 kb  Vector size: 5.4 kb 
Constructed by: Justine Holleman 
Construction Date: 08-23-12 
Location: Maxi Prep DNA Box 1 (4ºC); Glycerol Stock -80C 
 
Construction Details: 
Full-length DTX3L was cloned into BamHI and XhoI sites pET-21a(+) vector using 
below oligos and FLAG-DTX3L as a template: 
     
DTX3L-pGEX- F: 5’ ATATGGATCC GCC TCC CAC CTG CGC CCG CCG TC  
                                  BamHI 
 
pET-21a-DTX3L- R: 5’ ATAT CTCGAG CTC AAT TCC TTT GGC TTT CAG CTC 
         XhoI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pET-21a(+) 
- DTX3L 
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Plasmid name: His-DTX3L-3C/A 
Vector Backbone: pET-21a(+) (Katherine Knight lab) 
Insert size: ~2.1 kb  Vector size: 5.4 kb 
Constructed by: Justine Holleman 
Construction Date: 08-23-12 
Location: Maxi Prep DNA Box 1 (4ºC); Glycerol Stock -80C 
 
Construction Details: 
DTX3L-3C/A was cloned into BamHI and XhoI sites pET-21a(+) vector using below 
primers and Flag-DTX3L-3C/A as a template: 
     
DTX3L-pGEX- F: 5’ ATATGGATCC GCC TCC CAC CTG CGC CCG CCG TC  
                                  BamHI 
 
pET-21a-DTX3L- R: 5’ ATAT CTCGAGCTC AAT TCC TTT GGC TTT CAG CTC 
          XhoI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pET-21a(+) 
- DTX3L 
 
 [183] 
 
Plasmid Name: FLAG-AIP4-C830A ligase mutant 
Vector Backbone: p3xFLAG-CMV-10 (Product No. E4401; Sigma) 
Insert Size: ~656 kb  Vector Size: 6.4 kb 
Constructed by: Justine Holleman 
Construction Date: 07-14-2011 
Location: Maxi Prep DNA Box 1 (4ºC); Glycerol Stock -80C 
 
Construction Details: 
FLAG-AIP4-C830A was amplified from myc-AIP4-C830A. Primers used are listed 
below. Briefly, the forward primer carried a BamHI restriction site and started at amino 
acid residue Gly2, in frame with the 3xFLAG epitope. The reverse primer carried a XhoI 
restriction site and an in-frame stop codon and ended at E862. The PCR fragment was 
digested with BamHI and XhoI and cloned into the BamHI and XhoI sites of p3xFLAG-
CMV10. 
 
F: 5’- ATATGGATCC GGT AGT CTG ACC ATG AAA TCT TC 
                        BamHI 
 
R: 5’ - ATATTCTAGA TTA CTC TTG TCC AAA TCC TTC TGT TTC 
                           XhoI 
 
 
 
 
 
 [184] 
 
Plasmid Name: GST-AIP4-C830A 
Vector Backbone: pGEX-6p-1 
Insert Size: ~2.6 kb  Vector Size: 5 kb 
Constructed by: Justine Holleman 
Construction Date: 4-29-12 
Location: Maxi Prep DNA Box 1 (4ºC); Glycerol Stock -80C 
 
Construction Details: 
GST-AIP4-C830A was PCR amplified from FLAG-AIP4-C830A template DNA and 
sub-cloned into the BamHI-SmaI sites of pGEX6p1 using the below primers:  
 
F: 5’-ATAT GGA TCC GGT AGT CTG ACC ATG AAA TCT TC 
                         Bam HI 
 
R: 5’-ATAT CCC GGG TTA CTC TTG TCC AAA TCC TTC TGT TTC 
                         SmaI 
 
  
 
 
 
 
SmaI 
pGEX6p1-AIP4-
C830A 
~7.6 kb 
AMP 
BamHI 
 
 
AIP4-C830A 
GST 
 [185] 
 
 
Plasmid Name: FLAG-DTX1-Full Length 
Vector Backbone: p3xFLAG-CMV-10 (Product No. E4401; Sigma) 
Insert Size: ~1.9 kb  Vector Size: 6.4 kb 
Constructed by: Justine Holleman 
Construction Date: 10-12-2011 
Location: Maxi Prep DNA Box 1 (4ºC); Glycerol Stock -80C 
IMAGE clone ID: 5931062 
GenBank No.: BC048216 
 
Construction Details: 
FLAG-DTX1 was PCR amplified from human Deltex 1 (DTX1) DNA template. Primers 
used are listed below. Briefly, the forward primer carried a HindIII restriction site and 
started at amino acid residue S2, in frame with the 3xFLAG epitope. The reverse primer 
carried a XbaI site and an in frame stop codon and ended at A620. The PCR fragment 
was digested with HindIII and XbaI and cloned into the HindIII and XbaI sites of 
p3xFLAG-CMV10. 
 
DTX1-met-F: 5’-ATAT AAGCTT TCA CGG CCA GGC CAC GGT GGG C 
                                           HindIII     S2      R       P       G      H       G       G 
 
DTX1-stop-R2: 5’-ATAT TCTAGA TCA AGC CTG GTG TCG ACT CCG GC  
                                               XbaI        stop   A620   K      A       A      A      E 
 
 
 
 [186] 
Plasmid Name: FLAG-DTX2-Full Length 
Vector Backbone: p3xFLAG-CMV-10 (Product No. E4401; Sigma) 
Insert Size: ~1.9 kb  Vector Size: 6.4 kb 
Constructed by: Justine Holleman 
Construction Date: 10-12-2011 
Location: Maxi Prep DNA Box 1 (4ºC); Glycerol Stock -80C 
IMAGE clone ID: 4107018 
GenBank No.: BC008856 
 
Construction Details: 
FLAG-DTX2 was PCR amplified from human Deltex 2 (DTX2) DNA template. Primers 
used are listed below. Briefly, the forward primer carried a HindIII restriction site and 
started at amino acid residue A2, in frame with the 3xFLAG epitope. The reverse primer 
carried a XbaI site and an in frame stop codon and ended at Q622. The PCR fragment 
was digested with HindIII and XbaI and cloned into the HindIII and XbaI sites of 
p3xFLAG-CMV10. 
 
DTX2-Met-F: 5’-ATAT AAGCTT GCC ATG GCC CCA AGC CCT TCC C 
                                         HindIII     A2      M        A      P       S       P       S 
 
DTX2-stop-R2: 5’-ATAT TCTAGA TCA CTG CTG CTC CAG GCA GTC  
                                               XbaI      stop   Q622     Q       E     L  C       D 
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